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ABSTRACT
Alanine is synthesised de novo by skeletal muscle and 
released for glucose formation in the liver. For alanine to 
make a net contribution to the body glucose pool in times of 
dietary insufficiency its carbon must be derived from non­
carbohydrate sources.
A relationship between the. metabolism of branched-chain 
amino acids (BCAAs) and alanine release observed in the present 
study using muscle preparations incubated with clofibric acid or 
hypoglycin, suggested that BCAAs contributed carbon for alanine 
formation. A pathway for alanine formation from valine was 
proposed and developed. The phosphoenolpyruvate carboxykinase 
(PEPCK) inhibitor, 3-mercaptopicolinate, inhibited alanine 
formation and correlations were observed between dietary stimulation 
of BCAA oxidation, PEPCK activity and alanine formation. Amino- 
methoxybutenoate, an inhibitor which blocks mitochondrial aspartate 
transfer, inhibited BCAA-stimulated alanine release by muscle; 
from 48 h-starved rats. Aspartate aminotransferase was therefore 
implicated in the pathway.
The subcellular locations of enzymes implicated in this 
pathway were studied. Using fractional extraction techniques 
muscle branched-chain aminotransferase activity was found to be 
associated with the mitochondria-containing fractions. Aspartate 
aminotransferase, alanine aminotransferase and PEPCK were present 
in both the soluble and mitochondria-containing fractions.
When verification of the pathway was sought, incubating
muscle preparations in the presence of -valine, negligible
14
amounts of G were recovered in the alanine released from the 
muscle. It was concluded that the pathway for formation of the 
alanine released from starved muscle preparations therefore does 
not utilise exogenous BGAA carbon for pyruvate formation to 
any great.extent but still involves PEPCK and aspartate amino­
transferase. The source of pyruvate for alanine formation in 
these studies is therefore probably the amino acids derived from 
muscle protein breakdown.
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1C H A P T E R  O N E
INTRODUCTION
INTRODUCTION
1.1 METABOLIC FUELS AND FASTING
1.1.1 Requirement for Glueoneogenesis
Fasting In-man can be considered to consist of three 
metabolically distinct phases, namely the postabsorptive state 
(6 - 12 h after food intake), short-term starvation (lasting up 
to 7 days) and prolonged starvation, •which are characterised by 
changes in the utilisation of fuels by various tissues of the 
body. During the postabsorptive period adipose tissue: releases 
free fatty acids to meet the fuel requirements of muscle, heart 
and parenchymal tissues (liver and kidney) (Felig, 1979)» while 
carbohydrate utilisation occurs primarily in the brain, and, to 
a lesser extent, in red blood cells, kidney medulla and testis.
The daily glucose requirement for those tissues has been estimated 
as approximately 120 g for brain and ^ 0 g for the kidney medulla, 
testis and red cells combined (Newsholme & Start, 1973)* Muscle 
also uses carbohydrate as a fuel but-the amount that is consumed 
is dependent upon the extent and duration of mechanical activity, 
the respiratory quotient of resting muscle being close to 0.7 
(Andres et al., 195&)- The minimum glucose requirement for an 
average man at rest is therefore approximately 160 g per day.
During;the preliminary stages of fasting, glucose production 
is limited to the liver (Felig, 1979)* Maintenance of circulating 
glucose levels depends on the liver releasing glucose at a rate 
equal to glucose utilisation in brain and other tissues. In the
absence of hepatic glucose production the blood glucose pool 
would be halved in 40 - 60 min. Approximately 75 per cent of
i
the glucose released by liver after an overnight fast is derived 
from glycogen (Felig, 1973)* Liver glycogen stores (approximately 
70 g per 70 kg man) are rapidly depleted as starvation extends 
beyond 18 - 24 h (Hultman & Nilsson, 197l) and so can supply 
the glucose requirement of the brain for less than 24 h .
Therefore as fasting progresses beyond the post-absorptive period 
hepatic glucose output is more dependent on hepatic gluconeo- 
genesis than glycogenolysis.
In man an increase in gluconeogenesis can be detected 
after only a few hours fasting (Exton et al., 1970; Schimmel & 
Knobil, 1970).
1.1.2 Precursors for Hepatic Gluconeogenesis
Gluconeogenesis refers to the processes whereby glucose 
molecules are synthesised from precursor molecules, the main 
substrates being amino acids, glycerol, lactate and pyruvate.. 
Muscle lacks the enzyme glucose .6-phosphatase and therefore its 
glycogen cannot be mobilised into the circulation as glucose. 
However lactate and pyruvate formed from muscle glycogen are 
released to the liver where they act as precursors for glucose 
synthesis thus enabling muscle glycogen to contribute to blood 
glucose homeostasis (Sugden et al, 197&). The average man (70 kg 
body weight) has only 120 g of muscle glycogen (Newsholme &
Start, 1973) and even assuming total mobilisation to the liver, 
muscle glycogen is not sufficient to provide substantial amounts
of precursors for hepatic gluconeogenesis over a period of days. 
Lactate and pyruvate are also produced from glucose degradation 
in glycolytic tissues such as the kidney medulla and red blood 
cells. Gluconeogenesis from these substrates in this case 
is merely a recycling of carbon and does not represent net 
production of glucose for complete oxidation by the brain or 
other tissues.
During fasting adipose tissue triacylglycerol stores 
are mobilised yielding fatty acids and glycerol. While the 
fatty acids provide a fuel of respiration for several tissues, 
the glycerol is transported to the liver where it acts as a 
gluconeogenic precursor.
Glycerol, however, only plays a minor role in gluco­
neogenesis in man during both brief fasting, when it has been 
calculated that glycerol release during the breakdown of depot 
fat can provide only about 16 g out of a total of 180 g of glucose 
needed over 24 hours (Cahill et al., 1966), and during prolonged 
starvation (Cahill, 1970; Exton, 1972).
In man, as fasting proceeds beyond the postabsorptive 
period into the short-term fasting phase, the relative contribution 
of amino acids derived from body protein breakdown to total 
hepatic glucose production increases. It has been calculated 
that in fasting adult man, approximately 50 % of net glucose 
production is derived from amino acid precursors, 30 % from 
lactate and 10 % from glycerol (Cahill, 1970). Similarly, : when 
livers from fasted rats were perfused with mixtures of lactate, 
glycerol and amino acids in physiological concentrations, over
50 % of the glucose formed was derived from the amino acids 
(Exton & Park, 1967; Exton et al., 1970). Amino acids have 
also been found to be major substrates for hepatic glucose 
formation in human insulin-dependent diabetes, a situation 
where gluconeogenesis is elevated above normal (Wahren et al.,
1972).
Although all amino acids, with the exception of leucine, 
are potentially glucogenic (Krebs, 1964), only alanine, serine, 
threonine and glycine have been found to give rise to significant 
amounts of glucose in perfused rat liver in vitro (Ross et al., 
1967) and much evidence has been presented to show that alanine 
is the major amino acid involved in hepatic gluconeogenesis.
1.1.3 Importance of Alanine as a Gluconeogenic Precursor
Transhepatic catheterisation studies in man suggest that 
over 50 % of the glucose derived from gluconeogenic amino acids 
is formed from alanine, and the plasma alanine concentration 
exhibits the steepest decline of all amino acids during fasting 
in both adults and children (Adibi,_1968; Felig et al., 1969a*? 
Pagliara et al., 1972;. Pagliara et al., 1973)*
Alanine is taken up by rat liver in vivo (ishikawa, 1977) 
and in vitro (Fisher & Kerly, 1964), and by the human splanchnic 
bed in vivo (Felig et al., 1969a), to a greater extent than any 
other amino acid. It has been shown to be the best amino acid 
substrate for hepatic gluconeogenesis in the rat (Exton & Park, 
1967; Ross et al., 1967) and specific stimulation of alanine 
transport into hepatocytes has been observed in starvation
(Mallette et al., 1969a) and after glucagon stimulation of 
gluconeogenesis (Fehlmann et al., 1979)* Indeed a major factor 
in the increase in gluconeogenesis in short-term fasting has 
been proposed to be the increased hepatic extraction of 
alanine, despite a fall in its plasma concentration (Felig 
et al., 1969a). This suggestion receives support from the 
findings that the rate of precursor supply to rat liver has 
been demonstrated to limit the rate of gluconeogenesis in the 
rat in vivo (Aikawa et al., 1972) and in the perfused rat 
liver in vitro (Exton & Park, 1967) as the physiological 
concentrations of these precursors in blood lie well below 
saturating levels for hepatic gluconeogenesis. In addition 
recent evidence from Tager's group (Sips et al.t 1980; Groen 
et al., 1982) shows that the plasma membrane transport of 
alanine is probably rate-limiting for its utilisation by 
liver.
During prolonged starvation when the ketone bodies, 
acetoacetate and 3-hydro;xybutyrate, progressively replace 
glucose as a fuel for the brain (Owen et al., 1967)* the need 
for gluconeogenesis is decreased and the release of amino acids 
from body protein is reduced (Owen et al., 1969; Cahill, 1970).
The infusion of small amounts of alanine to humans in this 
situation results in a rapid rise in the blood glucose concentration 
confirming that a rate-limiting step to gluconeogenesis in 
fasted man is the concentration of the substrate, alanine, 
available to the liver (Felig et al., 1969b).
The key role of alanine as a glucose precursor which is
limiting to gluconeogenesis is also demonstrated in several 
conditions in which a deficiency in circulating alanine is 
associated with fasting hypoglycemia. Normal pregnancy results 
in an exaggeration and acceleration of the hypoglycemic, 
hyperketonemic and hypoinsulinemic response to starvation in 
humans (Felig & Lynch, 1970) and'in rats (Scow et al., 1964)_. _
In humans (Felig et al., 1972) and rats (Metzger et al., 1971) 
blood alanine levels are significantly reduced and fall more 
rapidly during starvation in pregnancy. The infusion of alanine 
into pregnant humans increased plasma alanine levels and a 
prompt rise in blood glucose was observed (Felig et al., 1972), 
implying that the fasting hypoglycemia of pregnancy was due to 
gluconeogenic substrate limitation. The importance of glucogenic 
amino acids as gluconeogenic substrates is also shown by the 
finding that in 48 h-starved pregnant rats circulating lactate, 
pyruvate and glycerol concentrations did not fall below the 
values observed in virgin rats, but a rapid and profound decrease 
was noted in the levels of circulating glucogenic amino acids, 
including alanine, coincident with the development of hypo­
glycemia (Metzger et_al., 197l).
Ketotic hypoglycemia is a disorder of childhood characterised 
by recurrent episodes of hypoglycemia and.ketosis, associated 
with hypoinsuli'nemia. A decreased circulating alanine concen­
tration has been shown, but rapid restoration of blood glucose 
to normal was found following alanine administration (Pagliara 
et al., 1972) or corticosteroid-induced hyperalaninemia (Haymond 
et al., 1974).
Hypoalaninemia may also contribute to ethanol-induced 
hypoglycemia. When ethanol is administered to normal (Kreisberg 
et al., 1972) and diabetic subjects (Kalkhoff & Kim, 1973) 
circulating alanine levels rapidly decrease.
Alanine availability may be the key factor in the sex- 
and age-related variability in tolerance to starvation found 
among healthy subjects. Normal women exhibit a greater degree 
of hypoglycemia during fasting than men (Merimee & Fineberg,
1973) and healthy children show an exaggerated fall in blood 
glucose compared to adults (Chaussain, 1973)* These findings 
correspond with the observations that alanine availability 
during fasting is highest in adult men, intermediate in women 
and lowest in children (Santiago, J., Haymond, M., Karl, I.,
Clarke, W., Pagliara, A. & Kipnis, D (1974) ’’unpublished results” 
referred to in Felig, 1975).
1.1.4 Sources of Alanine for Gluconeogenesis
Alanine is capable of being released into the circulation 
by a number of tissue. Using arteriovenous measurements 
in vivo, isolated organ perfusion systems or isolated tissue 
preparations in vitro, alanine release has been demonstrated 
from skeletal muscle (London et al., 1965; Felig et al., 1969a; 
Pozefsky et al., 1969; Marliss et al., 1971; Ruderman & Lund, 1972; 
Aikawa et al., 1973; Ruderman & Berger, 1974; Garber et al., 1976a), 
heart (Taegtmeyer et al., 1977)> small intestine (Windmueller & 
Spaeth, 1974; 1975; Hanson & Parsons, 1977)» kidney (Owen &
Robinson, 1963; Aikawa et al., 1973) and adipose tissue (Snell 
& Duff., 1977a; Tischler & Goldberg, 1980).
By far the most important of these tissues in supplying 
alanine to the bloodstream is skeletal muscle. This tissue 
comprises about 45 % of the adult human body weight (Miller, 
1969) and contains almost 60 % of the total body protein 
(Snell, 1980), thus representing a relatively large depot of 
gluconeogenic precursors which can be made available by 
proteolysis. Several investigators reporting the release of 
amino acids from postabsorptive human forearm by arterio­
venous difference measurements have shown that alanine and 
glutamine together account for about 50 % of the total amino 
acids released (Pozefsky et al., 1969? Marliss et al., 1971;
Aoki et al.#- 1974). Similar findings have also been obtained 
from the patterns of amino acid release by the perfused hind- 
quarter of the 48 h-starved rat (Ruderman & Lund, 1972; Ruderman 
& Berger, 1974)and by intact epitrochlaris muscle preparations 
(Garber et al., 1976a). The release of large amounts of these 
two amino acids from skeletal muscle during fasting thus makes 
alanine and glutamine available for hepatic gluconeogenesis 
and, as noted above (l.l.3)» hepatic extraction and gluconeo­
genesis from alanine is increased in fasting. The fate of the 
glutamine released by skeletal muscle, however, differs from 
that of alanine. Although it has been observed that a large 
amount of circulating glutamine is extracted by the splanchnic 
bed (liver and gut) (Marliss et al., 197l)» it has been found 
that most of the glutamine extracted is taken up by the 
intestinal tract rather than the liver, in man (Felig et al., 
1973a), in fasted rat (I'shikawa et al.. 1972) and in fasted dog
(Elwyn et al., 1968). The small intestine (Windmueller &
Spaeth, 1974), and more specifically the mucosal epithelial 
cells of the small intestine, have been identified as the major 
sites of glutamine utilisation in the non-hepatic splanchnic 
bed (Hanson & Parsons, 1977» Windmueller & Spaeth, 1978). 
Comparison of arterio-hepatic venous differences have shown 
that the intestinal tract in fasting man releases alanine into 
the circulation (Felig et al., 1973^). To this extent, 
measurements of alanine uptake across the splanchnic bed 
underestimate the hepatic uptake of alanine. The gut from the 
starved rat has also been found to release large amounts of 
alanine (ishikawa et al., 1972) and several preparations of 
rat small intestine have shown that glutamine can contribute 
both carbon and nitrogen to the alanine released (Windmueller, 
1980). Hence glutamine released by skeletal muscle can act 
indirectly as a precursor for hepatic gluconeogenesis via 
its contribution to alanine formation and release by the 
small intestine.
The kidney also takes up glutamine from the circulation 
and releases alanine (Owen & Robinson, 1963; Aikawa et al., 1973)* 
Kidney utilises glutamine to generate ammonia for the neutral­
isation of acid urine (Pitts, 1964), kidney extraction of 
glutamine from the circulation being elevated under acidotic 
conditions and in starvation. Glutamine can also serve as a 
substrate for renal gluconeogenesis (Hems, 1972), a process 
which becomes increasingly significant with prolonged starvation 
(Cahill & Owen, 1968). Studies with fasted rats, however,
have shown that evisceration causes a far greater accumulation 
of plasma glutamine than does nephrectomy (Matsutaka et al.,
1973) thus indicating that the gut is responsible for the 
greater proportion of glutamine catabolism compared to the 
kidney.
1.2 DE NOVO MUSCLE ALANINE FORMATION
1.2.1 Alanine and Glutamine Release by Muscle
The myofibrillar proteins constitute approximately 70 % 
of the intracellular protein of muscle (Perry & Corsi, 1958), 
and the proteins, myosin and actin, make up approximately 60 %
and 30 % respectively of the proteins of the myofibril (Waterlow
et al., 1978a). Basing the amino acid composition of muscle 
protein on a theoretical protein containing actin and myosin 
in the proportions as they exist in skeletal muscle (Kominz 
et al., 1954), alanine and glutamine together have been estimated 
to comprise only about 13 % of the amino acid composition of 
muscle protein (Ruderman & Lund, 1972; Ruderman & Berger, 1974).
A similar estimate has been derived by Waterlow.et al., (1978b). 
During starvation muscle proteins, including-those of myofibrils, 
undergo net breakdown (Haverberg et al., 1975) and, as noted 
above (1.1.4), alanine and glutamine together account for approx­
imately 50 % of the amino acids released by skeletal muscle 
from fasted subjects. Muscle release of these two amino acids 
is therefore far in excess of the relative amounts expected from 
their content in muscle protein. Chang & Goldberg (1978a)
directly confirmed these calculations with diaphragm preparations 
from rats starved for two days. They determined the amino acids 
released hy the tissue incubated in vitro in Krebs-Ringer 
bicarbonate buffer containing 5 mM-glucose. Total muscle protein 
contained similar proportions of alanine and glutamine as the 
myofibrillar proteins (Ruderman & Berger, 1974; Chang & Goldberg, 
197?a) and both glutamine and alanine were again released 
out :6f proportion to their percentage compositions of the tissue 
protein.
It is possible that preferential breakdown of labile 
proteins containing high proportions of glutamine and alanine 
residues could account for these observations (Ruderman & Lund, 
1972). However, in the absence of evidence for the existence 
of alanine- and glutamine^'rich" proteins in muscle, an explanation 
for the disproportionate alanine and glutamine release by muscle 
is that, in addition to the alanine and glutamine derived from 
protein breakdown, alanine and glutamine are synthesised dejnoyo 
within muscle.
The nitrogen of alanine and glutamine constitutes the 
major part of the nitrogen of the amino acids released from 
skeletal muscle. This suggests that amino acids released from 
muscle proteins in fasted rats are metabolised within the muscle 
and transfer their nitrogen for the formation of alanine and 
glutamine, which are then released from muscle into the circu­
lation (ishikawa, 1977). The output of valine, leucine and' 
isoleucine from human forearm muscle (. Pozefsky et al., 1969?
Felig et al., 1970) and isolated rat diaphragm (Odessey et al., 
1974; Chang & Goldberg, 1978a) accounts for only 10 - 12 % of
the total amino nitrogen released by muscle and yet these amino 
acids represent 20 % of the residues of muscle protein (Kominz 
et al., 195^ > Odessey et al., 197^ > Chang & Goldberg, 1978a), 
which suggests substantial catabolism of the amino acids in 
muscle. Similarly aspartate and asparagine together comprise 
12 % of the amino acid composition of muscle, yet only make up 
0.8 % of the total amino acids released by muscle (Chang &
Goldberg, 1978a). It would appear that these amino acids are 
the donors of the nitrogen released from muscle in the form 
of alanine and glutamine. Muscle does not possess the enzymes 
required for the synthesis of urea and therefore, by releasing 
nitrogen as alanine and glutamine, muscle may be able to use 
amino acids as a fuel without accumulating, or releasing into 
the circulation, large quantities of potentially toxic ammonia 
(Ruderman, 1975)•
The release of alanine from muscle has been found to be 
more closely related to nutritional variation than that of 
glutamine. Glutamine release from perfused rat hind-limb 
preparations was comparable in recently-fed and starved rats, 
whereas alanine release was negligible in fed rats but markedly 
increased after 2h - ^ 8 h starvation (Ruderman & Berger, 197^5 
Ruderman, 1975)* Also, glutamine release, measured by arterio­
venous difference across rat hindquarters was unaffected by 
starvation whereas alanine was taken up by hindquarters of fed 
rats but released from 52 h-starved rats (McDonald,et al., 1978). 
This suggests that alanine transports most of the extra nitrogen 
generated when the catabolism of amino acids in muscle is increased
during starvation.
1.2.2 Transamination of Pyruvate
Alanine can be formed de novo in skeletal muscle by the 
transfer of amino groups to pyruvate. This direct transamination 
of pyruvate in muscle is restricted to glutamate (Rowsell, 1958; 
Rowsell & Corbett, 1958) and is catalysed by alanine aminotrans­
ferase which is present in muscle in high activity (Williamson 
et al., 1987; DeRosa & Swick, 1975)*
Evidence that some of the alanine released from muscle 
does not arise from selective proteolysis of an alanine-rich 
protein but from de novo synthesis has been obtained using 
inhibitors of alanine aminotransferase. Garber et al., (1978a) 
showed that increasing amounts of the aminotransferase inhibitor, 
aminooxyacetate (Hopper & Segal, 1982), caused progressive decrease 
in muscle alanine release by intact rat epitrochlaris muscle 
in vitro. Similar findings were obtained in vivo try Blackshear 
et al., (1975) using the aminotransferase inhibitor, L-cyclo- 
serine (Barbieri et al., i960). In starved rats, after removing 
the liver from the circulation, the accumulation of alanine 
in the blood was decreased by 80 % after intravenous injection 
of L-cycloserine.
The reaction catalysed by alanine aminotransferase: 
L-glutamate + Pyruvate ^  2-oxoglutarate + L-alanine 
is freely reversible and has an equilibrium constant, K, of 0.66 
(Krebs, 1953» Williamson et al., 1967). where
^glutamate] £pyruvate]
K = -----=------------ ;--- ■
^2-oxoglutarate] [[alanine^
The concentrations of the reactants of the alanine amino­
transferase system in the abdominal wall muscle of the rat 
have been reported (Krebs, 1975) and suggest that at the measured 
concentrations of glutamate, 2-oxoglutarate and pyruvate, alanine 
must be formed until its concentration is approximately 3 “ ^
The measured alanine concentration in the muscle was much 
lower and hence equilibrium was not attained. The reason for 
the non-attainment of equilibrium is possibly the inability of 
the muscle cell membrane to retain alanine at a high concentration 
against a tissue/plasma concentration gradient for alanine 
which has been measured between skeletal muscle (peetoralis 
major) and blood to be about 4 (Banos et al., 1973 J Krebs, 1975). • 
Therefore a-reason for non-equilibrium would' be the removal of 
alanine, .from the cell before ^equilibrium concentration-- is 
reached.. The low-.;concentration of alanine in the" blood’ of - . 
fasted rats may therefore contribute to the high, rate of alanine 
release observed from the hindquarters of fasted rats (MacDonald 
et al., 197^).
The abdominal wall muscle study showed a large deviation 
from equilibrium of alanine aminotransferase after muscular 
activity, due mainly to the accumulation of pyruvate which rose 
more than 8-fold after 10 s tetanus. Thus altering the intra­
cellular availability of the reactants of the alanine amino­
transferase system alters the rate of alanine production because 
of the tendency of the enzyme to establish equilibrium between
its reactants. Increased intracellular pyruvate concentrations 
after infusing pyruvate into postabsorptive man increased the 
release of alanine into the circulation (Pozefsky & Tancredi,
1972). Perfusing rat hindlimb preparations with lactate, and 
hence increasing intracellular pyruvate, also increased alanine 
release (Ruderman & Berger, 197*0 • Increasing pyruvate availability 
has also been shown to increase muscle alanine release when 
rat diaphragm, preparations were incubated with glucose (Odessey 
et al., 197*+) and rat epitroehlaris muscles were incubated with 
pyruvate (Garber et al., 1976a).
Decreasing the intracellular pyruvate available for trans­
amination can be achieved by stimulating pyruvate oxidation with 
dichloroacetate which activates pyruvate dehydrogenase by 
increasing the proportion of active pyruvate dehydrogenase in 
muscle by inhibiting the pyruvate dehydrogenase kinase (Whitehouse 
& Randle, 1973; Whitehouse et al.t 197*+)• Reduction of.alanine 
release was observed from rat hindquarters perfused with dichloro­
acetate (Goodman bt al.t 1978)* Similarly, after functional 
hepatectomy, rats injected with dichloroacetate showed highly 
significant decreases in the rate of accumulation of circulating 
alanine compared to controls (Blackshear et al, 197*+)* These 
findings also demonstrate that pyruvate availability affects 
alanine production by muscle.
The amino groups for alanine synthesis may be derived 
from amino acids other than glutamate if transamination first 
occurs with 2-oxoglutarate to form glutamate for transamination 
via alanine aminotransferase as below:
amino acid + 2-oxoglutarate 55==^ glutamate + 2-oxo acid 
glutamate + pyruvate 55= *  2-oxoglutarate + alanine
Sum: amino acid + pyruvate 2-oxo acid + alanine
As transamination of 2-oxoglutarate in muscle has only 
been found to occur to any great extent with aspartate and the 
branched-chain amino acids, valine, isoleucine and leucine (Krebs, 
1975)» these four amino acids and glutamate must be the principal 
amino group donors for muscle de novo alanine formation.
The equilibrium constant , K, of the leucine aminotrans­
ferase catalysed reaction:
leucine + 2-oxoglutarate v 1 glutamate + 4-methyl-2-
oxopentanoate,
defined by the expression:
Q2-oxoglutarate] £leucine] is 0 65
[^ glutamate] [[4-methyl-2-oxopentanoate]
(Taylor et al., 1970)» ' Since, the equilibrium constant for 
alanine aminotransferase is 0.66, the overall equilibrium 
constant for the sum of the two freely reversible transaminations 
is O.43.
Thus at equilibrium the value of [alanine] x £4-methyl- 
2-oxopentanoate] is twice the value of [[pyruvate] x ^leucine].
The provision of branched-chain amino acids or aspartate to muscle 
should therefore make more glutamate available to the alanine 
aminotransferase catalysed reaction, displacing equilibrium to 
increase alanine formation and its subsequent release. Indeed,
in vitro experiments incubating preparations of diaphragm 
muscle in the presence of the three branched-chain amino acids 
(Odessey et al., 197*+)» incubating isolated epitrochlaris 
muscle in the presence of either leucine, isoleucine, valine 
or aspartate (Garber et al., 1976b), and perfusing hind-limb 
preparations with leucine or valine (Ruderman & Berger, 197*+) 
have demonstrated increased alanine release by the muscle 
preparation.
1.2.3 - The Glucose-Alanine Cycle
In view of the requirement for muscle alanine formation 
and release on the provision of adequate pyruvate, it has been 
proposed that the alanine released by muscle is part of a 
glucose-alanine cycle (Fig. l.l) operating between the liver 
and muscle (Mallette et al., 1969a; Feliget al., 1970)« .It 
was suggested that blood glucose taken up by skeletal muscle 
serves by glycolysis, or via glycogen by glycogenolysis, as the 
source of pyruvate for alanine synthesis. The alanine formed 
is released by the muscle, extracted by the liver as a gluco­
neogenic substrate and the glucose so-formed is returned to the 
circulation. The amount of alanine formed in muscle is thus in 
part, dependent upon the rate of muscle glycolysis or glycogen- 
olysis.
This proposed cycle is similar to that described between 
the liver and skeletal muscle for the interconversion of lactate 
and glucose (Cori, 1931)• Lactate is formed in muscle during 
contraction by anaerobic glycogenolysis. The lactate is
FIG* 1.1 The Glucose-Alanine Cycle (As Proposed by 
Fel'ig et al.t 1970)
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released by the muscle to the liver where it acts as a gluco­
neogenic precursor. The glucose formed is then returned to the 
blood by the liver, taken up by muscle and reincorporated into 
muscle glycogen (Cori, 1931)•
Alanine formation in muscle may function as an alternative 
fate of glycolytically-derived carbon to lactate, thus lessening 
an accumulation of lactate which could disturb the cellular 
redox state. Another possible role of the. proposed glucose- 
alanine cycle is a consequence of muscle not possessing the 
enzymic apparatus to synthesise urea*. Therefore when amino acids 
are deaminated in muscle, ammonia must be removed. This is 
required when amino acids are utilised as a fuel by muscle and 
may also be of importance during exercise. Exercise has long 
been known to increase the production of ammonia by muscle 
(Parnas, 1929» Schwartz et al., 1958). Ammonia formation in 
muscle occurs by virtue of a cyclic interconversion of the purine 
nucleotides, adenosine monophosphate and inosine monophosphate, 
known as the purine nucleotide cycle (Lowenstein & Tornheim, 1971 > 
Lowenstein & Goodman, 1978). The ammonia liberated may possibly 
be used for the synthesis of glutamate (by way of the glutamate 
dehydrogenase catalysed reductive amination of 2-oxoglutarate) 
which can then undergo transamination with pyruvate to form 
alanine, or further amination to form glutamine. During exercise 
net alanine release from muscle rises in proportion to the work 
intensity and hence the extent of anaerobic glycolysis (Wahren,
1979)• An increase in alanine release of 50 % has been observed 
with light work and rises of up to 500 % have been found during
heavy exercise (Felig & Wahren, 197l)» A function of alanine 
release by muscle may therefore be to provide a non-toxic 
alternative to ammonia for the transport of amino groups from 
muscle to the liver.
The glucose-alanine cycle is more useful to muscle than 
the Gori cycle with respect to ATP production. When lactate.-is 
produced from glucose there is a net production of 2 moles ATP 
per mole of glucose. However, when glucose metabolism results 
in alanine formation via transamination of pyruvate, two moles 
of NADH, produced per mole of glucose catabolised from the 
glyceraldehyde 3“Phosphate dehydrogenase step, which would other­
wise have been oxidised by lactate dehydrogenase, remain reduced. 
Since oxidation of NADH through the cytochrome electron-transport 
system leads to the formation of three high-energy phosphate 
bonds i.e. 3 moles of ATP are formed per mole of NADH oxidised, 
the benefit to muscle of glucose metabolism resulting in alanine 
and not lactate, format ion is 6 ATP.; per mole of glucose. Conversion 
of glucose to alanine therefore provides a net yield of 8 moles 
of ATP compared to 2 moles provided by conversion to lactate, 
and also makes available the 2-oxoacid remaining after transamin­
ation for possible oxidation by muscle (Odessey et al., 197^)•
It should be noted, however, that the operation of the 
glucose-alanine cycle as suggested by Mallette et al., (1969h) 
and Felig et al., (1970) does not allow for the provision of 
net carbon for new glucose synthesis during fasting. Carbon is 
merely recycled without any input into the total body glucose 
pool.
It is doubtful whether the glucose-alanine cycle always 
operates as originally proposed with the pyruvate for alanine 
formation being derived entirely from glycolysis. Situations 
in which the rate of alanine production is not directly 
dependent on the rate of muscle glycolysis and in which the 
pyruvate, subsequently transaminated for alanine formation, is 
derived from non-glycolytic sources, are discussed in Chapters 
3 and 4.
1.3 BRANCHED-CHAIN AMINO ACID METABOLISM
1.3*1' Muscle Branched-Chain Amino Acid Metabolism
The findings that branched-chain amino acids readily
transaminate with 2-oxoglutarate in muscle (Krebs, 1975) suggests
their usefulness in providing the amino groups required for
alanine synthesis de novo in muscle.
1I4.
It has been found that G-labelled branched-chain amino
acids injected intravenously in eviscerated rats are catabolised 
' 14producing CO^ while other amino acids are hardly oxidised 
(Miller, 1962). Also, after hepatectomy of dogs, plasma 
concentrations of branched-chain amino acids are decreased while 
those of others are increased (McMenamy et al., 1965) • These 
results suggest that branched-chain amino acids are at least in 
part metabolised extrahepatically. Muscle preparations in vitro 
have been shown to oxidise branched-chain amino acids to CO^ 
(Johnson et al., I96I; Manchester, 1965? Buse & Buse, 1967;
Buse et al., 1972; Odessey & Goldberg, 1972; Goldberg & Odessey,
1972). Comparing the ability of different tissues to oxidise
r 14 -i iZf,
LI- CJ-leucine, the order of the rate of leucine derived CO^
per gram of tissue has been found to be? kidney > brain > adipose -
tissue > muscle ^ liver (Odessey & Goldberg, 1972). However,
if the oxidative capacity is expressed per total weight of
the tissue, the total capacity of muscle to decarboxylate
branched-chain amino acids far exceeds that of other tissues
(Adibi, 1976).
The first two steps in the metabolism of the branched- 
chain amino acids are transamination, followed by oxidative 
decarboxylation of the resulting 2-?oxo acids. The ability of 
tissues to metabolise branched-chain amino acids is therefore 
dependent on the amounts and activities of the enzymes catalysing 
these first two steps.
Branched-chain transaminase activities measured in 
homogenates of various tissues have been found to be highest 
in heart and kidney, followed by brain, diaphragm and leg muscle 
in decreasing order of activity, and lowest in liver (ichihara 
& Koyama, 19 6^; Ichihara et al.t 19^7; Mimura et al., 1968; Wohl- 
hueter & Harper, 1970; Sketcher et al., 197^ ; Sketcher & James, 1974; 
Adibi et al., 1975; Shinnick & Harper, -1976) * Taking into account 
the mass of each tissue, Shinnick & Harper (197&) calculated 
the tissue activity distribution of branched-chain aminotransferase 
in the rat. Muscle made by far the largest contribution to total 
activity (8b %) whereas liver accounted for less than 2 % of 
total branched-chain aminotransferase activity. Similar findings 
were reported by other investigators (ichihara et al., 1973;
Cappuccino et al., 1978).
The low capacity of the liver for the transamination of 
branched-chain amino acids appears to be a major hindrance to 
the oxidation of these amino acids.
In experiments using chicks, addition of kidney homogenate, 
which is rich in branched-chain aminotransferase activity, to 
homogenates of liver and muscle did not increase CO^ production 
from leucine by the muscle but markedly increased CO^ from 
leucine by the liver (Featherston & Horn, 1973)• With rat tissue 
homogenates, oxidation of leucine by liver homogenates low in 
branched-chain aminotransferase activity, was vastly increased 
when heart homogenate was added, much more than would be 
expected from the oxidation of leucine by heart homogenate alone 
(Shinnick & Harper, 1976)• These experiments verify that 
removal of the amino group is a necessary first step for the 
oxidation of branched-chain amino acids and that liver has a 
lower capacity to transaminate BCAAs than some other tissues.
The activity of the enzyme catalysing the second step of 
BGAA metabolism, the branched-chain 2-oxo acid dehydrogenase, 
has also been determined in various tissues. Several invest­
igators failed to detect branched-chain 2-oxo acid dehydrogenase 
activity in muscle homogenates (Dancis et al, 1961; Connelly 
et al., 1968) or tissue slices (Wohlhueter & Harper, 1970) but 
found high activity in the liver. These findings led to the 
suggestion that branched-chain 2-oxo acids are produced by 
transamination of BCAAs in muscle and are then transferred to 
the liver for oxidation (Wohlhueter & Harper, 1970; Krebs & Lund,
1977)* This scheme would account for the presence of branched- 
chain 2-oxo acids in the circulation (Kaser et al., i960).
Indeed, it has recently been shown by arteriovenous difference 
measurements that considerable amounts of branched-chain 2-oxo 
acids are released by rat skeletal muscle into the circulation 
and similar amounts are removed by the liver (Livesey & Lund,
1980). Enzyme activity measurements, using tissue homogenates, 
subsequent to those of Wohlhueter & Harper,(1970)1 have found 
a small but significant activity of branched-chain 2-oxo acid 
de;hydrogenase activity in muscle (Noda & Ichihara, 197^ »
Shinnick & Harper, 1976)> but the percentage contribution by 
muscle to the total branched-chain 2-oxo acid dehydrogenase 
activity in the body was calculated as only about 1 % whereas 
liver contributed over 90 again suggesting the inter-organ 
relationships for whole body BCAA metabolism outlined above.
Studies using different muscle preparations however 
have resulted in largely different values for muscle branched- 
chain 2-oxo acid dehydrogenase capacity. Shinnick & Harper (1976)
calculated dehydrogenase activity in diaphragm muscle homogenates
—I -1as 0.^7 ^ o l  COg produced h g of tissue . Studies using
1^incubations of quarter diaphragms with 0.5 mM-L-Q- C]-leueine
. jZj,
as substia.te have revealed that approximately 2.6yumol GO^ are 
—  1 — 1
produced h g of tissue (Chang & Goldberg, 1978b). Therefore 
the rate of oxidative decarboxylation observed in the tissue 
incubations is greater than the rate of enzyme activity measured 
in cell-free homogenates using saturating substrate concentrations 
and hence supposedly representing estimates of maximum metabolic
capacity. Clearly, as these discrepancies exist between the 
assayed enzyme capacity and enzyme activity in the intact cell 
the conclusions concerning total body BCAA metabolism derived 
from branched-chain 2-oxo acid dehydrogenase measurements in 
various tissues are open to question. Furthermore, the activity 
of branched-chain 2-oxo acid dehydrogenase from a number of 
tissues has been shown to be affected by regulatory factors 
which effect marked variations in the measured activity level 
(Wohlhueter & Harper, 1970r Buse et al., 1975; Pettit et alV, 1978 
Van Hinsbergh et al., 1979)*
It is possible that the extraction procedures and the 
assay conditions can cause alterations in the measured branched- 
chain 2-oxo acid dehydrogenase activity. In fact it has been 
pointed out that the degree of activation of dehydrogenase 
extracted from various tissues of the rat varies considerably. 
Activation is near maximal in preparations from kidney and liver, 
whereas the dehydrogenase from heart and skeletal muscle is 
almost completely inactivated (Odessey, 1980). The comparison 
of branched-chain 2-oxo acid dehydrogenase activities from 
different tissues cannot therefore be made unless the state of 
activation or inactivation of the enzyme from each tissue is 
taken into account. These findings suggest that muscle may 
play a greater role in the oxidation of BCAAs than was suggested 
by Shinnick & Harper, (1976).
Species differences in the metabolism of BCAAs have 
been suggested by the studies of Khatra et al. (1977a). These 
workers showed that in rat over 70 % of the total body content
of branched-chain. 2-oxo acid dehydrogenase activity was located 
in the liver and, although the specific activity of the enzyme 
in muscle was only 1 - 2 % of the specific activity in the liver, 
muscle accounted for 10 ^  of whole body branched-chain 2-oxo acid 
dehydrogenase activity. In man, the specific activity of 
the enzyme in liver was only about 5 % of that found in rat 
liver, whereas the specific activity of the enzyme in human 
muscle was similar to that in rat muscle. Consequently the 
distribution of the dehydrogenase activity in man was different 
from that found for the rat, with liver only comprising 30 
and muscle over 60 %, of the measured whole body activity of the 
enzyme. This suggests that muscle is an important site of 
BCAA metabolism in man, more so than in the rat. An alternative 
explanation is that in liver preparations from man, in contrast 
to those from the rat, the dehydrogenase is considerably inactivated 
However, in agreement with the former interpretation is the 
finding that branched-chain 2-oxo acid transfer between muscle 
and liver in man is small compared to the rat (Elia & Livesey,
1981).
Three isoenzymes of the branched-chain aminotransferase 
have been reported and designated types I, II,and III (ichihara 
et al., 1975)* Type II which is found only in the liver, is 
specific for leucine (Goto et al., 1977) whereas types I and III 
are capable of transaminating all three BCAAs. Whereas the Km's 
of isoenzymes I and III for leucine .are approximately 2.5 - 
isoenzyme II differs in that its Km for leucine is very much 
higher, approximately 25 mM (ichihara et al., 1975). Enzymes
I and III have' very similar Km values for the threeu BCAAsbbut 
their tissue distribution and chromatographic and immunochemical 
properties differ. Isoenzyme III is found in the brain, ovary 
and placenta and predominates in fetal and cancerous tissue 
(Ichihara et al., 1975). Isoenzyme I however, is the only iso­
enzyme present in kidney, muscle, heart, spleen, lung, gut, 
adipose tissue and lactating mammary gland. Hence the trans­
amination of BCAAs in muscle is believed to be catalysed by an 
aminotransferase (Type i) which accepts all three BCAAs (leucine, 
valine and isoleucine) as substrates (ichihara et al, 1975)* 
Similarly, in muscle, a single branched-chain 2-oxo acid 
dehydrogenase complex is believed to accept all three BCAAs as 
substrates (Connelly et al., 1968? Odessey & Goldberg, 1979)•
It appears to be generally accepted that the remaining 
steps in the pathways for further catabolism of BCAAs by muscle 
are those-which have been established for their catabolism in 
liver (Meister, 1965; Rodwell, 1969) as shown for the catabolism 
of leucine and valine in Fig. 1.2. Although it has been reported 
by McGarry & Foster. (1969) that 3-hydroxy-3-methylglutaryl-CoA 
(HMG-CoA) lyase, the enzyme which catalyses the cleavage of HMG- 
CoA, was not found in homogenates of rat skeletal muscle, 
evidence to the contrary has been presented. Van Hinsbergh et al. 
(1979) studied the oxidation of ^ -methyl-2-oxopentanoate by 
intact rat skeletal muscle preparations and found that a large
Ah r  1^  -1 1proportion of the CO^ released from [U- CJ-4*-methyl-2-oxo- 
pentanoate was derived other than from the C-l position. For 
this further oxidation of ^-methyl^-oxopentanoate carbon to
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GOg to occur, by the catabolic route‘shown in Fig. 1.2, the
carbon chain must first be cleaved and such a pathway would
require the presence of 3“hydroxy-3“methylglutaryl-GoA lyase.
Valine carbon is also believed to be metabolised in
muscle by the route established in liver. Support for.this
has come from the reports that an intermediate of that pathway,
3~hydroxyisobutyrate is released from isolated rat hindquarters
perfused with valine (Spydevold, 1979) and that when isolated
r 1^ ~ihindquarters of rats starved for ^ 8 h are perfused with L.U- CJ-
iZj.
valine, G-labelled tricarboxylic acid cycle intermediates are
found..in muscle.
1.3.2 Branched-Chain Amino Acids and the Regulation of Protein 
Turnover in Skeletal Muscle
Branched-chain amino acids, and leucine in particular,
appear to be able to influence rates of protein synthesis and
degradation in muscle. The effects of adding glucose, amino
acids and the BCAAs on the synthesis and breakdown of protein
in diaphragm preparations from fed and starved rats have been
studied (Fulks et al., 1975)* Diaphragms from both fed and
starved-rats showed increased synthesis and decreased breakdown
of protein when amino acids were added at 5“fold normal or
normal plasma concentrations. These changes could be entirely
accounted for by the BGAAs alone. Similarly, Buse & Reid (1975)
observed that when a mixture of all three BGAAs (each at 3■ mM)
rl^was added to the incubation medium, L CJ-lysine incorporation 
into protein was stimulated by 20%, In fact, leucine alone at
0.5 mM stimulated incorporation by 25 %t whereas 0.5 mM-valine 
or isoleucine alone had little effect. These effects of leucine 
are of interest because they were demonstrated with leucine 
concentrations which are within the range over which blood 
leucine concentrations change in the fed and fasted states 
(Adibi, 1976)! and because they only occur in muscle. In liver 
or fibroblasts, BGAAs have no such effect (Goldberg & Tischler, 
1981).
The two effects of leucine i.e. stimulation of protein 
synthesis and inhibition of protein breakdown apparently involve 
different mechanisms. Experiments using a presumed inhibitor 
of leucine transamination, D,L-cycloserine, have shown that 
protein synthesis is stimulated when leucine is added to muscle 
incubations containing cycloserine to the same extent as in the 
absence of cycloserine.. However,, this transaminase inhibitor 
completely blocks the decrease in protein breakdown in muscle 
caused try leucine (Goldberg & Tischler, 1981). The inhibition 
of protein breakdown therefore requires leucine catabolism while 
increased protein synthesis does not. In support of the above 
suggestion, it has been shown that incubating muscle with the
2-oxo acid derived from leucine, 4-methyl-2-oxopentanoate, did 
not stimulate protein synthesis, but, like leucine, did inhibit 
protein breakdown (Goldberg & /Tischler, 1981). How these effects 
are mediated is at present unknown.
1.3*3’ Branched-Chain Amino Acids and Alanine Release from
Muscle
As noted above BGAA release by muscle is less than 
would be expected from their relative frequency in muscle 
proteins (Ruderman & Berger, 197*0 and in contrast with most 
other amino acids, that are largely metabolised in the liver, 
the principal tissue initiating BGAA metabolism in the body is 
muscle (Adibi, 1976). In vitro studies have shown that BGAAs 
are very effective in stimulating alanine formation and release 
by muscle (Ruderman & Berger, 197*H Odessey et al., 197*b Garber 
et al., 1976b). The greater release of alanine by the isolated 
muscle of starved rats compared with fed rats when BGAAs are 
added to the medium, seems related to the enhanced muscle 
oxidation of BCAAs in starvation (Odessey et al., 197^? Hutson 
et al., 1980). The in vivo rate of oxidation of leucine has 
been observed to increase when rats are starved for b days 
compared with fed controls (Meikle & Klain, 1972). Human patients 
undergoing weight reduction by fasting also showed a marked 
increase in the rate of leucine oxidation in vivo soon after 
starting to fast, which continued as long as caloric deprivation 
was maintained (Adibi, 1980).
Plasma concentrations of BGAAs in humans are greatly 
affected by alterations in dietary status. In response to 
fasting in man the most dramatic and prompt changes in plasma 
concentrations of amino acids are those of the BGAAs and alanine. 
Starvation, even for only one day, increases the concentrations 
of all three BGAAs in the plasma of healthy human subjects (Adibi,
1976). The levels of these BGAAs reach a'peak value by the 
second day of starvation and remain elevated during the first 
week. Resumption of a regular diet during the first week of 
starvation or prolongation of starvation to 2 weeks lowers the 
concentrations of BCAAs to basal levels. The direction of change 
in plasma concentrations of alanine during starvation is the 
opposite to that of the BGAAs (Adibi, 1976). Thus, in a situation 
of enhanced gluconeogenesis when hepatic extraction of alanine 
is increased and muscle release of alanine is increased, plasma 
concentrations of the BCAAs are increased - again suggesting a 
connection between the BGAAs and alanine release by muscle.
Dietary induced changes in plasma concentrations of BGAAs in rats 
are similar to those described in man. Starvation increases the 
concentrations of all three BGAAs in rat plasma, although the 
development of hyper branched-chain aminoacidaemia is not as 
rapid in the rat as it is in man (Adibi, 1971 )• In adult rats 
the plasma concentrations of BGAAs become elevated after 6 days 
of starvation, while in man they are increased after 1 day of 
fasting (Adibi, 1976). The source of these amino acids has not 
been defined although they may come in part from the liver which 
releases BGAAs during starvation in rats (Mallette et al., 1969b; 
Bloxham, 1972) and man (Marliss et al., 197l)»
Some investigators have maintained that under physiological 
conditions the relationship involving branched-chain amino acids 
and muscle alanine formation is confined to transamination, 
glucose being the main source of pyruvate for alanine synthesis 
in muscle (Chang & Goldberg, 1978a,b; Felig & Koivisto, 1979)*
Patients with hereditary enzymatic defects in the 
oxidative decarboxylation of BGAAs (maple syrup urine disease) 
have low serum alanine levels (Haymond et al., 1973; 1978).
Studies of alanine fluxes in these patients have indicated that 
BGAA catabolism is an important rate-limiting event for alanine 
production in vivo (Haymond et al., 1978), and therefore suggest 
that the involvement of BGAAs with muscle alanine release is 
dependent on metabolism of BCAAs beyond the transamination step.
Thus although it has been suggested that glucose is the 
principal source of pyruvate for alanine synthesis in muscle and 
that BGAA involvement in alanine formation is restricted to 
transamination, whatever the origin of pyruvate, the above 
findings demonstrate a relationship between alanine release and 
BGAA oxidation by muscle.
It has been shown that muscle is capable of fine control 
of the level of tricarboxylic acid cycle intermediates in order 
to maintain optimal oxidative conditions in various physiological 
situations, heart and skeletal muscle both having an increased 
content of tricarboxylic acid cycle intermediates in fasting or 
diabetic animals (Davis et al’., 1980). Challenging glucose- 
perfused rat hearts with a fatty acid or oxaloacetate (Williamson, 
1965» Bowman, 1966; Randle et al, , 1970* Davis & Bremer, 1973) also 
results in an elevation in the level of endogenous intermediates 
of the tricarboxylic acid cycle. A similar but smaller effect 
has also been seen with perfused skeletal muscle ( Spydevoid Vet al., 
1976) and it was suggested that muscle was capable of replenishing 
tricarboxylic acid cycle intermediates by carboxylation reactions
Indeed it has been shown that GO^ can be continuously fixed 
into carboxylic acids in skeletal muscle and that acetate and 
pyruvate stimulate this process (Lee & Davis, 1979)*
The metabolism of BGAAs results in the formation of
2-carbon units from leucine, but isoleucine and valine are 
converted to 4-carbon units that may replenish the tricar boxy fie 
acid cycle intermediate pools (Spydevold et al., 1976; Lee &
Davis, 1979)*
If valine and isoleucine do indeed contribute 4-carbon 
units to the tricarboxylic acid cycle which are subsequently 
used for alanine formation, then mechanisms must exist for the 
efflux of cycle intermediates to form 3-carbon compounds. Lee 
& Davis (1979) have suggested that such mechanisms are present 
in skeletal muscle. Muscle decarboxylation reactions result in 
the conversion of 4-carbon skeletons to the 3-carbon compound 
pyruvate and hence by transamination to alanine, showing a 
means whereby the carbon of amino acids can form the carbon 
skeleton of alanine released by the muscle. The possible 
existence of such a pathway therefore implies that in some 
situations alanine released from muscle and subsequently used as 
a precursor for hepatic gluconeogenesis may be protein-derived 
and hence capable of making a net contribution to the total 
glucose pool.
The above scheme would therefore provide mechanisms for 
control of the level of the endogenous pool of cycle intermediates 
net synthesis of a 3-carbon glucose precursor from a non­
carbohydrate source and amino nitrogen release from mus cle during
net protein breakdown.
Possible alternative routes for alanine synthesis from 
valine in muscle are-shown in Fig. 1.3. The routes differ by 
the enzymes which decarboxylate 4-carbon intermediates of 
the tricarboxylic acid cycle and supply pyruvate for alanine 
formation.
Route (a) is via malic enzyme (either NAD- or NADP-specific);
Route (b) is via "oxaloacetate decarboxylase"; and
Route (c) involves the enzymes phosphoenolpyruvate carboxy- 
kinase (PEPCK) and pyruvate kinase.
Skeletal muscle has been reported to contain appreciable amounts 
of malic enzyme (Nolte et al., 1972; Lee & Davis, 1979) and . 
PEPCK activities (Opie & Newsholme, 1967; Newsholme & Williams,
1978).
1.4 -AIMS OF THE PRESENT STUDY
The main aims of the present study were therefore to 
firstly establish that BGAAs stimulate alanine release from 
muscle, and then to clarify the possible relationship between 
BGAA metabolism and muscle alanine release and the possible 
sources of pyruvate .involved in de novo alanine formation in 
different nutritional states.
An attempt was made to determine whether BGAAs are 
capable of contributing carbon for de novo pyruvate and hence 
alanine formation in muscle and to elucidate the pathway(s) by 
which this could occur.
The Chapters which follow describe and discuss the
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Fig. 1.3
Alternative Routes of Alanine Synthesis in Muscle
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results of studies on alanine formation and BGAA metabolism 
in vitro in various physiological states and the measurement 
of relevant enzyme activities in muscle extracts, as well as 
investigating the subcellular distribution of some of these 
enzymes.
G H A  P T E R  T W O
MATERIALS AND METHODS
MATERIALS AND METHODS
2.1 CHEMICALS
1 ft, 1 II
Sodium £ C] bicarbonate (Q.l mCi.mmol ), L-Cl- CQ— 
leucine 50 mCi.mmol” )^, L-[jJ— \G-leucine (> 300 mCi.mmol""^ ), 
L-Cl'-^\f]-valine (*K) - 60 mCi.mmol’"^') and L-Cu-^C]-valine 
(> 250 mCi.mmol ) were obtained from Amersham International 
(formerly The Radiochemical Centre), Amersham, Bucks., U.K.
L-alanine dehydrogenase (EC 1.4.1;. 1), glutamate dehydrogenase 
(EC 1.^.1.2), lactate dehydrogenase (EC 1.1.1.2?), malate 
dehydrogenase (EC 1.1.1.37)» pyruvate kinase (EC 2.7*1.^0), 
hexokinase (EC 2.7*1«l)» glucose 6-phosphate dehydrogenase 
(EC 1.1.1.^9)» adenosine 51-diphosphate (disodium salt), 
p-nicotinamide-adenine dinucleotide (NAD), 0-nicotinamide- 
adenine dinucleotide, reduced ()NADH) (disodium salt), phospho­
enolpyruvate (sodium salt), oxaloacetic acid, 2-oxo-glutarate, 
streptozotocin '(N-D-glucosyl-(2)-N'-nitrosomethylurea), 
dithiothreitol, antimycin A and glucose test combination kit 
(glucose oxidase (EC 1.1.3*^)-peroxidase (EC 1.11.1.7) method) 
were obtained from Boehringer Corporation Ltd., Lewes, Sussex,
U.K.
Glutaminase (EC 3•5•1 * 2), adenosine 51-triphosphate 
(disodium salt), inosine 5’-diphosphate (sodium salt), inosine 
5'-triphosphate (sodium salt), acetyl coenzyme A (sodium salt), 
pyridoxal 5-phosphate, cycloheximide, 5»5'-dithiobis-(2-nitro- 
benzoic acid) (DTNB), tartronic acid (hydroxymalonic acid), 
aminooxyacetic acid, ^-methyl-2-oxopentanoic acid (oc-ketoiso-
caproic acid), 3“me‘thyl-2-oxobutanoic acid (a-ketoisovaleric 
acid), l-nitroso-2-naphthol, tyrosine standard solution 
(L-tyrosine, 0.025 mg/ml, in 0.2M trichloroacetic acid), 
L-leucine, Tris Ctris(hydroxymethyl)aminomethane], Hepes Qf-(2- 
hydroxyethyl)-1-piperazine-ethanesulphonic acid] and "Dowex"-50W 
(H+ form) cation exchange resin (8 % cross linked, 200 - ^ 00 
dry mesh) were obtained from Sigma Chemical Company Ltd.,
Poole, Dorset, U.K.
3-nicotinamide-adenine dinucleotide phosphate (NADP) 
was obtained from Cambrian Chemicals, Croydon, Surrey, U.K.
2,5-Diphenyloxazole (PPO) was obtained from Packard 
Instruments Company Inc., Downers Grove, 111., U.S.A. and 
l,4-di-(2-(^-methyl-5-phenyloxazolyl)-benzene (dimethyl P0P0P) 
from Fisons Scientific Apparatus, Loughborough, Leics., U.K. 
Synperonic NX supplied by Durham Chemicals Distributors Ltd., 
Birtley, Tyne and Wear,, U..K-. ? and hyamine 10X (hydroxide) by 
Intertechnique, Uxbridge, Middx., U.K.
The following generous gifts were received*
3-mercaptopicolinic acid from Dr. H.L. Saunders (SK & F 
Laboratories, Philadelphia, Pa., U.S.A.), L-cycloserine from 
Dr. D.H. Williamson (Nuffield Department of Clinical Medicine, 
Radeliffe Infirmary, Oxford,. U.K.); hypoglycin A from Dr. E.A. 
Kean (University of the West Indies, Kingston, Jamaica);
3-aminopicolinic acid from Dr. C.H. Reynold (Wellcome Foundation 
Ltd., Dartford, Kent, U.K.); L-2-amino-^-methoxy-trans-but-3- 
enoic acid from Dr. W.E. Scott (Hoffman-La Roche Inc., Nutley, 
N.J., U.S.A.) and clofibric acid from Dr. G.G. Gibson (University
of Surrey, Guildford, Surrey, U.K.
L-valine, insulin (crystalline, bovine), agidex powder 
(amyloglucosidase (EG 3*2.1.3) preparation), dichloroacetic 
acid, hydrazine hydrate, ninhydrin reagent spray and other 
inorganic chemicals were from BDH Chemicals Ltd., Poole, Dorset, 
U.K.
2.2 TREATMENT OF ANIMALS
Male rats of a Wistar Albino strain, bred in and obtained 
from the Animal Unit of the University of Surrey (.Director:
Mr. P. Scobie-Trumper) were maintained in conditions of 12 hours 
light, 12 hours darkness at 21 ± 2°C, were allowed free access 
to water at all times and were fed (Spratt's Laboratory Diet 
No. 1 pellets (Table 2.l), Spratt's Patent Ltd., Barking, London, 
U.K.) ad libitum unless otherwise stated.
2,2.1 Dietary Supplements
Some rats were weaned onto a powdered diet (Spratt's 
Laboratory Diet No. 2 (Table 2.1), Spratt’s Patent Ltd., Barking, 
London, U.K.). After 4 days on the powdered diet, rats were 
transferred to powdered diet supplemented with L-valine (5 1'w/w) 
or L-leucine (5 % w/w) and remained fed ad libitum on the diets 
for approximately 21 days until sacrifice. Controls were 
maintained on the unsupplemented powdered diet throughout.
2.2.2 Streptozotocin Treatment
Rats, which had been fasted for 24 h, were injected
TABLE 2.1 Composition of Spratt's Laboratory Diets
Average Calculated' Composition of Laboratory Animal Diets
Laboratory Diet 1 Laboratory Diet 2 
(pelleted) (powdered)
Chemical Composition
Moisture {%) 8.8 8.8
Ether Extract (%) 3*5 3*5
Crude Protein \%) 21.5 21.5
Crude Fibre {%) ' 2.7 2.7
Gross Energy (Mj/kg) 17.2 17*2
Digestible Energy (MJ/kg) 14.2 14.2
Vitamin and Mineral Composition
Lysine {%) " 1.1 1.1
Methionine (%) 0.39 0.39
Calcium {%) 0.9 0.9
Phosphorus (%) 0.8 0.8
Vitamin A (i.u./kg) 11,000 11,000
Vitamin D^ (i.u./kg) 1,200 1,200
a-tocopherol (i.u./kg) 24 24
Vitamin (mg/kg) 10 10
Riboflavin (mg/kg) 7 7
Pyridoxine (mg/kg) 1 1
Pantothenic Acid (mg/kg) 17 17
Nicotinic Acid (mg/kg) 80 80
Folic Acid (mg/kg) 0.2 0.2
Choline Chloride (mg/kg) 450 450
Cyanoco.balamin, ( g/kg) 15 15
Manganese (mg/kg) 65 65
Iron (mg/kg) 100 100
Iodine (mg/kg) 0.5 0.5
Copper (mg/kg) 20 20
Zinc (mg/kg) 40 40
Cobalt (mg/kg) 1 1
intraperitoneally with streptozotocin (lOOmg in 0.01 M Na citrate/
kg body weight) and then allowed to feed ad libitum. Two
days after injection, rat urine was checked for the presence
of glucose using Bili-Labstix (Ames Co., Stoke Poges, Slough,
Bucks., U.K.). If the glucose concentration found in the urine
-1was greater than 28 mmol.l the animals were designated 
"streptozotoein-diabetic” and sacrificed by decapitation.
Trunk blood was collected and blood'glucose concentration 
measured. Experimental parameters measured on tissues from 
the animals were only accepted as characteristic of "strept ozo- 
tocin-diabetic" animals when blood glucose levels in fed 
animals were > 15 mM. Control rats were injected with equivalent 
volumes of 0.01M Na citrate.
2.2.3 Triiodothyronine Treatment
Rats were given intraperitoneal injections of L-triiodo- 
thyronine (L-T^), dissolved in 0.9 % NaCl-5 mH-NaOH, at a dose 
of 250 yug L-T^/kg body weight daily for 6 days (Carter et al.,
1981). Control animals were injected over the same time period 
with equivalent volumes of diluent.
2.3 IN VITRO SKELETAL MUSCLE PREPARATIONS AND INCUBATIONS
2.3*1 Cut Hemi-diaphragm Preparations and Incubations
Hemi-diaphragm preparations were obtained from rats 
weighing 65 - 100 g. Above this weight the flat diaphragm 
becomes too thick to ensure that cells within the muscle are
exposed to concentrations of nutrients similar to those found 
in the incubation medium, and that the entire muscle is 
adequately oxygenated (Goldberg et al., 1975)*
Rats were killed by cervical dislocation and the 
diaphragms rapidly dissected free of the rib cage. After 
cutting through the skin on the ventral surface, the lower 
edge of the diaphragm was freed by cutting the several 
ligamentous attachments of the liver. The oesophagus and vena 
cava were severed below the diaphragm. The pleural cavity 
was exposed by snipping the diaphragm from the ribs close to 
the costal border. Peri cardial membranes were severed above 
the diaphragm and the diaphragm carefully trimmed free from 
the ring of ribs to which the muscle was attached.
The area of the diaphragm through which passed the 
oesophagus and vena cava is too thick to allow adequate 
oxygenation of all fibres at 37°G (Goldberg et al.♦ 1975) an<i 
was therefore cut away and discarded.
The remaining tissue was gently blotted, dried and 
bisected down the central tendon to yield heiai-diaphragms.
After rapidly weighing the hemi-diaphragms they were promptly 
placed in individual 10 ml flasks containing 2 ml of unsupplemented 
Krebs & Henseleit (1932) saline at room temperature. The 
Krebs-bicarbonate buffer had been equilibrated with 95 % 0^ :
5 % COg and contained 119 mM-NaCl, 5 mM-KCl, 3 mM-GaGl^, 1 mM-MgSO^, 
1 mM-KHgPO^ and 25 mM-NaHCO^ at pH 7*4. The flasks were gassed 
with Og/COg (95 %l5 %) for 1 min, tightly stoppered and incubated 
for 30 ifrin at 37°G in a shaking incubator (Mickle Laboratory 
Engineering Co., Gomshall, Surrey, U .K.) at 50 cycles min .
At the end of the 30 min pre-incubation period, the hemi- 
diaphragms were removed from the flasks, blotted dry, and 
transferred into flasks containing fresh Krebs-Henseleit 
saline and substrates or other additions as indicated. After 
gassing and sealing the flasks, they were incubated, for 2 h 
at 37°G in the shaking incubator. In preliminary experiments 
it was shown that re-gassing the flasks after incubation for 
1 h had no significant effect on the parameters measured.
2.3*2 Intact Soleus and Extensor Digitorum Longus Muscle
Preparations and Incubations
Preparations of intact soleus and extensor digitorum 
longus (EDL) muscles were obtained from rats weighing 50 - 70 g. 
Both of these leg muscles are cylindrical and in rats weighing 
more than 70 g the muscles are of sufficient thickness to 
cause problems of diffusion of nutrients into the incubated 
muscle (.Goldberg et al., 1975).
Soleus and EDL muscles are useful for studies comparing 
muscle types since they contain substantially different 
proportions of muscle fibre type. Approximately 80 - 90 % 
of the fibres of the soleus muscle are of the red slow-twitch 
variety whereas the EDL muscle contains primarily fast-twitch 
fibres (approximately 50 % white and 50 % fast-twitch red fibres) 
and very few slow ones (Close, 1975; Maizels et al., 1977).
Procedures for the dissection of soleus and EDL muscles 
were basically as described by Maizels et al., (1977).
Rats were killed by cervical dislocation and both hind-
limbs removed. Soleus and EDL muscles were dissected from 
both limbs thus yielding four muscle preparations per animal. 
After removing the skin, hind legs were anchored to the 
dissection board with dissection pins. The Achilles tendon 
was exposed and tied. The tendon was cut distal to the tie 
and the soleus and gastrocnemius (which also inserts into the 
Achilles tendon) muscles pulled away by traction to expose the 
proximal tendon of the soleus. By a combination of blunt and 
sharp dissection, the gastrocnemius muscle was peeled away 
from the soleus. A second tie was then placed around the 
proximal tendon of the soleus and the tendon cut proximal to 
the tie. The freed soleus was then extended and tied to a • 
stainless-steel frame and weighed. The frame and ties had 
been pre-weighed and hence muscle weight was obtained by 
difference.
After removal of the soleus, legs were turned and pinned 
to the dissection board. The tendon of the EDL was exposed, 
tied and cut distal to the tie. The EDL was exposed by combining 
traction and sharp dissection until its proximal tendon, 
attached to the patella, was exposed. The proximal tendon was 
tied and cut proximal to the tie. The isolated EDL was then 
secured to a stainless-steel frame and weighed as for the soleus.
Stainless-steel frames were employed to maintain the 
muscles under slight tension during the incubation procedures. 
After weighing, and trimming away excess cotton ties, muscles 
and frames were placed into polystyrene tubes (LP3, 10.5 mm x 
63.5 mm) containing 1.5 ml of Krebsf^enseleit saline at 37°C
and the tubes were stoppered, connected to the gassing apparatus 
which allowed continuous gassing of the media with 95 % Og s 5 % GO^ 
and agitation of the tissue, (Fig. 2.l) and incubated for JO min 
at 37°G.
After the 30 min pre-incubation period, frames and 
muscles were transferred to 1.5 ml of fresh medium containing 
any appropriate addition(s), and incubated for 2 h at 37°G 
with continuous gassing.
2.3.3 Processing of Samples
At the end of the incubation period the muscle preparation 
was removed and the incubation medium deproteinised by adding 
ice-cold 20 % (w/v) perchloric acid (HCIO^) (0.1 ml/ml medium) 
final concentration 0.18M). The acidified medium was centrifuged 
at 4°C and a known volume of the supernatant was neutralised 
with KOH. Further centrifugation at 4°C precipitated KCIQ^ 
and yielded a neutralised supernatant which was decanted and 
stored on ice prior to determination of metabolites within J 
hours.
When muscle tyrosine release was measured, 0.25 ml of 
incubation medium was added to 0.25 ml of ice-cold 0.6M trichloro­
acetic acid (CCl^COOH), centrifuged at 4°C and 0.4 ml of the 
resulting supernatant used for tyrosine determination.
When muscle content of metabolites was measured, on 
removal from the incubation medium the muscle preparation was 
quickly blotted and dropped into liquid The muscle was
powdered with a mortar and pestle pre-cooled with liquid
FIG. 2.1 Gassing Apparatus for Intact Leg Muscle Preparations
«t 1 ijil. syringe ‘barrel
LP3 Tube
Incubation Medium 
Portex Tubing
. Needle (25G)
Stainless Steel Frame
Soleus or Extensor digitorum 
longus: maintained: under 
slight tension
allowed to thaw into 1 ml 0.27M-perchloric acid (HGIO^) and 
homogenised using a ground-glass homogeniser and pestle. 
Neutralised extracts were prepared as for the incubation media.
A paired experimental design was used in every set 
of tissue incubation experiments e.g. one hemi-diaphragm 
from each rat was incubated in control medium and its pair 
in experimental medium. Similarly, soleus or EDL muscle from 
one leg was incubated in control medium while the corresponding 
muscle from the other hindleg was incubated in test medium.
Control flasks and tubes which did not contain muscle 
preparations but which contained the same incubation media 
as those used experimentally were simultaneously incubated in 
all studies. These control incubation media were treated 
identically to media in which muscle had been incubated and 
the resulting neutralised supernatants served as "blanks" in " 
metabolite assays.
2.4 METABOLITE ASSAYS
Spectrophotometry was carried out using a Gilford 
Model 250 Spectrophotometer (Gilford Instrument Laboratories 
Inc., Oberlin, Ohio, U.S.A.) fitted with a model 2451 automatic 
cuvette programmer, a constant temperature cell housing, and 
a Servoscribe RE 542-20 Chart recorder. 10 mm light-path 
silica cuvettes were used, either 3 ml or 1 ml volume,
A Perkin-Elmer 3000 Fluorescence Spectrometer (Perkin- 
Elmer Ltd., Beaconsfield, Bucks., U.K.) was used for fluorimetric 
measurements.
Alanine was determined enzymatically on aliquots of 
neutralised samples "by the method of Williamson (197*0 • The 
reaction observed was catalysed by the enzyme L-alanine 
dehydrogenase:
L-alanine + NAD+ H^O v pyruvate + MDH + H+ 
Hydrazine served to trap pyruvate in this system and 
the resulting increase in MDH was measured by the increase in 
absorbance at 3*^ 0 11111 after incubation at 30°C for 60 min, by 
which time the reaction was complete. In some cases NADH was 
measured fluorimetrically rather than spectrcphotometrically.
The excitation wavelength was 3*^ 0 11111 and the emission wave- 
; length was ^ 60 nm (Taegtmeyer et al., 1977)*
It has been shown that some commercial preparations of 
alanine dehydrogenase are. contaminated to varying extents with 
activity towards BCAAs and thus the presence of BCAAs in the 
assay for alanine can- give falsely high values (Lund & Baveral, 
1978). Although some slight activity towards BCAAs was observed 
with alanine dehydrogenase, at no time were any of the enzyme 
preparations contaminated to the extent observed by Lund & 
Baverel (1978). ; Neutralised extracts of incubation media, 
incubated without muscle, served as assay blanks in the present 
studies, hence correcting for any interference.
. Glutamate in neutralised samples was determined spectro- 
photometrically using glutamate dehydrogenase as described by 
Bernt & Bergmeyer, (197*0• To assay glutamine, an aliquot of 
sample was first treated with glutaminase to covert glutamine to 
glutamate (Lund, 197*0 and the total glutamate in the sample was
then measured. Glutamine was then calculated as the difference 
between the basal and glutaminase-treated samples.
Lactate and pyruvate were determined spectrophotometrically 
using lactate dehydrogenase by the methods of Hohorst (1963) 
and Bucher et al., (19^3)* respectively, and malate was 
measured spectrophotometrically using malate dehydrogenase 
by the method of Gutmann & Wahlefeld, (197*+) •
Tyrosine was measured by a modification of the method of 
Wong et al., (1964). Tyrosine reacts with l-nitroso-2-naphthol, 
forming a red colour. This coloured complex is unstable, but 
when heated in the presence of nitric acid forms a stable 
yellow compound which is fluorescent. The fluorescence was 
measured with an excitation wavelength of 440 nm and emission 
wavelength of 535 nm* and values for tyrosine obtained from a 
standard curve (prepared with L-tyrosine) which was linear over 
the range in which test values lay.
Adenosine 5'-triphosphate in neutralised tissue extracts 
was determined using hexokinase and glucose 6-phosphate dehydro­
genase (Lamprecht & Trautschold, 1974).
Glucose in neutralised samples was measured spectro­
photometrically with hexokinase and glucose 6-phosphate dehydro­
genase by the method of Slein (1963) or by the method of Werner 
et al., (1970) using glucose oxidase (EG 1.1.3*4) and peroxidase 
(EG 1.11.1.7)« Blood glucose was determined by the above two 
methods after deproteinisation with HCIO^ (0.24M, final conc­
entration).
Muscle glycogen was isolated as described by Cowgill
and Pardee (1957)* The muscle preparation was blotted dry and 
digested in JO % (w/v) KOH in a boiling-water bath for JO min.
The digest was then cooled to 40 - 50°0 and 95 % (w/v) ethanol 
added. After thorough stirring the mixture was incubated at 
80 - 90°C for 5 min, cooled to room temperature, centrifuged 
and the supernatant discarded. Glycogen was then redissolved 
in O.OjJM-sodium acetate buffer, pH 4.5* Glycogen concentration 
was determined after enzymic hydrolysis with Agidex, a preparation 
of amyloglucosidase, as described by Vernon & Walker (1970). 
Glycogen-derived glucose was estimated as described above.
2.5 CENTIFUGATION AND FRACTIONATION
2.5.1 Crude Extracts of Muscle
"Crude extracts” of diaphragm, soleus and EDL muscles 
were prepared by homogenising freshly dissected muscles, 
using a ground-glass homogeniser and motor-driven pestle, in 
9 volumes of ice-cold extraction medium consisting of 100 mM- 
Tris/HCl, 1 mM-EDTA, 5 mM-MgCl^ and 20 mM-2-mercaptoethanol at 
a final pH of 7*5 (Crabtree et al., 1972). The 10 % (w/v) 
homogenates were centrifuged at 600 g for 10 min at 4°G in 
a Beckman J-6 centrifuge (Beckman-RIIC Ltd., High Wycombe,
Bucks., U.K.). The resulting supernatants were termed "crude 
extracts”.
2«5«2 Subcellular Fractionation of Muscle
Subcellular fractionation of muscle was attempted by 
the methods described below and each fraction obtained was 
sonicated at 0 - 4°C (4 x 15 s at %  using a Soniprobe type 
1130/lDawe Instuments Ltd., London, U.K.) prior to assaying 
£.or__enzyme activities.
Method 1 - Rat muscle was minced in buffer as described 
by Crabtree et al. (1972). The tissue was homogenised using 
an all-glass homogeniser and the volume of homogenate adjusted 
to be ten times the weight of the tissue. The homogenate (H) 
was centrifuged at 800 g for 10 min, the supernatant (S^ ) 
decanted and the pellet (N) washed and resuspended in buffer.
The 800 g supernatant (S^) was centrifuged at 20,000 g for 
10 min. The pellet was then washed, re suspended in buffer 
and denoted the mitochondrial pellet (MT) and the supernatant 
(Sg) centrifuged at 100,000 g for 60 min. The resulting super­
natant was called the cytosolic fraction (c) and the pellet 
when rinsed and re suspended in buffer, denoted as the microsomal 
suspension (MC).
Method 2 - the method of Odessey & Goldberg (1979).
Rat muscle was minced and washed at 0 - 4°C in buffer A, 
consisting of 0.25 M-sucrose, 50 mM-KCl, 5 inM-MgCl^ i 5 mM- 
EGTA and 50 mM-Tris/HCl, pH 7*8. The tissue was homogenised 
using a motor-driven all-glass homogeniser and the volume of 
homogenate adjusted to give a final concentration of 100 mg 
tissue/ml. The homogenate (h) was centrifuged at 800 g for 
5 min, the supernatant (S^ ) decanted and the pellet re-extracted
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FIG. 2.2 Subcellular Fractionation of Muscle by Method 1 
(Crabtree et al.t 1972)
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FIG. 2.3 Subcellular Fractionation of Muscle by Method 2 
(Odessey & Goldberg, 1979)
in the above buffer and recentrifuged at 800 g for 5 min. Both 
800 g supernatants were then centrifuged at 10,000 g for 10 min. 
The 10,000 g supernatant of the second 800 g fraction (Sq) was 
discarded. The 10,000 g pellets from both fractions were 
combined, washed,resuspended in buffer B (0.25 M-sucrose, 50 mM- 
KC1, 10 mM-MgGl2, 0.1 mM-EDTA and 50 mM-Tris/'HGl, pH 7.8) and 
denoted the mitochondrial suspension (MT). The 10,000 g 
supernatant (-Sg) of the first 800 g fraction was centrifuged 
for 60 min at 100,000 g and the resulting supernatant denoted 
the cytosolic fraction (c) and the pellet, when rinsed.and 
resuspended in buffer B, denoted as the microsomal suspension 
(MG).
Method 3 - the method of Ernster & Nordenbrand (1967). 
Immediately after excision, rat muscle samples were quickly 
weighed and immersed in ice-cold 0.15 M-KC1. The tissue was 
cut with scissors into small pieces and rinsed with several 
portions of 0.15 M-KC1. The minced tissue was then rinsed with 
Chappell-Perry medium, consisting of 0.1 M-KC1, 0.05 M-Tris/HCl, 
pH 7.4, 1 mM-ATP (Na salt), 5 mM-MgS0^ and 1 mM-EDTA (Chappell 
& Perry, 1954), and suspended in 4 volumes of the same medium. 
Homogenisation was then carried out, at 0 - 4°C, with a-relatively 
loose-fitting all-glass Botter-Elvehjem homogeniser and the 
homogenate diluted with Chappell-Perry medium to a volume of 
10 times the initial weight of the muscle. This homogenate (h ) 
was centrifuged at 600 g for 7 min. The supernatant was decanted 
into a new tube and recentrifuged as before. The resulting 
supernatant (S^ ) was decanted and centrifuged at 14,000 g for
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FIG. 2.^ Subcellular Fractionation of Muscle by Method 3 
(Ernster & Nordenbrand; 19^7)
10 min in an MSE SS50 Superspeed (MSE Scientific Instruments, 
Crawley, Sussex, U.K.). The pellet was resuspended in 
Chappell-Perry medium and recentrifuged at 14,000 g for 10 min. 
The supernatant from this second 14,000 g x 10 min spin was 
discarded and the pellet (MT) resuspended in--Chappell-Perry 
medium.
The supernatant (S^ ) from the first 14,000 g x 10 min 
spin was centrifuged at 100,000 g for 60 min in an MSE SS50 
yielding the cytosolic fraction (c) (supernatant) and the 
microsomal pellet (MC)• The surface of the tightly packed 
microsomal pellet was riitsed twice with Chappell-Perry medium 
to remove any remaining cytosolic fraction and the microsomal 
pellet resuspended in Chappell-Perry medium.
Method 4 - the method of Surholt & Newsholme (i98l)« 
Muscle was removed, cut into small pieces and gently homogenised 
with 9 volumes of medium, consisting of 20 mM-Hepes, 300 mM-
mannitol, 1 mM-EDTA and.'0.1 % (w/v) bovine serum albumin at
pH in a glass homogeniser with a loose-fitting Teflon
pestle. The homogenate (h ) was filtered through two layers of 
muslin and then centrifuged at 600 g for 5 min. The 600 g
pellet (N) was washed twice with the above medium before re-
suspension in the medium and the 600 g supernatant (S^ ). was 
centrifuged at 5»000 g for 20 min. The pellet was washed twice 
in medium before-re suspension in that medium and denoted the 
mitochondrial suspension (MT). The 5>000 g supernatant (S^ ) 
was centrifuged at 100,000 g for 1 h. The resulting pellet 
was washed twice in medium before resuspension and then termed 
the microsomal suspension (MG). The 100,000 g supernatant 
was called the cytosolic fraction (c).
2.5.3 Fractional Extraction of Muscle
The fractional extraction procedure employed for 
muscle was essentially as described by Taylor et al. (1978)*
Freshly dissected muscle was rinsed with a medium 
consisting of 150 mM-KCl, 10 mM-Hepes (4-(2-hydroxyethyl)-l- 
piperazine-ethanesulphonic acid), 2 mM-EGTA and 2 % (w/v) bovine 
serum albumin (essentially fatty acid free) at pH 7*2, and finely
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FIG. 2.5 Subcellular Fractionation of Muscle by Method 4 
(Surholt & Newsholme, 1981)
chopped with scissors. Two portions of chopped tissue were 
removed for the preparation of whole homogenates (see below).
The remainder, in 20 volumes (volume A) of the above KCl-based 
medium, was transferred to a glass homogenising tube and gently- 
disrupted manually with about JO strokes of a very loose-fitting 
Teflon pestle. The resulting muscle suspension was transferred 
to a small glass beaker and stirred continuously for JO min at 
4°C. The suspension was then centrifuged at 30>000 S f°r 15 min 
in a Beckman L5-65B Ultracentrifuge. The resulting supernatant 
was assayed for enzyme activities. The sediment was resuspended 
in the original volume (volume A) of the above KCl-based medium 
and the entire procedure of stirring, centrifuging and enzyme 
activity determinations repeated. After J extractions of the 
tissue with the KG1-based medium the sediment was extracted once 
with volume A of 100 mM-potassium phosphate, pH 7.2. The sediment 
from this final extraction was thoroughly homogenised in 0.5 x 
volume A of 100 mM-Tris/HCl containing 1 mM-EDTA, 5 mM-Mgd^
20 mM-2-mercaptoethanol and 2.4 mM-sodium deoxycholate at pH 7*4 
with a ground-glass homogeniser and was then assayed for enzyme 
activities without further treatment.
Enzyme activities were determined in two whole homogenate 
preparations. Both were prepared by ground-glass homogenisation, 
one in the KCl-based medium including 2.4 mM-sodium deoxycholate 
and the other in the above Tris-based medium.
2.6 ENZYME ASSAYS
All enzyme assays were performed at 30°G unless otherwise
stated.
Phosphoenolpyruvate carboxykinase (PEPCK) (EC 4.1.1.32)
activity was assayed by four methods.
Method A was based on the radioactive incorporation
method of Chang & Lane (1966). The assay medium contained
100 mM-imidazole/HCl, pH 6.6, 3 mM-phosphoenolpyruvate (Na salt),
2 mM-IBP (Na salt), 2 mM-MnClg* 2 mM-dithiothreitol, 2.5 mM-
NABH (Na salt), 50 mM-NaH^CO^ (40 mGi. mole”'*'), 2.5/**g antimycin
A and 12 units of malate dehydrogenase (in glycerol) in a
final volume of 1 ml. Phosphoenolpyruvate was omitted from
controls. The assay was terminated after 15 min by adding 1 ml
of 2 M-HC1. Carbon dioxide was bubbled through the acidified
14assay solution for 10 min to drive off C0^ not incorporated 
into acid-stable products. A 0.5 ml aliquot was removed, 4 ml 
of scintillation cocktail (5 S PP0, 0.2 g dimethyl-POPOP/litre 
toluenes Synperonic NX (2:1 v/v)) added, and counted in a LKB 
1210 Ultrobeta Liquid Scintillation Counter (LKB-Produkter AB, 
Bromma, Sweden).
Units of enzyme activity for this method are defined 
as yumoles of ^00^ fixed/min.
Method B was the continuous spectrophotometrie assay 
for PEPCK activity as described by Opie & Newsholme (1967).
The assay medium consisted of 66 mM-Tris/HCl, pH 7«5» 1 mM-MnCl^, 
1 mM-phosphoenolpyruvate (Na salt), 0.l6 mM-NADH (Na salt),
1.54 mM-IBP (Na salt), 17 mM-NaHCO^ and 12 units of malate 
dehydrogenase (in glycerol) in a final volume of 1 ml. NaHC0o
j
was omitted from controls.
Method C was also a continuous spectrophotometric assay 
in the direction of oxaloacetate formation and was based on 
the method described by Bentle & Lardy (1976). The assay 
medium contained 50 mM-Hepes-NaOH, pH 6.5» 1 mM-MnCl^» 2 mM- 
phosphoenolpyruvate (Na salt), 0.25 mM-NADH (Na salt), 1 mM- 
IBP (Na salt), 50 mM-NaHCOy 1 mM-dithiothreitol, 2.5yt*g 
antimycin A and 7*5 units of malate dehydrogenase (in glycerol), 
in a final volume of 1. ml. Phosphoenolpyruvate was omitted 
from controls.
Method B measured the PEPCK reaction in the direction of 
phosphoenolpyruvate formation and was also described by Bentle 
& Lardy (1976), based on the method of Seubert & Huth (1965)*
Phosphoenolpyruvate was formed in medium containing 
50 mM-Hepes-NaOH, 2 mM-ITP, 3 mM-MgGl^ and 1.5 mM-oxaloacetate 
at pH 7*5 in a volume of 1 ml. After 5 min, the reaction was 
stopped by adding 10 - 15 mg KBH^ and the mixture was placed on 
ice. After a further 5 min, the mixture was acidified with 
0.4 ml 6 % (w/v) perchloric acid. The samples were then 
neutralised, centrifuged at 4°G and aliquots of supernatant 
removed for phosphoenolpyruvate determination. Phosphoenol­
pyruvate was determined in medium containing 70 mM-Tris/HCl,
0.15 mM-NABH, 1.67 mM-ABP, 4.2 mM-MgSO^, 33 mM-KCl and 5.5 
units of lactate dehydrogenase and 4 units of pyruvate kinase 
at pH 7*6 in a final volume of 1 ml,
The assay of pyruvate kinase (EG 2.7.1*4o) activity 
was based on that described by Zammit et al.,(197B). The assay 
medium for the measurement of maximal activities contained
160 mM-triethanolamine/HCl, pH 7»35» 10 mM-MgCl^, 80 mM-KCl,
0.17 mM-NADH, 5 mM-ADP, 2 mM-phosphoenolpyruvate, 2.5/*g antimycin 
A and 25 /ag of lactate dehydrogenase in a final volume of 1 ml. 
Phosphoenolpyruvate was omitted from controls.
Lactate dehydrogenase (EC-1.1.1.27) activity was 
determined by the method of Kornberg (1955)• The assay medium 
contained 33 mM-potassium phosphate, pH 7*4, 0.33 mM-sodium 
pyruvate and 0.1 mM-NADH in 3-nil. Pyruvate was omitted from 
blanks.
NADP-dependent malate dehydrogenase, ’’malic enzyme"
(EG 1.1.1.40) activity was assayed by the method of Swierczynski 
et al. (1980), the assay mixture containing 50 mM-Tris/HCI, 
pH 7*4, 1 mM-MnClgi 10 mM-L-malate (omitted from blanks), 0,5 mM- 
NADP and 2 yug antimycin A. NADP-dependent "malic enzyme" was 
also determined by the method of Nagel et al. (1980). The ‘ 
assay medium contained 50 mM-Tris/HCI, pH 7•3» 10 mM-L-malate 
(omitted from blanks), 2 mM-MnSO^, 0.1 mM-dithiothreitol and 
0.5 mM-NADP.
The activity of NAD(p )-dependent "malic enzyme", with 
either NAD or NABP as cofactor, was measured as described by 
Nagel et al. (1980) in medium containing 50 mM-Tris/HCI, pH 7»3»
10 mM-L-malate (omitted from blanks), 2 mM-MnSO^, 0.1 mM- 
dithiothreitol, 5 mM-sodium fumarate and either 0.5 mM-NAD or 
0.5 mM-NADP.
Oxaloacetate decarboxylase (EG 4.1.1.3) activity was 
assayed by measuring oxaloacetate consumption and pyruvate 
production by the methods described by Dean & Bartley (1973)
for "supernatant" oxaloacetate decarboxylase activity and by
Wojtczak & Walajtys (1974).
Branched-chain aminotransferase (EG 2.6.1.42) activity
was assayed as follows. The assay mixture, containing 100 mM-
potassium phosphate buffer, pH 8.4, 15 mM-2-oxoglutarate,
14
0.1 mM-pyridoxal phosphate and 3 mM-L-£l- C]-leucine or valine 
—1
(167 mGi.mole ) in a final volume of 1 ml, was incubated in
10 ml.conical flasks containing glass centre wells and stoppered
with rubber serum caps. In the glass centre wells were placed
gelatin capsules (Parke, Davis & Company, Hounslow, London, U.K.)
which in turn contained 1 cm x 2 cm glass fibre paper wicks
(Whatman GF/c) and 0.2 ml hyamine 10X (hydroxide). The assay
mixture was warmed for 5 min at 37°G in a shaking water bath.
The tissue preparation was then added and the reaction terminated
after 10 min by the injection of 0.5 ml 0.5 M-H^SO^ through the
serum caps into the assay mixture. The flasks were then placed
on ice and when cool 1 ml of JO % (w/v) H^O^ was injected to
decarboxylate the 2-oxoacids produced by transamination. The
o  1 Zl
flasks were then gently shaken for 1 h at 20 C. The GO^ 
evolved was absorbed by the hyamine-soaked glass fibre paper 
wick in the gelatin capsule. The capsule was lifted out by 
forceps at the end of the 1 h period and immersed in 4 ml 
scintillation cocktail (see above) + 0.3 ml distilled water. 
Tissue blanks contained acid inactivated tissue samples.
The activity of succinate dehydrogenase (EG 1.3*99»l) 
was assayed as follows. 0.25 ml 1.25 % (w/v) 2-(4-iodophenyl)- 
3**(4-nitrophenyl)-5-phenyltetrazolium chloride (INT) in 0.2 H-
potassium phosphate buffer, pH 7.0 and 0.25 ml 0.3 M-Na succinate 
and diluted tissue sample were incubated in a 1 ml volume for 
10 min at 37°G* 0.25 ml O.3 M-Na malonate, a competitive
inhibitor of succinate dehydrogenase, replaced Na succinate in 
the assay blanks. The reaction was stopped by the addition of 
6 ml of a mixture of 10 % (w/v) trichloroacetic acid: 96 % (v/v) 
ethanol: ethyl acetate (2:13:20) by volume. The mixtures were 
then centrifuged at approximately 500 g for 5 min and the 
absorbance of the supernatants measured at 490 nm. Activity
was calculated assuming' that reduced INT has an extinction
8 - 1 - 1  coefficient of 20 x 10^ l.mol cm .
Alanine aminotransferase (EC 2.6.1.2) activity was 
assayed by the method of Segal et al. (1962) in a volume of 3 ml. 
The assay volume contained 100 mM-Tris/HCI, pH 8.0, 6.6 mM-2- 
oxoglutarate, 0.1 mM-NADH, 33 mM-L-alanine (omitted from blanks) 
and 25/Ag lactate dehydrogenase.
Aspartate aminotransferase (EC 2.6.1.1) activity was 
assayed by the method of Herzfeld & Greengard (l97l) in a volume 
of 1 ml. The assay mixture contained 100 mM-Tris/HCI, pH 7*6,
6.6 mM-2-oxoglutarate, 0.2 mM-NADH, 80 mM-L-aspartate (omitted 
from blanks) and 5 units of malate dehydrogenase.
Glutamate dehydrogenase (EC 1.4.1.2) activity was 
assayed in a volume of 1 ml containing 50 mM-potassium phosphate, 
pH 7*5* 60 mM-NH^Cl, 3 mM-2-oxoglutarate (omitted from blanks) 
0.15 mM-NADH, 1 mM-EDTA, 1.6 mM-ADP and 2 ymg antimycin A, based 
on the method of Williamson et al. (1967b) which was in turn a 
modification of the method of Schmidt (1963) assayed in the
presence of NADH and 1.6 mM-ADP which activated the enzyme 
(Tomkins et al., 1963)*
Citrate synthase (EC ^.1.3*7) activity was determined 
by the method of Alp et al. (l9?6). The 1 ml assay volume 
contained 50 mM-Tris/HCI, pH 8.1, 0.2 mM-DTNB (5»5'-dithiobis- 
(2-nitrobenzoic acid)), 0.1 mM-acetyl-CoA and 0.5 mM-oxalo- 
acetate (omitted from blanks). The assay for citrate synthase 
is based on the reaction of CoASH with Ellman’s reagent (DTNB) 
(Ellman, 19595 Srere et al., 1963).
CoASH + 0oN
”00C 000
The mercaptide ion absorbs light at ^12 nm. Thus when 
acetyl-CoA and oxaloacetate react in the presence of citrate 
synthase and DTNB the rate of CoASH formation can be followed 
spectrophotometrically. Activity was calculated assuming a 
molar extinction coefficient of 13*6 x 10Jl.mol cm for the 
mercaptide ion (Srere et al., 1963)•
2.7 OXIDATION AND TRANSAMINATION OF BRANCHED-CHAIN AMINO
ACIDS IN VITRO
Branched-chain amino acid oxidation was assessed "by the
14 14release of COg from muscle incubated in the presence of C-
lahelled valine or leucine. L-^l-^C]-valine, L-[U-^\f)-valine,
L-£1-^G]-leucine and L-Qj-^C]-leucine were employed in these
studies. Muscle preparations previously pre-incubated as
described (Section 2.3) were incubated at 37°C in a shaking
incubator under an atmosphere of 95 % 0^:5 ^  CO^ in narrow
necked (14/23) 25 ml conical flasks. The incubation media
contained either L-^l-^C] or L-^U-^C]-valine or leucine
(67 mCi.mole ). The flasks were stoppered with self-sealing
caps fitted with polyethylene hanging centre wells (Kontes
Scientific Glassware, Vineland, N.J., U.S.A.). After incubation
for 105 min, 0.2 ml hyamine 10X (hydroxide) was injected through
14the caps into the centre wells to trap GO^ evolved. 15 min
later (i.e. after 2 h incubation), the caps were opened, muscle
removed from the flasks, the caps rapidly replaced and 1 ml of
0.5 M-HgSO^ injected through the caps into the incubation medium.
14The CO^ driven from the incubation medium by the acidification 
was collected during 1 h shaking at 37°0* The caps were then 
removed from the flasks and the hyamine taken for radioactivity 
counting. Hyamine was removed from each well by Pasteur pipette 
and the wells rinsed with 0.3 ml distilled H^O which was then 
combined with the hyamine. 4 ml of scintillation cocktail.
(see Section 2.6) was added and radioactivity counted.
In experiments using L-Cl-^\f|-leucine or valine, branched-
chain 2-oxo acids released during the incubation can be measured
by decarboxylation of the 2-oxo acids with and measuring
14the CO^ evolved. The relevant flasks were therefore re­
stoppered with fresh cups of hyamine 10X (0.2 ml) and 1 ml of
1430 % (w/v) injected into the media. The GO^ evolved
was collected for a further hour with shaking at 37 °C and the
hyamine removed for radioactivity counting as above. Thus a
value for branched-chain 2-oxo acid release into the media
14was obtained which, when added to the oxidation of 1- G
observed, gave a measure of the total transamination of the
amino acid and also provides information on the branched-chain
2-oxo acid dehydrog’enase (EG 1.2.4.4) activity of the muscle
14
preparation. Comparison of the rates of GO^ production for 
L-Ci-^C] or L-Cu-^C]-amino acids provided information on to 
what extent the branched-chain amino acid carbon skeleton was 
oxidised by the muscle preparations (see Chapter 3)•
2.8 CHROMATOGRAPHIC PROCEDURES
After 2 h incubation and removal of tissues, the . 
incubation media for muscle preparations incubated as described 
in Section 2.? were acidified with 20 % (w/v) HCIO^ (0.1 ml/ml 
medium). The flasks were shaken at 37°C for 1 h and the hyamine 
10X counted as previously. The acidified media were centrifuged
and the supernatants neutralised as in Section 2.3»3* A 2.5 ml
*
aliquot of deproteinised, neutralised extract was then applied 
to a Dowex 50W H -form column ( 1 x 4  cm) and Washed through 
with 20 ml deionised H^O. The amino acids absorbed on the 
column were eluted with 35 ml 1.5 M-HC1 (Spydevold, 1976).
The first 20 ml through the column and the next 35 nil were 
collected. Both these samples were lyophilised and the residue 
taken up in 3 nil deionised H^O. These samples were further 
lyophilised, then each taken up in 200 ^ul deionised H^O. 20yul 
of a sample derived from the 1.5 M-HC1 wash-through were spotted 
in one comer of a cellulose thin-layer chromatography plate 
(pre-coated 20 x 20 cm, layer thickness, 0.1 mm? Merck 5716 
supplied by BDH Chemicals, Poole, Dorset, U.K.) for 2-dimensional 
separation by electrophoresis and thin-layer chromatography.
10 jxl of an amino acid carrier mixture was applied on top of the 
experimental sample spot. Electrophoresis was carried out at 
pH 1.9 (2.5 % (v/v) formic acid; 7*8 % (v/v) acetic acid in 
deionised H^O (Walker & Bark, 1966)) in an electrophoresis tank 
(Chemlab Instruments Ltd., Ilford, Essex, U.K.) supplied by an 
Electrophoresis Power Supply Type 264 (Medical & Biological 
Instrumentation Ltd., Ashford, Kent, U.K.) at 450V potential
( <10mA) for 1,5 h. Each plate was then thoroughly dried, 
turned through 90°> and developed by thin-layer chromatography. 
The solvent system in the second direction was butan-l-ol/acetic 
acid/water (3/l/l ty volume), (Walker & Bark, 1966). Spots 
corresponding to amino acids were visualised by spraying with 
^ninhydrin reagent (BDH Chemicals, Poole, Dorset, U.K.) scraped 
from the plates and counted for radioactivity. Spots were 
identified by their Rf values on chromatography and relative 
mobilities on electrophoresis (Katz & Lewis, 1966; Chudzik & 
Klein, 1968).
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ALANINE RELEASE AND BRANCHED-CHAIN AMINO ACID METABOLISM IN
MUSCLE IN VITRO
3.1 INTRODUCTION
Since the studies of Odessey et al., (197*0 it has "been 
known that adding certain amino acids to the incubation medium 
pf in vitro muscle preparations stimulates the release of alanine 
from those preparations. As noted in Chapter 1 there is'controversy 
about the source of pyruvate for alanine synthesis in muscle. 
Although some investigators have maintained that under physio­
logical conditions glucose is the main source (Odessey et al^,
197*h Chang & Goldberg, 1978b), others have implicated amino 
acids as the primary precursors for pyruvate in the muscle 
(Goldstein & Newsholme, 1976; Garber et al., 1976b). Whatever 
the origin of pyruvate there appears to be a relationship between 
alanine release and branched-chain amino acid oxidation, .by the 
muscle. The greater release of alanine by isolated muscle of 
fasted rats compared with fed rats when branched-chain amino 
acids are added to the medium seems related to the enhancement 
of the muscle oxidation of branched-chain amino acids by ‘ 
starvation (Odessey et al., 197*0• Patients with hereditary 
enzymatic defects in the oxidative decarboxylation of branched- 
chain amino acids (Maple Syrup Urine Disease) have low serum 
alanine levels (Haymond et al., 1973;1978)* Studies of alanine 
fluxes in these patients have indicated that branched-chain amino 
acid catabolism is an important rate-limiting event for alanine 
production in vivo (Haymond et al., 1978).
The main aim of the experiments described in this chapter 
was to study the interrelationship between muscle alanine release 
and branched-chain amino acid metabolism by examining the 
incubation conditions necessary for alanine release by muscle, 
by studying the extent of branched-chain amino acid metabolism 
and its involvement with alanine production by muscle, and by 
comparing the release of other metabolites from muscle with 
the release of alanine. Incubations of rat hemi-diaphragm and 
intact soleus and extensor digitorum longus (EDL) preparations 
were employed. The muscles were taken from fed and fasted / , 
animals in order to observe how muscle amino acid metabolism 
and production in vitro varies in different nutritional states 
in which adaptations of the enzymes involved have occurred.
3.2 RESULTS AND DISCUSSION
3.2.1 The Muscle Preparation
The diaphragm is a thin sheet of muscle fibres which 
can be rapidly dissected from the rat. The muscle is composed 
of three distinct regions: two larger lateral portions, which 
are referred to as hemi-diaphragms and a smaller dorsal segment 
adjacent to the spinal cord, which is too thick to be used for 
tissue incubations, through which passes the oesophagus, aorta 
and vena cava. In the experiments reported here, the small 
dorsal triangular segment of muscle has been discarded and the 
responses of the contralateral hemi-diaphragms compared in a 
paired experimental design. This muscle preparation offers the
advantage of comparisons between muscle segments from the 
same animal, thereby reducing problems caused by biological, 
variability. Young growing rats weighing 60 - 100 g or less 
were used. Diaphragms of rats of this size are thin enough to 
avoid problems of diffusion of nutrients between the medium and 
the incubated muscle (Goldberg et al., 1975).
Goldberg et al. (1975) reported that the cut hemi-diaphragm 
preparations may leak intracellular components during the 
first half hour after the muscle is trimmed away from the ribs 
and bisected. However, after this initial leakage, these 
reporters found the preparation to be stable by several criteria, 
including the tissue content of ATP and inorganic phosphate 
which did not fall significantly during a subsequent 90 min 
incubation. They also showed that the leakage of total creatine 
and proteins is about 10 times more rapid during the first 30 
min than afterwards. They observed that the ratio of phospho- 
creatine:total creatine and ATP:total creatine remained constant 
during a subsequent incubation period suggesting that the 
majority of cells in the tissue preparation maintain their 
energy reseves. In addition, intracellular concentrations of 
several amino acids (e.g. phenylalanine and tyrosine) remained 
constant during the incubation. They therefore recommend a 30 
min pre-incubation when using hemi-diaphragm preparations in 
studies involving measurements of the incubation medium and 
this was employed in the present study. Following the pre­
incubation period, Goldberg et al;.(1975) found that rates of 
glucose oxidation, amino acid oxidation, protein synthesis,
protein degradation and nucleic acid synthesis were all linear 
for at least 2 hours. Hemi-diaphragm ATP content was found not 
to fall significantly in the present study during the 2 h 
incubation period. Using paired hemi-diaphragms from *1*8 h fasted 
rats, the tissue concentration of ATP was found to be 2.9 — 0.3 
(3) jxmoles/g after the initial 30 min pre^-incubation and 2.4 ±
0*5 (3) moles/g after a further 2 h incubation, indicating 
that the tissue preparations remained viable throughout the 
incubation period.
With regard to muscle fibre type, diaphragm is a mixture 
in which red fibres predominate (60 %) but white and intermediate 
fibres each make up 20 % of the total (Goldberg et al., 1975)*
For studies involving the comparison of muscle types, preparations 
of soleus and EDL muscles are useful. They are of similar size 
and shape but contain substantially different proportions of 
fibre types. 80 - 90 % of the fibres of the "red” soleus muscle 
are of the slow twitch variety whereas the "white" EDL muscle 
contains mainly fast twitch fibres and very few slow ones.
Both muscles are cylindrical and so a limitation on their use­
fulness is imposed by size. In rats heavier than 70 S» the 
muscles become too thick to allow adequate diffusion of nutrients, 
oxygen and precursors into the muscle. Therefore, in this study, 
the animals from which soleus and EDL preparations were removed 
for incubation weighed no more than 70 g.
The soleus and EDL muscle-^  preparations used in this 
study do not involve cutting the muscle. The intact muscle 
preparations were held on frames under slight tension during
incubation (Maizels et al., 1977)* Stretched muscle has been 
shown to maintain higher concentrations of high-energy phosphates 
at the end of an incubation period than'unstretched muscles 
(Seider et al., 1980). Maizels et al. (1977) have shown these 
preparations to maintain phosphocreatine and ATP concentrations, 
and constant rates of glucose uptake and lactate release 
throughout a 2 h incubation.
3.2.2 Effect of Amino Acid Substrates on Muscle Alanine Release
In Vitro
Alanine .can be formed de novo in skeletal muscle by the 
transfer of amino groups to pyruvate. The direct transamination 
of pyruvate in muscle is largely restricted to glutamate 
(Rowsell, 1956; Rowsell & Corbett, 1958) and is catalysed by 
alanine aminotransferase. If the amino groups for alanine 
synthesis are derived from other amino acids, transamination 
with 2-oxoglutarate must occur to form glutamate for transamination 
via alanine aminotransferase. As transamination of 2-oxoglutarate 
in muscle has only been found to occur to any great; extent with 
aspartate and valine, isoleucine and leucine (the branched- 
chain amino acids) (Krebs, 1975)» these four amino acids and 
glutamate were expected to be the principal .amino group' donors 
for alanine formation.
Following a JO min pre-incubation period in the absence 
of exogenous substrates, hemi-diaphragms were incubated for. a 
further 2 h in the presence of the individual amino acids.
Table 3*1 shows that the branched-chain amino acids were indeed
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found to stimulate alanine release from muscle. Valine and 
leucine both significantly increased alanine release from 
diaphragm preparations from fed or 48 h-starved rats. The 
presence of 3 mM-valine or 3 mM-leucine caused a 6? % and a 
74 % increase, respectively, in alanine release from fed rat 
diaphragm and a 82 % and a 95 % increase from 48 h-starved 
rat diaphragm*
The presence of 3 mM-glutamate, which is the immediate 
donor of amino groups for the transamination of pyruvate to 
alanine, increased alanine release to a greater extent than 
3 mM-valine or 3 mM-leucine from muscle of both fed (143 %) 
and fasted (207 %) rats.
The finding that valine and leucine appreciably, 
increased the release of alanine by hemi-diaphragm muscle 
preparations in vitro was in agreement with earlier observations 
that alanine release by diaphragm preparations is stimulated by 
a mixture of valine, leucine and isoleucine together at 
physiological concentrations (Odessey et al., 1974) or by 
isoleucine alone (Goldstein & Newsholme, 1976). A mixture of 
other plasma amino acids (omitting the branched-chain amino 
acids) failed to increase alanine output by diaphragm muscle, 
even at amino acid concentrations which were 5“times the normal 
plasma levels (Odessey et al., 1974). 10 mM-subtrate concentrations
of branched-chain and other amino acids increased alanine output 
by the isolated perfused hindquarter (Ruderman & Lund, 1972;
Ruderman & Berger, 1974) and by an epitrochlaris muscle preparation 
in vitro (Garber et al., 1976b). These observations, together
with those reported here, support the enzymic data that the 
branched-chain amino acids are, together with aspartate and 
glutamate, the major amino nitrogen donors for alanine formation 
in muscle tissues (Krebs, 1975)•
The addition of 10 mM-glucose to the incubation medium 
increased alanine, pyruvate and lactate release by hemi-diaphragms 
from fed and fasted rats (Table 3»l)» With fed rats, the 
stimulation of lactate and pyruvate release by glucose, presumably 
reflecting increased glycolysis, was more than doubled (256 % 
of lactate plus pyruvate release in glucose-free medium), 
whereas alanine release was increased by only 28 %• Similarly, 
with fasted rats, lactate and pyruvate release was increased 
more than five-fold (540 % of lactate + pyruvate release in 
glucose-free medium), whereas alanine release was increased T^y 
only 58 %• The rate of lactate and pyruvate release in the 
presence of 10 raM-glucose with fasted rats was about double 
that with fed rats, whereas increased alanine release was only 
marginally greater with fasted rats compared to fed rats in these 
experiments. These findings suggest a limitation of alanine 
production by muscle under the above circumstances which is not 
governed by the rate of glycolysis.
The addition of 10 mM-glucose and 3 mM-valine together • 
increased alanine release to a greater extent than the sum of 
the rates with each substrate separately : +2.15 as against +1.48 
for the sum of the separate rates with fasted rats (in ^ umol/2 h/ . 
g tissue). This effect of valine and glucose together on alanine 
release was greater with fasted rats (l45 % of the sum of the
separate rates) than with fed rats (112 %)* With glucose as the 
sole added substrate the provision of amino groups was the 
factor limiting alanine release. With valine alone as substrate, 
the provision of pyruvate was limiting. Therefore the addition 
of substrate amounts of both glucose and valine synergistically 
increased the rate of alanine release which was seen to depend 
on both the supply of donor amino groups and pyruvate.
In the absence of glucose in the incubation media, the 
stimulation of alanine release by valine, leucine and glutamate, 
was accompanied by a decrease in pyruvate release, except in the 
case of stimulation of alanine release by valine from hemi- 
diaphragms from fed rats. This observation agreed with a role 
for valine, leucine and glutamate in providing the amino groups 
for transamination of pyruvate to form alanine. However, the 
decrease in pyruvate release was only equivalent to the increase 
in alanine release in the case of leucine with fasted rats. In 
the other cases, the decrease in pyruvate release was less than 
was expected on the basis of increased alanine release. This 
raises the possibility that these substrates may themselves 
contribute carbon for pyruvate formation for alanine release.
When hemi-diaphragms were incubated in the presence of 
the 2-oxo acids of valine and leucine, i.e. 3"me‘thyl-2-oxo- 
butanoate and ^ -methyl-2-oxopentanoate, the rates of release 
of alanine by the muscle preparations were markedly decreased 
(Table 3>Z), This was to be expected as the provision of 3 roM- 
2-oxo acids would displace the coupled transaminations towards 
branched-chain amino acid and 2-oxoglutarate formation. The
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resulting lowered glutamate concentration would thus displace 
the alanine aminotransferase reaction towards pyruvate formation.
BGAA 2-oxoglutarat e Alanine
Glutamate Pyruvate
However, in the case of 3”methyl-2-oxobutanoate (keto- 
valine) and tissue from 48 h-fasted rats, the decrease in alanine 
release observed was much less than the resulting increase in 
pyruvate (and lactate) release.
Among the possible explanations for the above observations 
are inhibition of intracellular pyruvate oxidation by the 
branched-chain 2-oxo acids (either supplied exogenously, Table 
3.2, or formed by the transamination of the branched-chain amino 
acids, Table 3«i) (Dreyfus & Prensky, 1967; Kanzaki et al., 1969; 
Bowden et al., 1971) or pyruvate formation from the added amino 
acids (Goldstein & Newsholme, 1976) or 2-oxo acids.
3*2.3 A Non-Glycolytic Source of Pyruvate for Alanine Formation?
The amounts of lactate and pyruvate released from hemi- 
diaphragms were substantial when the preparations were incubated 
in unsupplemented Krebs-bicarbonate medium, even when the ■ 
preparations were taken from 48 h-starved rats. This implies 
that the carbon for the lactate and pyruvate release is derived
from endogenous sources. Muscle glycogen is a logical suggestion 
as pyruvate can be provided directly via glycogenolysis and 
glycolysis. Indeed muscle glycogen has been suggested as the 
source* in vivo of the muscle-derived lactate, pyruvate (and 
perhaps alanine) which may give rise to glucose formation via 
the circulation and hepatic or renal glueoneogenesis during 
short-term starvation (Sugden et al., 1976). Goldstein and 
Newsholme (1976), however, reported that hemi-diaphragm 
preparations showed no statistically significant difference in 
glycogen content before of after a 60 min period of incubation 
with glutamate as the only added substrate. Their results 
were obtained with-tissue taken from fed rats, suggesting that 
in the fed state the carbon of the lactate, pyruvate and alanine 
released cannot be derived from net muscle glycogenolysis.
Similarly, other workers have shown an increased rate of 
alanine release and a lower rate of net glycogen breakdown when 
hemi-diaphragms from fed rats were incubated in-the presence of 
3 mM-glutamate compared with no addition to the incubation 
medium (Odedra & Palmer, 198l). If the carbon for alanine 
formation had -been derived exclusively from glycogen an increased 
rate of net glycogen breakdown would have been expected when 
alanine release was stimulated in the presence of glutamate.
However, Table 3*3 shows that hemi-diaphragm preparations 
from fed rats in the present study do in fact show a decrease 
in glycogen content during a 2 h incubation period. The difference 
observed between glycogen content at the start and end of the 2 h 
was substantial (5«5 /*• mol glucosyl units/g tissue). This amount
TABLE 3*3 Effect of Incubation on the Glycogen Content of Hemi-
Diaphragms From a) Fed, and b) ^8 h-Fasted Rats
Hemi-diaphragms were pre -incubated for 30 min in unsupplemented ; 
Krebs-bicarbonate medium. One.of each pair was then taken for 
glycogen determination. The other was incubated in fresh medium 
for a further 2 h before glycogen determination.
Values represent the means of measurements from different rats and 
are given together with S.E.M. and the number of observations in 
parentheses. Statistical analysis (Student's t-test) was carried
out on paired observations and differences are shown by:
* p < 0.05, ** p< 0.01, *** p <  0.001.
a) FED
30 min pre-incubation
30 min pre-incubation 
+ 2 h incubation
9.58 ± 1.97 GO 
4.11 £ 2.00 GO***
b) 4-8 h-FASTED
Glycogen content ( jxmol/g tissue)
30 min pre-incubation 
+ 2 h incubation
30 min pre-incubation 0.9^  ± 0.2^ GO 
0.05 £ 0.05 GO**
of 6-carbon units is sufficient to provide the carbon for the 
lactate, pyruvate and alanine (3-carbon compounds) released 
by fed muscle preparations incubated in the absence of glucose 
from the medium. The decrease in glycogen content during the 
2 h incubation period found with diaphragm preparations from 
48 h-fasted rats (0.89 jxmol glucosyl units/g tissue) would, 
however, not be sufficient to supply the carbon for the lactate, 
pyruvate and alanine release. These results suggest that in 
certain circumstances muscle is capable of producing pyruvate 
by pathways other than glycolysis. It is possible that in this 
case the carbon of the lactate, pyruvate and alanine released 
by the tissue may be derived from the carbon skeletons of amino 
acids, arising from muscle proteolysis.
The pathways may therefore exist in muscle to provide 
net pyruvate for alanine formation. Such pathways are at 'v 
variance with the proposal that alanine released from skeletal 
muscle forms part of a glucose-alanine cycle (Mallette et al., 
1969; Felig et al., 1970) in which circulating glucose taken up 
by skeletal muscle serves by glycolysis as the source of pyruvate 
for alanine formation, which has received strong support (Chang 
& Goldberg, 1978a, b). This pathway does not allow for the 
provision of net carbon for new body glucose synthesis during 
fasting. However, pyruvate derived from muscle protein breakdown 
would make a net contribution via alanine and gluconeogenesis.
The lack of a direct relationship between the rate of 
muscle alanine release and glycolytic pyruvate production was 
also suggested by the effects of starvation on- metabolite release
by hemi-diaphragms incubated in the presence of 10 mM-glucose 
or 10 mM-glucose and 3 mM-valine (Fig. 3«l)* In both media 
alanine release was significantly decreased (p < O.Ol) by 
24 h of starvation, but was significantly increased (p <  O.Ol) 
as starvation progressed for longer time periods. In contrast, 
both pyruvate and lactate release from the muscle preparations 
increased progressively with starvation and did not show the 
reduction at 24 h observed with alanine. Interestingly, this 
pattern of alanine release during progressive starvation 
correlates with protein degradation (Li & Goldberg, 1976).
3»2.3«1 Effect of Insulin on Muscle Alanine Release
Table 3»1 showed that when the intracellular provision 
of pyruvate was increased by incubating muscle preparations in 
the presence of glucose, the release of alanine, pyruvate, and 
lactate were stimulated. The effect on alanine release of a 
further stimulation of glycolysis from glucose by insulin is 
shown in Table 3*^» Insulin significantly stimulated glucose 
uptake by the muscle preparations. It also stimulated pyruvate 
and lactate release by approximately 50 % from muscle from fed 
rats and about 100 % from muscle from 48 h-starved rats, but 
significantly decreased alanine release by about 25 % from hemi- 
diaphragms from fed rats and decreased alanine release (although 
not significantly) from hemi-diaphragms from starved rats. Thus, 
the presence of insulin, which stimulated glucose metabolism 
sufficiently to almost double.'.lactate and pyruvate release, 
actually lowered alanine release. These results are in agreement
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with those of other workers (Ruderman & Berger, 197^ i Odessey 
et al., 197*0.
The level of insulin is, however, probably one of the 
most important factors regulating protein balance in skeletal 
muscle (Gahill et al., 1972). After food intake, the elevated 
plasma level of insulin promotes the net uptake of amino acids 
by muscle and their incorporation into protein, while on fasting, 
the fall in insulin leads to a net release of amino acids from 
muscle (Felig, 1975; Ruderman, 1975)* It is possible that the 
reduction in alanine release by insulin observed in the present 
study may have been in part due to the actions of the hormone 
in not only promoting the incorporation of amino acids into 
proteins but also in inhibiting protein degradation (Fulks et al., 
1975; Rannels et al., 1975; Li & Goldberg, 1976; Hansen et al., 
1977)* For these reasons the effect of insulin on muscle 
alanine release was re-investigated using different experimental 
conditions. 3 mM-valine was present in all incubations together 
with 5 mM-glucose in order to provide adequate amino groups 
(i.e. glutamate) and pyruvate for alanine formation. A measure 
of the rate of net protein breakdown was also obtained by 
measuring the rate of tyrosine release from the hemi-diaphragms. 
Tyrosine was measured because this amino acid is not appreciably 
synthesised nor catabolised by muscle (Fulks et al., 1975)* As 
a result its production by isolated muscle must reflect net 
protein breakdown. Thus the effect of insulin on the degree of 
protein degradation observed from the hemi-diaphragms could be 
taken into account when considering alanine release. Some
experiments were also conducted in the presence of cycloheximide, 
an inhibitor of protein synthesis (Stanners, 1966; Pestka, 1971)*
The reasoning behind this addition was that cycloheximide would 
inhibit the incorporation of alanine into muscle proteins and 
hence the stimulatory effect of insulin on this process would 
be negated. A better estimation of the effect of insulin on- 
hemi-diaphragm.alanine production could thus be made. Cyclo­
heximide was added to the incubation medium at a concentration 
(0.5 toM) used by other workers to inhibit protein synthesis in 
incubated muscle preparations (Goldberg et al., 1980). Insulin 
was again found to substantially increase the rate of glucose 
uptake by hemi-diaphragm preparations (by 68 % in the absence 
of cycloheximide, and by 58 % in the presence of cycloheximide) 
(Table 3*5)• The rates of pyruvate and lactate release were 
also substantially increased by the presence of insulin (71 % 
and 58 % respectively with cycloheximide present). Under these 
experimental conditions insulin was not observed to cause a 
decrease in the rate of alanine release from the muscle preparations 
but gave a slight (although statistically insignificant) increase 
(ll % with cycloheximide absent, and 10 % with cycloheximide 
present). Other workers have reported that 0.1 mM-cycloheximide 
has no effect on alanine release by rat epitrochlaris muscle 
preparations (Karl et al., 1976). In the present study the 
alanine release when 0.5 mM-cycloheximide was present was slightly, 
(although not significantly) greater than that observed when it 
was omitted from the incubations. This was to be expected as 
the reincorporation of alanine into muscle proteins would be
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"blocked. The increase, however, was unaffected "by the presence 
of insulin. The rate of protein degradation, as measured by 
tyrosine release, was not significantly different in the presence 
or absence of insulin. Other workers have also observed no 
effect of insulin on amino acid release from rat muscle incubated 
in vitro (Garber et al.,'1976a, 1976b; Karl et al., 1976). In 
those studies the concentration of insulin (when added) was 
varied over a wide range of concentrations (10 ^units/ml to 
100 m unit s/ml) producing increases in the rates of glucose 
uptake and pyruvate release but no significant effect on alanine 
release or the rate of release of any :b£ the amino acids studied 
(Garber et al., 1976a). Fulks et al. (1975) on the other hand, 
have reported that insulin (added at 100 munits/ml) significantly 
decreased the rate of tyrosine released by diaphragms of 2 day 
starved rats in vitro. Their results are expressed as percentage 
changes in comparison with tyrosine released from diaphragm 
pieces incubated in unsupplemented medium. The addition of 
insulin (100 munits/ml) to unsupplemented medium caused a 
significant (15 %) decrease in tyrosine release. The addition 
of 10 mM-glucose caused a 10 % decrease in tyrosine release and 
when 10 mM-glucose was added together with insulin (0.1 units/ml) 
a 19 % decrease in tyrosine release was observed. Both these 
results were statistically significant when compared with the 
release of tyrosine from diaphragm preparations incubated in 
unsupplemented medium. However, those? investigators made no 
study of whether insulin caused a significant reduction in 
tyrosine release from muscle incubated in the presence of glucose.
Their findings are therefore not directly comparable with those 
of Garber and coworkers or of the present study. In the present 
experiment, it appears therefore that decreased degradation 
of muscle protein and increased incorporation of alanine into 
muscle protein by insulin can be discounted as reasons for the 
alanine release in the presence of insulin to appear low in 
comparison with the increased release of lactate and pyruvate 
observed in the presence of insulin.
This experiment, as in the previous insulin experiments 
of this study and those of Garber et al. (1976a)', failed to 
confirm a correlation between the rates of glucose uptake, 
pyruvate production and alanine release and these findings were 
contrary to the concept of the glucose-alanine cycle.
Other evidence that glucose metabolism and amino acid 
release are functionally independent processes in skeletal 
muscle 1ms been presented by investigators who employed inhibitors 
of glycolysis. Garber et al. (1976a) and Goldstein & Newsholme 
(1976) have reported that inhibiting glycolysis with iodoacetate 
and fluoride did not decrease the rate of alanine synthesis and 
release by preparations of skeletal muscle. However conflicting 
results have been reported by Chang & Goldberg (1978b) who found 
a decreased rate of alanine release in the presence of iodoacetate 
or fluoride. They also commented that besides affecting 
glycolysis these compounds could increase the rate of net protein 
breakdown (as observed for sodium fluoride by Goldstein & 
Newsholme, 1976). Cha.ng & Goldberg (1978b) found that 10 mM- 
sodium fluoride increased the rate of net protein breakdown
by over 70 % and that 0.2 mM-iodoacetate accelerated proteolysis 
by about 90 %• These findings suggest that the supposedly 
unaltered alanine releases observed in the presence of those 
inhibitors in the studies of Goldstein & Newsholme (1976) and 
Garber and coworkers (1976a) may..have been the result of decreased 
alanine formation and increased release of alanine derived 
from protein breakdown.
However, although the glucose-alanine cycle probably 
functions as proposed,, under some Conditions the source of pyruvate 
for alanine formation in muscle may not always be from glycolysis.
The experiments in the present study in which alanine release ,
from muscle taken from 48 h-starved rats was stimulated by BGAAs 
as-sole added substrate, while muscle glycogen levels were' 
very low,. strongly suggest (as was concluded by Garber et al.,
1976b and Goldstein & Newsholme, 1976) that amino acids can be 
a source of pyruvate for alanine formation in some cases.
Chang & Goldberg (1978a) have, however, stated that the 
formation of the carbon skeleton of alanine from amino acids 
is of little or no quantitative importance and that the glucose- 
alanine cycle as originally proposed, adequately explains their 
data for alanine formation. They"also state that some of their 
data appear to show net synthesis of glutamine from BCAAs and 
succinate but discount net alanine production from these pre­
cursors. It is possible that their conclusions may not be justified. 
The muscle incubations they used;were carried out in the presence 
of glucose and their data show that glycolysis was extremely 
rapid. Maizels et al. (1977) have shown that the rate of
glycolysis in such muscle preparations is many times greater 
than in resting muscle in vivo or in perfused hindquarter so 
that accumulation of: lactate and pyruvate is rapid and substantial. 
This situation would lead to a decrease in the observed amount 
of amino acid-derived carbon forming alanine because:of the 
large pool of glycolytically-derived lactate and pyruvate 
present in these muscle preparations.
To summarise : the proposed glucose-alanine cycle cannot 
explain some of the experimental findings of this present work.
It is suggested from the results of this study that amino acids 
are potential sources of pyruvate for alanine formation in 
skeletal muscle and may be of particular importance in situations 
when the glycolytic rate in muscle is low.
3*2.4 Branched-Chain Amino Acid Metabolism by Rat Hemi-Diaphragm
Preparations
The capacity for alanine production by muscle increases 
during starvation (Fig. 3*l)• Similarly, starvation is accompanied 
by increased branched-ehain amino acid metabolism by muscle 
(Goldberg & Odessey, 1972; Buse et al., 1976; Paul & Adibi,
1976). This section describes experiments on the effect of 
starvation on the metabolism of the BGAAs, valine and leucine 
by rat hemi-diaphragm preparations in vitro.
Transamination of a BGAA results in the formation of 
the corresponding branched-chain 2-oxo acid (BCOA) with the 
next step of metabolism being decarboxylation at the Cl position 
of the carbon chain by BCOA dehydrogenase(s). The total
FIG. 3«1 Changes in Metabolite Release by Hemi-Diaphragm 
During Starvation
Each column represent mean ± S.E.M. using tissues from at least
k different animals.
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transamination of the BCAA by muscle can therefore be determined 
by measuring the sum of the CO^ released from the Cl position 
and the amount of BCOA produced and released by the muscle.
t kBy using BCAAs radio-labelled in the Cl position only, the CO^
released by the action of BOAA dehydrogenases can be collected
and measured. The 2-oxo acids can be determined by making use
of the fact that treatment ;of 2-oxo acids -will specifically
decarboxylate at the Cl position (Odessey & Goldberg, 1979)®
The BCOA derived from £l-^\f]-BCAAs -will therefore release 
lkCOg when treated with H^O^ which can be collected and counted 
to measure the amount of the BCOA present.
Total transamination of valine (Fig. 3*2) by hemi-
1^diaphragm preparations was therefore measured as the sum of CO^
and ^C-ketovaline (3-methyl-2-oxobutyrate) produced from Ci-^c]-
valine. In addition, an assessment of the branched-chain 2-oxo
Ikacid dehydrogenase activity was made from the CO^ collected
A/l
during incubations with £i- C]-branched-chain amino acids 
(Odessey & Goldberg, 1979)®
_ \k -i
Values for the rate of oxidation of'LI- CJ-BCAAs 
Ik
obtained by measuring CO^ production tell us little of the 
extent to which the carbon skeletons of.leucine and valine are 
oxidised by the hemi-diaphragm muscle preparations. To explore 
this aspect, one hemi-diaphragm from each pair was incubated in 
the presence of Ll“^C]-BCAA and the other hemi-diaphragm in 
the presence of Rj-^CQ-BCAA. If both labelled species of the 
amino acid, i.e. Ll-^cG- and [U-^\f]-, are added to their 
respective incubation media at the same specific radioactivity
FIG. 3«2 Effect of Starvation on the Hate of Transamination of
3 mM-Valine by Rat Hemi-Diaphragm Preparations 
Incubated a) in the Absence of Glucose, and b) in the 
Presence of 5 mM-€lucose
Each value represents the mean ± S.E.M. of at least 4 observations.
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the ratio of:
14 r 14 “iCO^ released from [_U- Cj-amino acid
7R I JZj—  *
GO^ released from LI" CJ-amino acid -
will give a measure of what proportion of the amino acid carbon
is oxidised by hemi-diaphragm preparations. If all the BGAA
carbon skeletons which are decarboxylated in the Cl position
are completely oxidised to GOg the expected ratio would be 1.0.
14
If, however, decarboxylation of Cl is the only source of CO^ 
released from the carbon skeleton, the expected ratio would be 
0.20 for valine (which has a-five carbon skeleton) and 0.17 for 
leucine (which has a six carbon skeleton).
Thus, by incubating one of a pair of hemi-diaphragms in
_ l4 -i r 14 -i
the presence of L—[_1— Cj-amino acid and the other with L-LU- CJ
amino acid the following information can be obtained:
14(1) Ci- a] -amino acid oxidation, giving an indication of 
the branched-chain 2-oxo acid dehydrogenase activity 
of the tissue;
(2) branched-chain 2-oxo acid formation and release;
(3) total transamination of the amino acid (the sum of (l) 
and (2) above);
(4) £u-^c]-amino acid oxidation, giving an indication (when 
compared to (l) above) of the extent to which the amino 
acid carbon skeleton is oxidised.
Fig. 3*2 shows the effect of starvation on the rate of 
transamination of valine incubated in the presence or absence 
of 5 mM-glucose. Branched-chain 2-oxo acid dehydrogenase activity
-  1 ^ -1
was assessed from the decarboxylation of |_1- CJ-valine and
is shown in Fig. 3*3 and 3”roethyl-2-oxobutyrate release is shown
in Fig. 3 .^ . With valine as substrate both branched-chain
aminotransferase and branched-chain 2-oxo acid dehydrogenase
activities increased with starvation. The increase in release 
r "iM" -1of COg from [_1- CJ-branched-chain amino acids by muscle 
preparations during starvation has been reported previously 
(Goldberg & Odessey, 1972; Adibi et al., 197^)• Similarly, 
other workers have found that the rates of total transamination 
(sum of BCOA released and BCOA oxidised) were higher by hind- 
quarter preparations from 3 day-starved rats than by fed - 
controls and the percentage of BCOA formed which was oxidised 
was also higher (Zapalowski et al., 1981), in agreement with 
the findings of the present study (Fig. 3*5)•
It might be concluded that the activity of the dehydro­
genase was increased because a greater proportion of the 2-oxo 
acids formed were decarboxylated. However, as it is well-known 
that as branched-chain amino acid concentration is increased 
a greater proportion of the 2-oxo acids formed are oxidised 
(Hutson et al., 1978; 1980; Spydevold, 1979)» it is possible 
that this effect of starvation could be the result of an increased 
intracellular concentration of branched-chain amino acids. The 
increased oxidation could result,from activation of the dehydro­
genase by branched-chain amino acids (Khatra et al., 1977b;
Roberts & Sokatch, 1978; Frick et al., 198l) or T^y the 2-oxo 
acids themselves (Waymack et al., 1980; Hughes & Halestrap, 1981). 
Alternatively, Zapalowski et al., (l98l) have suggested that if
FIG. 3«3 Effect of Starvation on the Rate of Decarboxylation
r 14 -1
of 3 mM-[ 1- GJ-Valine by Hat Hemi-Diaphragm Preparations
Incubated, a) in the Absence of Glucose, and b) in the 
Presence of 5 mM-Glucose
Each column represents mean £ S.E.M. using tissues from at least 
4 different animals.
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FIG. 3.^ Effect of Starvation on the Rate of fl- C~]-3-Methyl-
2-oxobutyrate Release From Rat Hemi-Diaphragms 
Incubated in 3 mM- C l - V a l i n e  a) in the Absence 
of Glucose and b) in the Presence of 5 mM-Glucose
Each value represents the mean ± S.E.M. of at least k observations.
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FIG. 3.5 Effect of Starvation on the Percentages of
Valine Transaminated by Rat Hemi-Diaphragm Preparations
Which are Released as -3-Methyl-2-oxobutyrate,
r \k nHemi-Diaphragms Incubated with 3 roM-ll- C 1-Valine 
a-) in the Absence of Glucose and b) in the Presence 
of 5 mM-Glucose
Each column represents the means ± S.E.M. of observations from 
tissues from at least k different animals.
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it is assumed that transport of BGOA into the mitochondria is 
limited when BCAA concentrations sire low (as suggested by the 
hindquarter perfusion studies of Hutson et al., 1978; 1980) then 
another explanation exists. A carrier for the efflux of BGOA 
from the cells may become saturated before that for transport 
into mitochondria. As a result the rate at which BGOA cross 
the mitochondrial membrane would continue to increase, and 
hence a greater percentage would be oxidised, as their concentration 
increased.
The effect of starvation on the rate of 3 mM-leucine
metabolism by rat he mi-diaphragm preparations is shown in
Figs. 3*6 - 3*9* Differences were observed between the effect
of starvation on leucine and valine metabolism. There was a (p <  O.Ol)
significant reduction in leucine transamination by tissue from
2^ h-fasted rats, (tissue incubated both in the absence and
presence of glucose), after which the rate of transamination
increased as starvation progressed and the percentage BGOA formed
that was oxidised, progressively increased (Fig. 3*9)* This
initial decline in leucine metabolism with fasting is difficult
to compare with other reports of starvation. Paul & Adibi (1978)
reported that starvation increased the rate of a-decarboxylation
of leucine but used'Iiomoge nates of muscle taken from 5-day fasted
1A
rats. Similarly, the small increase in GOg production from 
Cl-^cQ-leucine reported by Hutson et al. (1980) was comparing
3-day starved rats with fed controls.
1^It is interesting to note the rates of GO^ release 
observed from £l-^C]-leucine or [l-^G]-valine in. the present
FIG. 3«6 Effect of Starvation on the Rate of Transamination
of 3 mM-Leucine by Rat Hemi-Diaphragm Preparations 
Incubated a) in the Absence of Glucose and, b) in 
the Presence of 5 mM-Glucose
Each value represents the mean ± S.E.M. of at least 4 observations.
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FIG. 3.7 Effect of Starvation on the Rate of Decarboxylation
_ 14 -1
of 3 mM-Ll- GJ- Leucine by Rat Hemi-Diaphragm 
Preparations Incu~bated, a) in the Absence of Glucose 
and b) in the- Presence of 5 mM-Glucose
Each value represents the mean ± S.E.M. of at -least 4 observations
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FIG. 3.8 Effect of Starvation on the Rate of Tl- C~|-4-Methyl-
2-oxopentanoate Release From Rat Hemi-Diaphragms
14Incubated in 3 mM-fl- Cl-Leucine a) in the Absence 
of Glucose and b) in the Presence of 5 mM-Glucose
Each value represents the mean ± S.E.M. of at least 4 observations.
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FIG. 3»9 Effect of Starvation on the Percentages of fl-^cl]-
Leucine Transaminated by Hat Hemi-Diaphragm Preparations
Which are Released as Cl -4-Methyl-2-oxopentanoate.
r 1^ -iHemi-Diaphragms Incuhated with 3 mM-Ll- C|-Leucine 
a) in the Absence of Glucose and b) in the Presence 
of 5 mM-Glucose •
Each value represents the mean ± S.E.M. of at least k observations,
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experiments using hemi-diaphragm preparations. The rate of
^-methyl-2-oxopentanoate decarboxylation by diaphragm muscle
homogenates under so-called optimal conditions has been reported
as being 0.^7 fxmol CO^/h/g tissue (Shinnick & Harper, 1976).
14However, the observed GO^ production from leucine by hemi- 
diaphragm from fed rats in the present experiment was 2.8yumol 
CO^/h/g tissue. This suggests that on homogenisation there is 
a substantial loss of branched-ehain 2-oxo acid dehydrogenase 
activity.
The extent of hranched-chain amino acid metabolism by 
muscle was studied in order to ascertain whether BGAAs could 
provide the carbon for de novo alanine synthesis by muscle.
Previous workers have suggested that muscle BGAA metabolism is 
restricted to 2-oxo acid decarboxylation (Paul & Adibi, 1976).
It has been suggested, in view of the reported distribution 
of activities of the first two enzymes of BGAA metabolism between 
the liver and muscle of the rat, i.e. rat muscle contains 
relatively high activity of branched-chain aminotransferase but 
low BCOA dehydrogenase activity, whereas rat liver contains low 
branched-chain aminotransferase activity but high BCOA dehydro­
genase activity (Shinnick & Harper, 1976), that the metabolism 
of BGAAs in vivo involves cooperation between both tissues. It 
is proposed that rat muscle transaminates BGAAs and then releases 
a large proportion of the resulting 2-oxo acids into the circulation 
from which they are removed and oxidised by the liver (Livesey 
& Lund, 1980; Hutson et al., 1980). Human muscle, in contrast, 
does not release such a large proportion of the BGOAs formed
from the transamination of BGAAs. The BGOAs appear to be more 
important respiratory fuels for human muscle than for rat muscle 
(Elia & Livesey* 1981). To assess the extent to which the 
carbon chain of valine was oxidised in rat muscle under the
conditions of the present study, a comparison was made of the
1^ r  1^  ^ 1^ "iamount of CO^ released from LU- Cj-valine and [_1_ CJ-valine.
The rates of oxidation of -valine during fasting
in hemi-diaphragm preparations are shown in Fig. 3*10 and the
1A _ i A . iA
ratios of, COg release from LU- Cj-valine / G0^ release
r ~ifrom Ll" Cj-valine are shown in Fig. 3*H-*- The ratios obtained 
at all times were intermediate between 0.2 and 1.0 indicating 
that oxidation did not only involve decarboxylation by branch© d- 
chain 2-oxo acid dehydrogenase but also that the valine carbon 
skeleton was not completely oxidised. Despite the increased 
metabolism of valine with starvation in the presence of 5 mM- 
glucose, the ratio decreased with starvation. This indicates 
that as starvation,progresses the valine carbon is being less 
completely oxidised, allowing for the provision of valine- 
derived carbon as a potential source of pyruvate for alanine 
synthesis.
The effect of starvation on the oxidation of 3 mM-Lu-^c]- 
leucine by hemi-diaphragm preparations is shown in Fig. 3*12.
Paul & Adibi (197&) using muscle homogenates found that the
1/j,
source of CO^ released from the oxidation of leucine by 
skeletal muscle was mainly the carboxyl group of leucine.
According to the established pathways for leucine oxidation 
(Meister, 1965)» isovaleryl-CoA, the product of leucine de-
FIG. 3*10 Effect of Starvation on the Rate of Oxidation of
r 14-,
3 mM-[_U- CJ-Valine hy Rat Hemi-Diaphragm Preparations 
Incubated a) in the Absence of Glucose, and b) in the 
Presence of 5 mM-Glucose
Each value represents the mean ± S.E.M. of at least k observations.
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FIG. 3.11 Effect of Starvation on the Ratio of CO ,^ Released 
From 3' -Valine to From 3 iriM-Tl-^cQ-
Valine by Paired Rat Hemi-Diaphragm Preparations
Incubated a) in the Absence of Glucose and, b) in the 
Presence of 5 mM-Glucose
Each column represents the means ± S.E.M. of observations from 
tissues from at least k different animals.
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FIG. 3*12 Effect of Starvation on the Rate of Oxidation of
3 mM-Cu-^G]]-Leucine by Rat Hemi-Diaphragm Preparations 
Incubated a) in the Absence of Glucose and, b) in the 
Presence of 5 mM-Glucose
Each value represents the mean ± S.E.M. of at least 4 observations.
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carboxylation, through a series of reactions is converted to
3-hydroxy-3-methyl glutaryl CoA (HMG-CoA); there is no release 
of GO^ from these conversions. The cleavage of HMG-CoA to aceto- 
acetate and acetyl-CoA and their subsequent oxidation by the 
tricarboxylic acid cycle is necessary for the production of 
additional GO^ molecules from leucine. McGarry and Foster
Lues'S e,
(1969) have reported that HMG-GoA^is not present in the skeletal 
muscle of rats. Therefore the lack of HMG-CoA lyase could 
account for the failure of the muscle homogenates, observed 
by Paul & Adibi (1976) to release CO^ from leucine other than 
its carboxyl group! The results of this study, however, do 
not agree with the conclusions of Paul and Adibi (1976).
lA r 1^ -1
Fig. 3*13 shows the ratios of GO^ release from LU- CJ-leucine 
r 1^ nto LI- CJ-leucine.,./As for .valine, the ratios obtained indicate 
that muscle can metabolise leucine beyond the decarboxylation 
step catalysed by bran'ched-chain 2-oxo acid dehydrogenase, 
resulting in the release of further COg* This either indicates 
that HMG-CoA lyase activity is in fact present in muscle or that 
leucine is not metabolised by the conventionally accepted route.
The finding in the present study that muscle is capable 
of oxidising the carbon skeleton of BGAAs beyond the initial 
decarboxylation step receives support from the work of Veerkamp 
and Wagenmakers (l98l). They compared the ratio :of ^GO^ 
released from [U-^cf] to Ll-^G]-^-methyl2-oxopentanoate and
3-methyl-2-oxobutyrate by homogenates of diaphragm and by hemi- 
diaphragm preparations. Their results for the ratios were: 
^-methyl-2-oxopentanoate, homogenate 0.1^ ± 0.01 and hemi-
14FIG. 3*13 Effect of Starvation on the Ratio of CCL Released 
From 3 mM-rU-^C]-Leucine to From 3
Leucine by Paired Rat Hemi-Diaphragm Preparations 
Incubated a) in the Absence of Glucose and, b) in the 
Presence of 5 mM-Glucose
Each column represents the means ± S.E.M. of observations from 
tissues from at least 4 different animals.
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diaphragm 0.57 ± 0,0^ ; and 3-methyl-2-oxobutyrate, homogenate
0.21 ± 0.03 and hemi-diaphragm 0.^6 ± 0.09. Similar results
were also reported when comparing homogenates with intact
fibres of human skeletal muscle (Veerkamp & Wagenmakers, 198l).
Other workers have reported contradictory findings for the
further metabolism of leucine. In agreement with Paul & Adibi
* 1
(1976), Van Hinsbergh et al. (1979) found that GO^ was only
1^liberated from ftj- C]-leucine by a-decarboxylation of 4-methyl- 
2-oxopentanoate with homogenates and mitochondria of quadriceps 
muscle.. However, these workers found that in intact muscle
4-methyl-2-oxopentanoate oxidation proceeds more to completeness. 
This was also observed by Odessey and Goldberg (1972) and Buse 
et al. (1975)* The discrepancy might be explained by loss of 
enzyme activity or by alterations in the mitochondrial environ­
ment during homogenisation. However, appreciable oxidation of 
leucine (25 - 60 % of total GO^ produced) has been reported 
by some investigators beyond the 4-methyl-2-oxopentanoate 
dehydrogenase step, using homogenates of quadriceps and gastro­
cnemius muscles (Dohm et al., 1976). Perhaps the conditions 
involved in some muscle homogenate' preparations have an inhibitory 
effect on branched-chain 2-oxo acid dehydrogenase activity. On 
comparing the results of the present study with those of workers 
who used muscle homogenates (Paul & Adibi, 1976; Shinnick &
Harper, 1976; Van Hinsbergh et al., 1979)» not only does the 
diaphragm preparation exhibit a substantially higher rate of
1 «j u
COg release from £l- C]-BCAA than homogenates but also the 
metabolism of the BGAA carbon chain is more complete than with
homogenates. Obviously, initial decarboxylation of BGAA is 
obligatory before metabolism can proceed further and so it 
appears that in some homogenate preparations the a-decarboxyl- 
ating dehydrogenase activity is limiting for further metabolism.
Early studies of Johnson & Connelly (1972) suggested 
that the branched-chain 2-oxo acid dehydrogenase complex may 
be subject to inter-conversion by a phosphorylation-dephospho- 
rylation mechanism. Pettit et al. (1978) did not obtain evidence 
for such interconversion with the enzyme purified from kidney. 
However, Parker and Handle (1978) found ATP'to inactivate the 
rat heart enzyme and Odessey (1980) and Paul and Adibi (1982) 
made the same observation with branched-chain 2-oxo acid 
dehydrogenase from rat muscle. Likewise, other workers have 
presented evidence that the branched-chain 2-oxo acid dehydro­
genase :6f< various tissues may well be subject to regulation by 
covalent modification (Gubler & Malquist, 1979; Odessey & 
Goldberg, 1979).
Parker and Randle (1978) reported that the oxidation of
4-methyl-2-oxopentanoate by extracts of heart mitochondria can
be greatly increased by incubating isolated mitochondria
without an oxidisable substrate. This.finding was confirmed by
other workers (Sans et al., 1980..a),who also found that hearts
r 14 -1perfused without other substrates oxidise [_1- CJ-leucine at 
very rapid rates and that extracts of mitochondria prepared
Ah
from such hearts also oxidise £l- c]-4-methyl-2-oxopentanoate 
at very rapid rates. On the other hand, they found that hearts 
perfused with glucose, pyruvate, {3-hydroxybutyrate, acetoacetate
and palmitate have a greatly reduced capacity to oxidise Cl-^cQ- 
14leucine to CO^ and that extracts of mitochondria prepared
from such rats oxidise ^-methyl-2-oxopentanoate at a much
reduced rate (Sans et al., 1980a). The results are interesting
when compared with the present study. The hemi-diaphragm
preparations were pre-incuhated in substrate-free incubation
media which may have promoted activation of the decarboxylating
dehydrogenase. However, the presence of 5 mM-glucose in the
subsequent experimental incubation media did not cause a
r 14 -|
sizeable decrease in |_1“ CJ-BGAA oxidation compared to glucose- 
free media (Fig. 3*7)•
It is also possible that the rate of CO^ production 
from [l^Vj-labelled BGAAs inay depend not only on the trans­
amination or decarboxylation reactions but also on the further
oxidation route. Reactions distal to oxidative decarboxylation 
14
may influence CO^ production by accumulation of intermediates 
(Tanaka et al., 1976; Rhead et al., 1981). The finding of the 
lower ratios of release from Qj-^\f]- to £l-^\f]-BCAAs
with muscle homogenates may possibly be due to loss of activity 
of the enzymes catalysing reactions beyond 2-oxo acid decarboxy­
lation, or by alterations in the mitochondrial environment 
during homogenisation (Krebs & Lund, 1977)*
The metabolism of BGAAs by muscle under the conditions 
used in this study makes available substantial amounts of. carbon 
to the muscle which could possibly be used for pyruvate formation, 
resulting in de novo synthesis of alanine derived from BCAA 
carbon. The maximum potential provision of 3"car^on or ^ -carbon
units to muscle in this way was calculated, on the assumption
14
that carbon not oxidised to CO^ or released in the form of 
branched-chain 2-oxo acids'was available to the muscle. These 
calculated values will be overestimates because, for example, 
Spydevold (1979) studying valine metabolism has reported that 
muscle is capable of releasing not only 3“i&ethyl-2-oxobutyrate 
but also 3"hydroxyisobutyrate• Nevertheless, by comparing 
rates of Ll-^cQ- and oxidation it is possible to
calculate the amount of carbon made available to muscle from 
measurements of the decarboxylation of the 2-oxo acid and the 
amount of the remaining carbon which is then oxidised. For 
example, in the case of hemi-diaphragm preparations from fed
rats incubated in the presence of ^ .^M-valine, valine oxidation
14 l4-i ,
measured as CO^ release from LI- Cj-valine = 2.49 ±0.07
I Ll
jhmol/2 h/g tissue and from ftj- G]-valine = 1.40 ± 0.06 ^ mol/
2 h/g tissue, where both the Ll“^0]-valine and Q l - v a l i n e  
had been present at the same specific radioactivity. Thus,
5 x 1.40 = 7*0 ^Jimol of carbon were oxidised/2 h/g tissue and 
4 x 2.49 = 9*96 ^ Amol of carbon were made available by decarboxy­
lation of the 2-oxo acid/2 h/g tissue. Of the 7*0 u^mol of 
carbon oxidised/2 h/g tissue, 2.49 jmol were from the initial
1-C oxidation. Hence, 4.51 ^ mol of carbon were oxidised from 
positions 2,3>4 and 5» The remaining BGAA derived carbon is 
therefore 9*96 - 4.51 /amol carbon atoms = 5*45 fxmol C atom
i.e. 1.82 jxmol of 30 units or I.36 ju.mol of 4G units. The values 
for the different periods of starvation studied are shown in 
Table 3*6. As starvation proceeds BGAA makes available
TABLE 3.6 Potential Amount of 3 or 4-Carbon Units Made Available
to Muscle From the Carbon Skeleton of Valine and 
Leucine During Starvation? a) When Incubated in the 
Absence of Glucose and b) When Incubated in the Presence 
of 5 mM-Glucose
a) ' •
Nutritional Carbon Units Made Available ( mol/2 h/g tissue)
State From Valine . From Leucine
Starvation Time 3C units 4C units 30 units 4C units 
(h)
0 1.82 1.36 4.70 3.53
24 1.83 1.38 2.18 1.64
48 3.30 2.48 4.42 3.32
72 2.55 1.91 5.96 4.47
t>)
Carbon Units Made Available (yu.mol/2 h/g tissue) 
From Valine From Leucine
Starvation Time 3C units 4C units 3C units 4C units 
(h)
0 1.0 0.75 4.22 3-16
24 2.0 1.50 1.90 1.42
48 3.20 2.40 3.46 2.60
72 4.52 3.39 8.28 6.21
substantial amounts of non-oxidised carbon to the muscle. The 
potential, amount of four-carbon units available from valine 
metabolism is more than sufficient to account for the.valine 
stimulated alanine release observed at all stages of starvation 
(c.f. Fig. 3.1). The pathway for the provision of pyruvate 
from valine would require the withdrawal of carbon from the 
tricarboxylic acid cycle and will be discussed in more detail 
later. The possible involvement of leucine as a direct supply 
of carbon for pyruvate production ismuch more dubious as the 
accepted route of'-leucine metabolism would make such a path­
way of leucine carbon impossible. This aspect was also 
considered by Garber et al., (1976b). They suggested that as 
leucine metabolism had been characterised in liver but not in 
skeletal muscle, that possibly leucine metabolism in skeletal 
muscle may proceed via a route which would permit the provision 
of net pyruvate. Leech et al. (1979) have also encountered 
this apparent puzzle. Although acknowledging that leucine is 
generally accepted as being entirely ketogenic these workers 
reported that alanine synthesis from dogfish muscle proceeded 
as rapidly with leucine as in the presence of. any other substrate 
even in the absence of glucose. However, alternative explanations 
can be proposed to account for leucine stimulation of alanine 
formation in the absence of glucose. Garber et al. (1976b) 
presented no direct evidence for leucine carbon contributing 
directly to alanine formation. / The source of the pyruvate in 
incubations without added glucose could be from other amino acids 
made available by muscle protein breakdown and leucine has been
reported to inhibit the oxidation of pyruvate in skeletal 
muscle during fasting (Chang & Goldberg, 1978c). Also, the 
concentration of the added leucine (and’ in particular with 
the high leucine concentration - 10 mM - used by Garber and 
coworkers) would stimulate the transamination of leucine and 
2-oxoglutarate towards 4-methyl-2-oxopentanoate and glutamate 
formation. The subsequent increased amount of glutamate present 
would drive the transamination of pyruvate to increase alanine 
formation. Thus in the experiments performed without added 
glucose, involving muscle from 48 h-starved rats in which 
glycogen breakdown is not believed to be the source of pyruvate 
for leucine-stimulated alanine release, it is possible that 
pyruvate is formed from other amino acids. The inhibition of 
pyruvate oxidation by leucine observed under these circumstances 
would therefore enable substantial transamination with glutamate 
resulting in alanine production.
3.2.4.1 Effect of Glucose on Branched-Chain Amino Acid Metabolism
by Rat Hemi-Diaphragm Preparations
As mentioned above, leucine has been reported to inhibit 
the oxidation of glucose and pyruvate in skeletal muscle during 
fasting (Chang & Goldberg, 1978c). In heart:, however, both 
glucose and pyruvate sire inhibitory to leucine oxidation (Buse 
et ad., 1972; Sans et al., 1980b).
A summary of the effect of the presence of 5 mM-glucose 
in the incubations of the present study on leucine and valine 
metabolism is shown in Table 3*7• Interestingly, whereas in
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heart the presence of glucose as a potential substrate leads 
to a sizeable decrease in amino acid oxidation (Sans et al., 
1980b) the presence of glucose was found to increase the 
oxidation of leucine by rat hemi-diaphragm preparations without 
altering the response to fasting i.e. the decrease at 2k h 
starvation was still observed.
The presence of glucose may stimulate leucine catabolism 
in hemi-diaphragm preparations by making pyruvate available for 
transamination to alanine. The subsequent lowering of the level 
of glutamate will permit more leucine to be transaminated and 
hence more ^-methyl-2-oxopentanoate will be made available for 
oxidation.
Although Chang & Goldberg (1978c) have reported that 
leucine is the most effective of the BCAAs at inhibiting pyruvate 
oxidation, they also found that 3 mM-isoleucine can inhibit 
pyruvate oxidation by diaphragms from fasted rats. In the 
present study- the presence of glucose caused a small decrease 
in the metabolism of valine by hemi-diaphragms from fed rats 
(Table 3*7)• However, as starvation progressed the inhibitory 
effect of glucose on valine metabolism, as measured by release
1^  r \k -iof COg from [_1- Cj-valine decreased until at 72 h starvation 
the presence of glucose caused stimulation of valine oxidation. 
Valine was shown by Chang & Goldberg (1978c) not to be as 
effective an inhibitor of glucose and pyruvate oxidation as 
leucine. However, Table 3*8 shows that when hemi-diaphragms 
are incubated with valine in the presence of glucose there 
appears to be a sparing of glucose in the fasted state. The
TABLE 3.8 Effect of 3 mM-Valine on Lactate, Pyruvate and Alanine
Release by Hemi-Diaphragms Incubated in the Presence 
of 10 mM-Glucose
Values represent the means of measurements from different rats 
and are given together with S.E.M. and the number of observations 
in parentheses. Statistical analysis (Student's t-test) was 
carried out on paired observations and differences are shown by:
* p <  0.05, ** P <  0.01, ***p< 0.001.
a) FED
Additions to 
Incubation Medium
10 iriM-Glucose
10 mM-Glucose + 
3 mM-Valine
Metabolite Formation (jxmol/2 h/g tissue 
Alanine Pyruvate Lactate
1.88 ± 0.12 
(12)
3.00 + o.io 
(12)***
1.74- ± 0.26 
(12)
1.70 ± 0.21 
(12)
15.84 ± 1.11 
(12)
16.95 + 0.64 
(12)
t>) 48 h-FASTED
Additions to 
Incubation Medium
10 mM-Glucose ..
10 mM-Glucose + 
3 mM-Valine
1.96 ± 0.15 5.72 ± 0.^ 7
(8) (8)
3.3^  + 0.28 3.58 ± 0.25
(8)*** (8)***
32.8^+2.39
(8)
23.46 ± 1.45 
(8)**
amounts of pyruvate and lactate released by muscle from 48 h- 
starved rats were significantly lower when 3 mM-valine was 
present. While the results of the present study suggest that 
3 mM-valine may decrease glucose utilisation by -hemi-diaphragms 
prepared from 48 h-fasted rats it is doubtful whether the effect 
is on pyruvate oxidation alone (Chang & Goldberg, 1978c). A 
decrease in pyruvate oxidation would presumably cause an increase 
in lactate and pyruvate release by the muscle preparation, 
whereas significant decreases of pyruvate and lactate release 
were observed.
All the BGAAs may therefore exert an inhibitory effect 
on glucose oxidation by muscle from starved rats. The present 
experiments uphold the finding of other workers that skeletal 
muscle differs from heart muscle with respect to BGAA and glucose 
metabolism. Differences were also observed .in experiments 
reported in Chapter 4 (4.2.2.l).
The in vitro observations that leucine inhibition of 
glucose oxidation occurs with muscle from starved animals but 
not from fed animals (Chang & Goldberg, 1978c) may explain the 
paradox!cal effects of intravenously administered leucine before 
and after 4 weeks of starvation in man, (Sherwin,. 1978) . ’ Initially 
leucine infusion decreased plasma glucose concentration possibly 
as a consequence of leucine stimulated insulin secretion (Milner, 
1970; Andersson et al., 1977)i whereas after fasting it increased 
plasma glucose concentration. Studies of the rates of endogenous 
glucose production and utilisation in these human subjects 
revealed that the increases are largely due to a reduction in
glucose utilisation when leucine was infused. Apparently, the 
inhibition of gluconeogenesis by leucine, as shown in vitro 
(Greenberg & Reaven, 1966), is not involved in the effect of 
leucine on plasma glucose concentration in vivo in fasted man.
Apart from its action on muscle, leucine has been 
found to inhibit glucose oxidation by brain slices in vitro 
(Palaiologos et al., 1979)• The site of this inhibition appears 
to be at the level of pyruvate oxidation (Chang & Goldberg, 1978c). 
In fact, the branched-chain 2-oxo acid inhibition of pyruvate 
uptake and oxidation by brain mitochondria has been suggested 
as a biochemical basis of mental retardation in patients with 
Maple Syrup Urine Disease (Halestrap et al., 1974).
3*2.4.2 Effect of Insulin on Branched-Chain Amino Acid Metabolism 
by Rat Hemi-Diaphragm Preparations 
Table 3*9 shows the results of experiments comparing 
the oxidation of 3 mM-valine by hemi-diaphragm preparations from 
48 h-fasted rats incubated both in the presence and absence of 
insulin (50 munits/ml incubation medium). The presence of insulin
A h  ~
stimulated the decarboxylation of [[l- C]-valine by over JO % 
while decreasing 3~methyl-2-oxobutyrate release by over 40 %•
The percentages of 3“methyl-2-oxobutyrate formed by transamination 
of 3 mM -£ 1 - - valine which were released from the muscle or
decarboxylated were 21.9 ± 2.6 and 78.1 ± 2.6 respectively in 
the absence of insulin but 11.0 + 2.8 and 89.0 ± 2.8 respectively 
in the presence of insulin. The increase in valine carbon 
oxidation stimulated by insulin was not however confined to
TABLE 3.9 Effect of Insulin (50 munits/ml Incubation Medium) on 
the Metabolism of 3 raM-Valine by Hemi-Diaphragm 
Preparations From 48 h-Starved Rats
Results shown are the means of at least four observations ± S.E.M. 
The control values were measured at the same time as those where 
insulin is present.
CONTROL +INSULIN .
( jj1 mol/2 h/g tissue)
Release of 1^ C02 from 3.83 ± 0.21 5*02 ± 0.20
[l-^Cl-Valine
Release of 3”ineth;yl- 1.07 ± 0.10 0.62 ± 0.15
2-dxobutyrate
Total transamination 4.90 ± 0.10 5*64 ± 0.05
of Cl-^c]'-valine
14
Release-<jf 00^ from 1.71 i 0.01 3*04 ± 0.02
-valine
CONTROL +INSULIN
from_Cu-jV.vailne 
Ci- c]
14Ratio of C02 released
0.45 ± 0.02 0.61 ± 0.03
1 Ij,
decarboxylation at the Cl position. The CO^ released from 
3 mM-£u- C]-valine m s  increased by 78 % in the presence of.
1 ^  r  -iinsulin and the ratio of CO^ released from [_U- Cj-valine to 
Cl-^cf]-valine m s  increased by 38 % indicating that in the 
presence of--insulin a much higher proportion of the valine 
carbon chain m s  oxidised. Thus although no sizeable difference 
in the rate of transamination m s  observed -with insulin, the 
extent of oxidation of the resulting carbon skeleton m s  
increased. This suggests that insulin has an effect other 
than simply by increasing the transport of amino acids into the 
muscle. Using rat hindquarter preparations Hutson et al. (1980) 
found that when insulin m s  present decarboxylation rates of 
leucine were 4- to 5“fold greater in hindquarters from starved 
versus fed rats. These workers used 0.2 mM-leucine in their 
experiments. It is possible that insulin stimulation of leucine 
transport into the muscle m s  contributing to the stimulation 
of decarboxylation observed. However, at the high concentration 
of valine employed in the present study it is unlikely that this 
factor contributes greatly to insulin stimulation of BGAA 
oxidation. The above findings are consistent with the suggestion 
that the carbon skeleton of valine may be made available for the 
formation of pyruvate and hence alanine in skeletal muscle. With 
increased oxidation of the carbon chain, less carbon would be 
available for alanine synthesis and so in the presence of insulin 
less alanine would be expected to be derived from valine carbon. 
An increase in the proportion of valine oxidised by the perfused 
rat hind-limb preparation in the presence of insulin m s  also
observed by Zapalowski et al. (l98l).
A situation in which muscle alanine release has been 
reported to be increased is diabetes (Ruderman & Berger, 1974;
Karl et al., 1976). It was of interest therefore to see whether 
muscle from diabetic animals made more BGAA carbon available to 
the muscle than muscle-from normal fed animals. Chemical diabetes 
was induced with streptozotocin. This compound has diabetogenic 
activity (Junod et al., 1967) which is apparently the result of 
irreversible damage to the insulin secreting beta cells of the 
pancreas without affecting glucagon secretion by the alpha cells. 
The destruction of the beta cells produces permanent diabetes 
in experimental animals (Brosky & Logothetopoulus, 1969; Chang 
& Schneider, 1971; Rossini et al., 1977)* Rats made diabetic 
by a single intraperitoneal injection of streptozotocin (lOO mg/ 
kg body weight) were used 2 days after injection in the fed state". 
The use of 48 h-starved streptozotocin-induced diabetic rats was 
not possible as death resulted when animals were starved for 
longer than 24 h. The results shown in Table 3*10 therefore 
compare the oxidation of 3 mM-valine by tissues from fed strepto­
zotocin-induced rats with those from fed controls. No appreciable 
difference between the tissues was observed. Karl et al. (1976) 
have measured the activity of branched-chain aminotransferase 
in muscle from streptozotocin-diabetic rats and found it to be 
no different from activity in muscle taken from control animals. 
However, other workers using lower BGAA concentrations have 
observed that in fed streptozotocin-induced diabetic animals, 
a much higher percentage of the branched-chain 2-oxo acid
TABLE 3.10 Effect of Streptozotocin-induced Diabetes on the
Metabolism of 3 mM-Valine by Hemi-Diaphragm Preparations 
From Fed Rats
Results shown are the means of at least four observations ± S.E.M. 
Control values were measured at the same time as those using 
tissue from diabetic rats.
CONTROL STREPTOZOTOCIN DIABETIC
Release of lZ*C02 from 3*10 ± 0.25 3.09 ± 0.26
[l-lZ*C]-valine
Release of 3-methyl-
2-oxobutyrate
0.49 ± 0.30 . 0.60 ± 0.04
Total transamination 3*60 ± 0.56 3*69 ± 0.40
of [l-^C]-valine
Release of 1 C02 from 1.46 ± 0.08 1.57 ± 0.05
[U-^C] -valine
CONTROL STREPTOZOTOCIN DIABETIC
Ratio of ^002 released 0.47 ± 0.02 0.51 ± 0.05
from rnJ-Vl-
Blood glucose (mM) 6.72 ± 0.06 20.6 ± 1.5
dehydrogenase of muscle exists in the active form, leading to. a
14 r 14 ngreater release of C02 from Li- CJ-leucine than in controls
(Paul & Adibi, 1982). It is difficult to compare my results
with this other study however, since totally different muscle
preparations were employed, Paul & Adibi, (1982) using isolated
mitochondria.
3.2.5 Glutamine Release by Skeletal Muscle
The other amino acid released by skeletal muscle in
quantities which far exceed its relative abundance in muscle 
proteins, is glutamine (Ruderman & Lund, 1972). Branched-chain 
amino acids have been observed to stimulate the release of 
glutamine by muscle (Garber et al, 1976b) and it has been 
suggested that BGAAs may also serve as sources of carbon for the 
glutamine released (Chang & Goldberg, 1978a). Provided that 
alanine was derived from BGAA metabolism it would therefore be 
expected that alanine and glutamine release by muscle would 
follow the same pattern. Alanine production from rat skeletal 
muscle has been shown to be increased by starvation (Fig. 3*1
and Blackshear et al. ,1974; MacDonald et al., 1976; Goodman
et al., 1978) and diabetes (Karl et al., 1976). These conditions, 
however, appear to elicit no change or a reduction in glutamine 
release by skeletal muscle (MacDonald et al., 1976; Karl 
et al. ,1976)-. There therefore seems to be a closer relation­
ship between muscle BGAA metabolism and alanine release than 
with glutamine release. Fig. 3*14 shows the release of alanine 
and glutamine by muscles from 48 h-starved rats incubated in
FIG. 3.14 Alanine and Glutamine Release by Muscles From
48 h-Starved Rats
Each column represents the mean ± S.E.M. of at least 4 observations. 
Statistically significant differences (by paired t-test) between 
metabolite release in the absence and presence of 3 mM-valine 
are shown by: * p -<0.05; ** p-^O.Ol; *** p--< 0.001.
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the absence and presence of 3 mM-valine. Valine was found to 
stimulate both alanine and glutamine release by hemi-diaphragm 
preparations. However, although the increase in alanine release 
from soleus and EDL muscles stimulated ;by valine was substantial, 
the valine-stimulated increase in glutamine release was 
negligible from both muscles.
The above findings call into question whether glutamine 
and alanine release from muscle bear a direct relationship to 
one another and agree with the suggestion that alanine transports 
most of the extra nitrogen generated when the catabolism of 
amino acids in muscle is increased during starvation (see 
Chapter 1, 1.2.1).
3*2.6 Summary
Branched-chain amino acids stimulate the release of 
alanine from muscle and the rate of alanine release is not 
necessarily related to the rate of pyruvate formation via 
glycolysis.
Although it has been suggested that rat muscle releases 
most of the carbon skeleton of BCAA as the corresponding 2-oxo 
acid after transamination, due to a restriction on further 
metabolism by low branched-chain 2-oxo acid dehydrogenase 
activity, the present study lias established in incubations with L- 
£l-^C]-valine and L-Cl-^C]-leucine (in the presence or absence 
of 5 mM-glucose), that of the valine and leucine which is 
transaminated at least 60 % and 80 % respectively is further
Ah
decarboxylated. Experiments employing both L-£l- c]- and
r lb -[L-[JJ- CJ-BGAA have shewn that muscle metabolises BGAA carbon 
chains beyond the decarboxylation step of the 2-oxo acid 
dehydrogenase, but not to complete oxidation. The amount of 
the BCAA-derived carbon not oxidised is sufficient to account 
for the observed synthesis de novo of alanine by muscle. 
Starvation, a situation where increased alanine release is 
observed is also characterised by increased muscle availability 
of BGAA carbon. The extent to which this occurs in different 
nutritional states in the intact animal, however, remains in 
question, although BGAAs may prove to be a useful source of 
alanine carbon during starvation when muscle glycogen stores 
have been depleted.
C H A P T E R  F O U R
EFFECT OF METABOLIC INHIBITORS ON MJSCLE METABOLISM IN VITRO
EFFECT OF METABOLIC INHIBITORS ON MJSCLE METABOLISM IN VITRO
4.1 INTRODUCTION
The previous chapter suggested that the carbon skeleton
of alanine, formed and released by muscle, may be derived in 
some situations from branched-chain amino acids (BGAAs). The 
experiments described in this chapter were conducted with a view 
to providing more details of the interrelationship between the 
metabolism of BCAAs and alanine formation in skeletal muscle.
Use was made of several compounds known to act as specific 
inhibitors of various metabolic reactions involved in the proposed 
pathway of conversion of BCAA carbon to alanine.
4.2 RESULTS AND DISCUSSION
4.2.1 De Novo Alanine Synthesis Involving Transamination
of Pyruvate
Alanine released by skeletal muscle can be derived from 
two possible sources, degradation of muscle proteins or de novo 
synthesis by transamination of pyruvate. Evidence that the BCAA- 
stimulation of alanine release was largely the result of increased 
de novo synthesis of alanine, rather than the result of enhanced 
proteolytic release of alanine residues from muscle proteins, 
was obtained by using the aminotransferase inhibitors, amino- 
oxyacetate and L-cycloserine. L-cycloserine is an inhibitor of 
cytoplasmic transamination and particularly of alanine amino­
transferase (Wong et a!., 1973 > Williamson et al.t 1974). Amino-
oxyacetate is a less specific aminotransferase inhibitor 
(Rognstad & Katz, 1970) that affects both mitochondrial and 
cytoplasmic transaminations (Longshaw et al., 1972; Williamson 
et al., 1974). The increase in alanine release from rat hemi- 
diaphragm preparations observed in the presence of 3 mM-valine 
was inhibited 60 % by 5 mM-cycloserine (Table 4.l). The results 
obtained using 1 mM-aminooxyacetate were comparable with those 
found with 5 mM-cycloserine (Table 4.1 + Fig. 4.l). Other workers 
have made similar observations with other muscle preparations 
in vitro (Ruderman & Berger, 1974; Garber et al., 1976a; Taegtmayer 
et al., 1977) and with the hepatectomised rat in vivo (Blackshear 
et al.. 1975).
Further evidence that valine stimulation of alanine 
release is the result of de novo alanine formation by transamination 
of pyruvate in muscle comes from experiments involving dichloro- 
acetate. The presence of dichloroaeetate causes the activation •> 
of the enzyme pyruvate dehydrogenase in tissue preparations.
This effect was first demonstrated by Whitehouse & Randle (1973) 
on pyruvate dehydrogenase of rat heart. Using purified heart 
enzyme preparations these workers found that dichloroaeetate 
inhibits the ATP-dependent phosphorylation and inactivation of 
pyruvate dehydrogenase by pyruvate dehydrogenase kinase (Whitehouse 
et al., 1974). Dichloroaeetate therefore activates pyruvate 
dehydrogenase by exerting its effect on the kinase rather than 
by binding directly to the pyruvate decarboxylase component of the 
complex.
The effect of the presence of 10 mM-dichloroacetate on
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FIG. ^.1 Effect of Aminooxyacetate on 3 mM-Valine-Stimulated
Alanine Formation by Hemi-Diaphragm
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Each column represents the means of’ measurements of alanine 
release from tissues prepared from at least 4 animals and are 
expressed as a percentage of the alanine released "by control 
tissues incubated in the absence of added valine.
valine-stimulated alanine production is shown in Fig, 4.2. In 
both the fed and fasted state dichloroaeetate inhibits valine- 
stimulated alanine release by the hemi-diaphragm preparations and 
greatly decreases the release of lactate and pyruvate into the 
incubation medium. Similar results have been reported by 
Goodman et al., (1978). These workers found that when 1 mM- 
dichloroacetate was present in media perfusing hindquarters of 
fed, fasted or streptozotocin-induced diabetic rats, releases 
of alanine, pyruvate and lactate from the hindquarters were 
significantly reduced. The low amounts of lactate and pyruvate 
released are due to the stimulation of pyruvate oxidation by the 
dichloroaeetate activation of pyruvate dehydrogenase. These 
results show that valine-stimulated alanine release is affected 
by the availability of pyruvate and provide further evidence that 
the valine-stimulated increase in alanine release is not due 
merely to increased alanine release frcm muscle proteins but to 
de novo alanine formation via transamination of pyruvate.
4.2.2 Effect of Inhibition of Branched-Chain Amino Acid 
Metabolism on Alanine Release
4.2.2.1 Dichloroaeetate
The pyruvate for alanine formation has been suggested 
to be partly derived from the carbon of valine in certain 
circumstances (e.g. in moderate starvation). Alterations in 
the metabolism of BGAAs would therefore be expected to produce 
corresponding changes in muscle alanine production.
FIG, fy.2 Effect of Dichloroaeetate on Alanine, Pyruvate and
Lactate Release From Hemi-Diaphragms From a) Fed Rats, 
and b) 48 h-Starved Rats
Values represent the means ± S.E.M. of at least k observations.
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Dichloroaeetate increases leucine oxidation by both 
liver-(Crabb & Harris, 1978; Harris et al., 1978) and heart 
preparations (Sans et al., 1980a; 1980b). The dichloroaeetate 
stimulation of leucine oxidation by liver is a consequence of 
the ability of this tissue to dechlorinate dichloroaeetate to 
form glyoxylate (Harris et al., 1978; Demangre et al., 1978). 
Glyoxylate then increases leucine catabolism by accepting amino 
groups by leucine transamination (Harris et al., 1978). The 
stimulation of BGAA metabolism by dichloroaeetate in liver is 
therefore due to a stimulation of the initial transamination.
No evidence has been found for branched-chain 2-oxo acid 
dehydrogenase activation in liver by dichloroaeetate (Crabb et al., 
1981).
In heart the mechanism of stimulation of BGAA metabolism 
by dichloroaeetate differs. Dehalogenation of dichloroaeetate 
has not been demonstrated in mammalian tissues other than liver 
(Crabb et al.» 1981) and the mechanism of stimulation in the 
heart is considered to involve activation of the branched-chain 
2-oxo acid dehydrogenase complex (Sans et al., 1980a; 1980b).
As there is considerable evidence that the above complex of heart 
(and skeletal muscle) is regulated by covalent modification by 
phosphorylation-dephosphorylation (Parker .& Handle, 1978; 1980; 
Odessey, 1980; Harris & ICeezer, 198l), it is tempting to suggest 
that dichloroaeetate causes activation of the heart branched-chain
2-oxo acid dehydrogenase complex in a similar manner to which it 
activates pyruvate dehydrogenase i.e. by inhibiting the 
dehydrogenase kinase..
However, dichloroaeetate has not "been found to stimulate 
BGAA metabolism in skeletal muscle. In response to dichloroaeetate, 
muscle from fasted rats releases less alanine and more BGAAs 
(Goodman et al., 1978). An increase in BGAA release also occurs 
during dichloroaeetate.infusion into intact rats (Blaekshear 
et al., 1975)* An inhibitory effect of dichloroaeetate on the 
oxidation of leucine by hemi-diaphragms prepared from 48 h- 
starved rats is shown in Table 4.2. Dichloroaeetate therefore 
inhibits BGAA metabolism in skeletal muscle, in contrast to its 
effect in the heart.
Possible reasons for the inhibitory effect of dichloro- 
acetate on skeletal muscle BGAA metabolism includes impaired 
transamination due to a shortage of pyruvate to regenerate 2-oxo- 
glutarate via alanine formation: decreased oxidation of the 2-oxo 
acids due to either an inhibitory effect of dichloroaeetate on 
the muscle dehydrogenase or to decreased amounts of available 
GoASH. GoASH is necessary for further metabolism of the BGAAs, 
but dichloroaeetate stimulation of pyruvate oxidation to acetyl- - 
CoA will lower the available GoASH levels.
The total amount of BGQA formed during a tissue incubation
employing Ql-^\fj-BCAA can be calculated as the sum of the
14
BGGA released into the incubation medium and the CO^ given off 
during the experiment due to decarboxylation of the BCOA.
The percentage of 4-methyl-2-oxopentanoate formed from 
leucine which was oxidised (decarboxylated) (Table 4.2) was 
similar whether dichloroaeetate was present or absent (82.0 % 
and 80.7 % respectively in the absence of glucose* and 86.4 % and 
88.3 % respectively in the presence of glucose). This suggests
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that dichloroaeetate did not have its effect by inhibiting 
branched-chain 2-oxo acid dehydrogenase. Results in agreement 
with this suggestion are shown in Table 4«3» In experiments 
comparing the effect of 10 mM-dichloroacetate on the metabolism 
of 3 nM-Cl-^cO-leucine and 3 mM-Qj-^\f]-leucine, it was again 
found that dichloroaeetate lowered the transamination of leucine 
but had no appreciable effect on the percentage of 4-methyl-2- 
oxopenatanoate formed which was oxidised. On comparing Cl-^c]-. 
with -leucine metabolism it was noted that the presence
of dichloroaeetate does not alter the extent to which the carbon 
skeleton of leucine is oxidised to GO^ by hemi-diaphragm preparations. 
Dichloroaeetate therefore appears to inhibit BGAA metabolism in 
muscle by attenuating transamination, possibly due to a decreased 
availability of pyruvate as noted above. It greatly reduced 
the total transamination of leucine both in the presence or 
absence of glucose, which shows that the decreased transamination 
observed was not merely due to the muscle preparation having 
an inadequate glycolytic source of pyruvate. Dichloroaeetate 
may therefore be considered to inhibit the proposed pathway of 
alanine formation from BGAA carbon by two means as a consequnece 
of stimulating pyruvate oxidation. The decreased pyruvate levels 
cause a decrease in BGAA transamination and, in addition, the 
oxidation of pyruvate formed from the BGAA carbon will be increased. 
Both these effects may contribute towards the decrease in valine- 
stimulated alanine release observed in the presence of dichloro- 
acetate (Fig. 4.2).
TABLE 4.3 Effect of 10 mM-Dichloroacetate on the Metabolism
of 3 roM-Cl-Leucine and 3 mM-ru-^Gl-Leucine 
by Hemi-Diaphragms Prepared From 48 h-Starved Rats
Paired hemi-diaphragm preparations were used for all incubations,
r 14 -| _ 14 -1one incubated with 41- Cj-leucine, the other with l_U- Cj-leucine.
Values shown are the means ± S.E.M. of 3 observations.
Incubation Additions
5 mM-Glucose 5 mM^Glucose
+10- mM-dichloroacetate
3 mM-^l-^C]-leucine oxidation 
( ^ imol/2 h/g tissue)
4-methyl-2-oxopentanoate 
release ( jmol/Z h/g tissue)
Transamination of 3 mM-£l-^\f]- 
leucine ( mol/2 h/g tissue) 
r 14 13 idM-l.U- CJ-leucine oxidation 
( yumol/2 h/g tissue)
Ratio ru-^\f| -leucine oxidation
6.50 ± 0.72 
1.05 ± 0.03 
7.55 ± 0.73 
3.20 ± 0.46 
0.49 ± 0.08
2.45 ± 0.08 
0.53 ± 0.10 
2.98 ± 0.02 
1,24 ±0.09 
0.51 ± 0.05
4.2.2.2 Hypoglycin
Hypoglycin (L-2-amino-3-me thylene cyclopropylpropionic 
acid) is present in the unripe arillus of the Jamaican ackee 
fruit and its ingestion causes a disease characterised biochemically 
by severe hypoglycaemia and disturbances of carbohydrate and 
lipid metabolism (Sherratt & Osmundsen, 1976; Billington et al.,
1978). Hypoglycin is transaminated to methylenecyclopropyl- 
pyruvate, which is oxidatively decarboxylated to methylenecyclo- 
propylacetyl-Gok (Kean & Rainford, 1973 > Sherratt & Osmundsen,
1976). Methylenecyclopropylacetyl-Gok has been proposed as the 
active hypoglycaemic metabolite owing to its inhibition of 
hepatic gluconeogenesis, largely as a result of changes in 
acyl-CoA/CoA distributions which inhibit pyruvate carboxylase 
activation by acetyl-CoA (Billington et al., 1978; Kean & Pogson,
1979).
Metabolism of hypoglycin, a cyclic analogue of leucine, 
is initiated by branched-chain aminotransferase and continued 
by branched-chain 2-oxo acid dehydrogenase (Tanaka/ 1975)• Due 
to the presence of appreciable amounts of the enzymes involved 
in BGAA metabolism;in muscle, hypoglycin and its metabolites could 
owe part of their hypoglycaemic action to effects on the metabolism 
in muscle. Indeed, Osmundsen et al. (1978) have shown that 
hypoglycin almost completely abolishes glucose recycling via 
muscle lactate and alanine. Therefore the effect of hypoglycin 
on the BGAA-stimulated alanine release from muscle was studied.
These experiments used incubations of intact soleus and EDL 
muscles. Both valine and leucine stimulated alanine production
from those tissues. The presence of hypoglycin (l mM) abolished 
the amino acid-stimulated release of alanine from muscles of 
starved rats (Fig. 4.3)*
Both valine and leucine-stimulated alanine release m s  
inhibited i.e. alanine production m s  blocked from both the 
glucogenic and the ketogenic amino acid. This would imply that 
hypoglycin inhibits the provision of amino nitrogen for alanine 
formation rather than the pathmy for conversion of valine carbon 
into pyruvate for alanine formation. The structural similarity 
of hypoglycin to BGAAs and the metabolism of hypoglycin by the 
enzymes involved in BGAA oxidation (Fig. 4.4) suggested that 
decreased alanine release m s  the result of inhibition of branched- 
chain aminotransferase and a decrease in the formation of glutamate 
for transamination to alanine. The activity of branched-chain 
aminotransferase in homogenates of soleus and EDL muscles m s  • 
therefore studied. 1 mM-hypoglycin only caused a 13*5 % and 5 % 
inhibition of enzyme activity in soleus and E33L homogenates 
respectively.
An alternative proposal for the inhibition of alanine 
release by hypoglycin could be sequestration of GoA through 
metabolism of hypoglycin to. methylenecycloprppylacetyl-GoA 
(Bressler et al., 1969)* In muscle, GoA sequestration would 
inhibit branched-chain 2-oxo acid dehydrogenase causing an • 
accumulation of the branched-chain oxo acids and secondarily of 
BGAAs. As it is suggested that inhibition of protein degradation 
is mediated by an intermediate of leucine metabolism (Goldberg 
& Tischler, 198l), and that in humans 4-methyl-2-oxopentanoate
FIG. ^.3 Effect of Hypoglycin on Alanine Release a) by
Soleus Muscles In Vitro, and b) by EDL Muscles In 
Vitro, Prepared From ^ 8 h-Starved Rats 
Soleus and EDL preprations were incubated as described in 
Chapter 2, Result's.-shown are increases in alanine release in 
the presence of branched-chain amino acids (3 mM-^  valine or 
3 iM-leucine)* . The effect -of -the presence-of 1 mM-hypoglycin 
on the valine- or leucine -stimulated alanine release is also-..’ 
shown. Results shown are means of at .'least 4 observations.
□  ^8 h-starved " £2 ^  h-starved + hypoglycin
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clinically improves protein nitrogen balance (Mitch et al.» 198l)» 
it is tempting to consider that hypoglycin causes the decrease 
in alanine release observed in this experiment by two different 
means in addition to lowering BCAA transamination. With valine 
as substrate the proposed pathway of valine metabolism is 
blocked and hence pyruvate will not be formed for alanine synthesis. 
With leucine as substrate, the lowered levels of CoA due to 
hypoglycin metabolism may decrease leucine metabolism and cause 
a build up of 4-methyl-2-oxopentanoate which is possibly the 
leucine metabolite responsible for’decreasing protein breakdown.
Thus less alanine will be derived via proteolysis when leucine 
is incubated in the presence of hypoglycin. Whatever the mechanism 
involved, an interrelationship between muscle BCAA metabolism 
and alanine release can be inferred from these experiments 
with hypoglycin.
4.2.2.3 Clbfibric Acid
A further study of the relationship between BCAA metabolism, 
and alanine synthesis and release in skeletal muscle was 
conducted using the hypolipidaemic drug, clofibric acid (p-chloro- 
phenoxymethylpropionic acid). Clofibric acid has been shown 
to interfere with BCAA metabolism in cultured skeletal mus&le cells 
(Pardridge et al., 1980; 1981).and is associated with myopathy 
in man and experimental animals (Langer & Levy, 19&8; Havel &
Kane, 1973 > Abowizk et el., 1979)* The effect of clofibric
acid on valine- and leucine-stimulated alanine release by diaphragm,
soleus and EDL muscles is shown in Table 4.4. Tyrosine release
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into the incubation medium was also measured to give an indication 
of net proteolysis by the muscles.
With all three muscle types studied from fed rats, 
incubation with leucine produced a lower:rate of tyrosine release 
than incubation with valine, thus confirming that leucine (or 
a metabolite) can inhibit muscle protein degradation.
Clofibric acid greatly inhibited leucine-stimulated 
alanine release from diaphragm, soleus and EDL muscles in vitro.
In contrast, valine-stimulated alanine release was not so 
dramatically affected by the drug. Tyrosine release, the measure 
of net protein breakdown, was stimulated by clofibric acid (by 
32, 88 and 88 % from diaphragm, soleus and EDL respectively) in 
the presence of leucine. Again the effect of clofibric acid on 
muscles incubated in valine was not so great. Further studies 
with diaphragm muscle using L-£1-^cQ-amino acids, showed that 
clofibric acid inhibited total leucine transamination (sum of 
and Cl-^C]-2-oxo acid release) by 63 %, but inhibited 
valine transamination by only 24 % (Fig. 4.5). The observed 
inhibition of transamination is secondary to an inhibition of 
branched-chain 2-oxo acid dehydrogenase and accumulation of
branched-chain 2-oxo acids as shown by the sizeable inhibition
14 r 14 -1 14of COg production from Li- Cj-leucine and increase in C-2-oxo
acid release. This inhibition of transamination accounts for
the decrease in alanine release found in the presence of clofibric
acid since alanine formation is linked to the BCAAs by coupled
transaminations. Clofibric acid inhibition of BCAA oxidation
and alanine release from cultured rat skeletal muscle cells has
FIG. 4.5 Effect of 2 mM-Clofibric Acid on the Rate of Oxidation
_ jk _
and Transamination of 3 mM-Ll- CJ-Leucine and 3 mM- 
14;fcl- cl-Valine by Hemi-Diaphragms Prepared From ,
a) Fed Bats, and b) 48 h-Starved Rats
Results obtained from incubations -with 2 mM-clofibric acid 
added are expressed as a percentage of paired values found in 
the absence of 2 mM-clofibric acid. Results are the means of 
four paired observations.
□  3 mM-Valine X/a 3 mM-Leucine
a) Fed
200
Percent 
of Control 
Values 100
TOTAL RATE OF ^CO,
TRANSAMINATION PRODUCTION
iz
i d ZZ3
RATE OF 
2-0X0 ACID
PRODUCTION
IT'
b) 48 h-Starved 
200 r
Percent of
Control
Values 100
0 L
been reported by Pardridge et al,, (1980; 198l). A similar 
demonstration of the effect of clofibric acid on the metabolism 
of the BGAAs has come from the work of Danner et al. (1982) who 
demonstrated clofibric acid inhibition of the purified branched- 
chain 2-oxo acid dehydrogenase from bovine liver.
An interesting observation from the experiments of 
Pardridge et al. (l98l) in which muscle cells were found to 
export alanine and citrate during periods of active BGAA utilisation 
and clofibric acid inhibited BCAA-stimulated alanine release, was 
that clofibric acid also blocked citrate release and markedly 
reduced the intracellular levels of citrate, malate, 2-oxo- 
glutarate and pyruvate. These studies imply that BGAAs contribute 
significantly to anaplerotic pathways in cultured skeletal muscle 
cells and that these pathways lead to the net production of 
alanine and citrate during periods of lowered carbohydrate 
utilisation.
In addition to demonstrating further the dependence of 
muscle alanine release on BGAA metabolism some other important 
points arise from the experiments using clofibric acid in the 
present study. Inhibition of protein degradation may be mediated 
by an intermediate of leucine metabolism whereas stimulation of 
protein synthesis apparently depends on leucine itself (Goldberg 
& Tischler, 198l). In the present study inhibition of leucine 
metabolism by clofibric acid led to an increase in net protein 
breakdown (as measured by tyrosine release). Presumably this 
effect is the result of preventing the formation of the leucine 
metabolite which inhibits proteolysis. The inhibition of the
dehydrogenase by clofibric acid leads to a build-up of ^-methyl-
2-oxopentanoate. This compound cannot then be the proteolysis- 
inhibiting leucine metabolite as has been suggested (Mitch et al., 
198l). This interpretation would also invalidate the suggestion 
in the preceding section (^.2.2.2) that hypoglycin inhibition 
of leucine metabolism resulted in increased amounts of 4-methyl-
2-oxopentanoate which decreased alanine release further by 
inhibiting proteolysis. However, it is possible that the 
inhibitory effect of hypoglycin on BCAA metabolism in muscle is 
at a stage beyond the oxidative decarboxylation of the branched- 
chain 2-oxo acids.
It has been reported that, when hypoglycin is injected 
into humans blood concentrations of branehed-pentanoic acids 
(mostly isovaleric acid) increase to over 50 times the levels 
found in controls (Tanaka et al., 197l)• These-results correlate 
well with reports of several in vitro studies which suggest that 
a hypoglycin metabolite inhibits isovaleryl-CoA dehydrogenase 
activity (Tanaka, 1975)• If this explanation of'inhibition of 
BCAA metabolism by hypoglycin is accepted, together with the 
previous explanation for the increase in tyrosine release > 
observed in the' presence ofleucine and hypoglycin, it is possible 
that the proteolysis-inhibiting metabolite of leucine is not 
^-methyl-2-oxopentanoate but isovaleryl-CoA or isovalerate.
The primary effect of clofibric acid was to inhibit the 
oxidative decarboxylation of the 2-oxo acids derived from BCAAs. 
The inhibition of leucine metabolism led to an acceleration of 
protein catabolism and this effect of clofibric acid may, .in part,
account for the myopathic side-effects of the drug. It is also 
of interest that valine metabolism was not inhibited to the 
same extent as the metabolism of leucine. This finding and the 
different responses of the metabolism of these two amino acids to 
starvation (Chapter 3) suggest either that regulatory changes 
occur during starvation and in response to clofibric acid which 
somehow affect the metabolism of leucine to a greater extent 
than that of valine, or that separate enzymes may exist for the 
transamination and/or oxidative decarboxylation of valine and 
leucine in muscle.
4.2.3 Muscle Alanine Formation From Tricarboxylic Acid Cycle
Carbon
As mentioned previously../Chapter.1;, I.3.I), the accepted 
pathway for the catabolism’ of valine is via methylmalonyl-CoA to 
succinyl-CoA which feeds into the tricarboxylic acid cycle. For 
the carbon of valine to contribute to muscle pyruvate formation 
(and hence alanine formation) carbon must be withdrawn from the 
tricarboxylic acid cycle. In Chapter 1 (l.3*3)» the possible 
enzymes involved in carbon withdrawal from the cycle were described, 
withdrawal being either via malate or oxaloacetate.
In order to examine whether tricarboxylic acid cycle 
carbon did contribute to the carbon of alanine released from 
muscle, experiments were conducted using sodium malonate, a 
highly specific inhibitor of succinate dehydrogenase at low 
concentrations ( <0.01 M) (Mahler & Cordes, 1971)• Addition 
of malonate to a respiring system leads to an abolition
of the catalytic effect of succinate dehydrogenase in promoting 
the conversion of succinate to fumarate and an accumulation of 
succinate results. Inhibition of succinate dehydrogenase was 
chosen as this enzyme is located in the cycle between the points 
where valine carbon feeds in and where carbon could be removed 
for pyruvate formation. -
The effect of 8 mM-malonate on the release of alanine 
from muscle from fed and 48 h-starved rats is shown in Table 4.5* 
With muscle from fed rats no inhibition in alanine release was 
observed, whereas with muscle from 48 h-starved rats alanine 
release was significantly (p < O.Ol) reduced. This decrease in 
alanine release was not due to decreased proteolysis. Tyrosine 
release was measured and on this basis no difference in net 
protein degradation was found in the presence or absence of 8 mM- 
malonate. It can therefore be concluded that the decreased alanine 
production was due to the inhibition of succinate dehydrogenase 
and that carbon derived from-the tricarboxylic acid cycle is 
a source of carbon for alanine formation by muscle from 48 h- 
starved animals.
These results suggest that in the fed animal, pyruvate 
for muscle alanine formation is probably obtained from glycolysis 
or glycogenolysis in accordance with the proposal of the glucose- 
alanine cycle. However, they also show that muscle alanine in 
starved animals can be formed from pyruvate which is supplied via 
the tricarboxylic acid cycle from the amino acid valine. Alanine 
from such a source, released from muscle and arriving at the liver 
as a gluconeogenic precursor, would thus be contributing net
TABLE 4.5 Effect of Sodium Malonate'on the Release of Alanine 
From Hemi-Diaphragms Prepared From a) Fed Rats, and
b) 48 h-Starved Rats
Hemi-diaphragms were incubated in the presence of 3 mM-valine 
with or without 8 mM-sodium malonate. Values represent the 
means of measurements from different-rats and are given together 
with S.E.M. and the number of -observations in parentheses. 
Statistical differences (by paired t-test) between incubations
with and without sodium malonate are denoted as * p < 0.05,
** p <  0.01.
a) Fed
Additions to medium
3 mM-valine 
3 mM-valine + 
8 mM-malonate
2.26 ± 0.20 (4)
Additions to Alanine Tyrosine
Release
Ratio: Alanine 
TyrosineMedium Release
w
0.87 ± 0.07
0.91 ± 0.05 2.17 ± 0.10
3 mM-valine + 1.68 ± 0.17 
8 mM-malonate (6)**
1.65 ± 0.21
carbon to the total body glucose pool.
4.2.3 Enzymic Route of Pyruvate Formation From Tricarboxylic
Acid Cycle Intermediates
The experiments described in this section were designed 
to establish more clearly the route by which four carbon units 
of the tricarboxylic acid cycle in skeletal muscle are withdrawn 
to form pyruvate for de novo alanine formation.
As discussed in the following chapter (Chapter 5) 'the 
most likely enzymic routes involved are via NADP-malic enzyme 
or via PEPCK and pyruvate kinase. Alanine release was therefore 
measured in the presence of specific inhibitors of both routes, 
in order to clarify which route is involved in the formation of 
alanine de novo t^y muscle.
The inhibitors used were hydroxymalonate (tartronate) 
for malic enzyme and 3-me^captopicolinate for PEPCK. Hydroxy- 
malonate has been shown to be a competitive inhibitor of cytosolic 
NADP-dependent malic enzyme (Schimerlik & Cleland, 1977) and a 
competitive inhibitor of both NAD- and NADP-dependent mito­
chondrial malic enzymes in heart muscle (Hiltunen & Davis, 198l). 
The effect of hydroxymalonate on the NADP-dependent malic enzyme 
activity of diaphragm muscle homogenate was investigated in 
the present study and is shown in Fig. 4.6 as a double reciprocal 
plot (l/V vs 1/[S]). From these graphs it was concluded that 
hydroxymalonate was a competitive inhibitor of the NADP-dependent 
malic enzyme of diaphragm muscle, with a calculated Ki- of 
approximately 0.13 mM. At the concentration of hydroxymalonate
FIG. 4.6 Inhibition by Hydroxymalonate of Hat Diaphragm
NADP-Malic Enzyme -with Respect to Maiate Concentration
NADP+-dependent malic enzyme activity in crude extracts of 
diaphragm from fed rats was measured in the presence of 50 mM- 
Tris/HCl, pH 7*4; 0.5 mM-NADP; 1 mM-MnCl^ ,, 2yug/ml antimycin A 
and malate and hydroxymalonate as indicated.
a) no inhibitor t l/v vs l/fmalatel
(jx mol .min. 
g tissue)
■20 -Km 0 5°
l/ [malate]] • (mM~*)
100
b) slth hydroxymalonate : l/V vs 1 / fmalatel Hydroxymalonate
,4 mM
2 mM5 -( ymmol
g tissue)
1 mM
0.5
l/ [malate] (mM )^
used in the muscle incubations described below (2 niM), 70 % 
inhibition of malic enzyme activity in the crude extract of 
diaphragm was observed when assayed with a malate concentration 
of 10 mM (l,72 and 0.55 ^mol/min/g tissue in the absence and 
presence of 2 mM-hydr oxymalonate respectively) and over 90 % 
inhibition when assayed with a malate concentration of 1 mM 
(1.93 and 0.17 ^ mol/min/g tissue in the absence and presence of 
2 mM-hydroxymalonate respectively). The malate content of rat 
skeletal muscle has been measured as approximately 100 nmol/g 
(Goodman et al.,\1978). The malic enzyme activity of diaphragm 
preparations would therefore be expected to be substantially 
inhibited when incubated in the presence of 2 mM-hydroxymalonate,
3-mercaptopicolinate is a potent inhibitor of the 
cytosolic and mitochondrial forms of PEPCK (Robinson & Oei,
1975; Kostas et al., 1975)* Most reports of the effect of
3-mercaptopicolinate on PEPCK activity have studied the reaction 
in the direction towards PEP formation (Robinson & Oei, 1975*
Jomain-Baum et al., 1976; MacDonald & Lardy, 1978a). Owing to 
the low level of PEPCK activity in muscle, however, the more 
sensitive assay in the direction towards oxaloacetate formation 
was employed in the present study (PEPCK method A, Chapter 2).
3-mercaptopicolinate has been reported to be a competitive 
inhibitor of liver PEPCK activity with respect to phosphoenol- 
pyruvate concentration when PEPCK is assayed in the direction of 
oxaloacetate synthesis (Reynolds, 1980a). That report is 
consistent with the inhibitory effect of 3~mercaptopicolinate 
on the activity of PEPCK in diaphragm muscle extracts shown in
Fig. 4.7. 1 mM-3-mercaptopicolinate produced 60 % inhibition
of PEPCK activity when assayed with a phosphoenolpyruvate 
concentration of 3 mM (23.8 and 10.4 nmoles/min/g tissue in 
the absence and presence of 1 mM-3-mercaptopicolinate respectively) 
and over 80 % inhibition with a phosphoenolpyruvate concentration 
of 1 mM (25.4 and 5*0 nmole s/min/g tissue in the absence and 
presence of 1 mM-3-mercaptopicolinate respectively). 1 mM-3-
mercaptopicolinate was used in diaphragm incubations described 
below. As the level of phosphoenolpyruvate in mammalian muscle 
has been reported as 10 - 20 yaM (Newsholme & Start, 1973)* 
additions of 1 mM-3-mercaptopicolinate should produce substantial 
inhibition of PEPCK activity in the diaphragm incubations.
The effects of hydroxymalonate and 3-mercaptopicolinate 
on the release of alanine from hemi-diaphragms incubated in the 
presence of the BCAAs, valine or leucine, are seen in Table 4.6.
2 mM-hydroxymalonate had no effect on alanine production in the 
presence of 3 mM-valine or 3 mM-leucine from hemi-diaphragms 
from fed or 48 h-starved rats. In' contrast, 1 mM-mercaptopicolinate 
decreased alanine release. To make allowances for the contribution 
made to alanine release by possible effects of the inhibitors on 
protein degradation, tyrosine release was measured. Correction 
for the slight increases in net muscle proteolysis found in the 
presence of the inhibitors was made by expressing the data as the 
ratio of alanine release to tyrosine release (shown in Table 4.7). 
Again 3-mercaptopicolinate but not hydroxymalonate was found to 
inhibit muscle alanine production. These results provide 
support for a route of alanine synthesis from BCAA carbon in
FIG. k-,7 Inhibition by 3-Mercaptopicolinate (3MP) of Rat
Diaphragm PEPCK with Respect to Phosphoenolpyruvate 
Concentration
PEPCK activity in crude extracts of diaphragm from fed rats by 
Method A, Chapter 2, except that phosphoenolpyruvate concentration 
was varied as indicated.
a) no inhibitor: l/V vs l/ [[Phosphoenolpyruvate]
(nmoles 
min.g tissue)
0.125
A
/ [[Phosphoenolpyruvate] (mM
b) with 3~raercaptopicolinate: l/v vs l/ [[Phosphoenolpyruvate]
.0 mM,0.30 3-mercapto-
picolinate
concentration
(nmoles . 
min.g tissue)0«l5”
0.1 mM
0 211
1/ [[Phosphoenolpyruvate] (mMr )
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skeletal muscle involving PEPCK rather than malic enzyme.
Hydroxymalonate had no significant effect on glutamate 
or glutamine release but 3-mercaptopicolinate significantly 
(p < 0.05) reduced valine-stimulated glutamine release from 
hemi-diaphragms from fed rats and valine-stimulated glutamate 
release from hemi-diaphragms from 48 h-starved rats. The method 
by which inhibition of PEPCK by 3-mercapt opi colinate causes 
these effects is not clear. One possibility is that inhibition 
of the amount of carbon leaving the tricarboxylic acid cycle 
via PEPCK limits the amount of pyruvate available for acetyl-CoA 
formation. The lowered acetyl-CoA levels may then lead to 
lowered citrate and hence 2-oxoglutarate levels within the muscle. 
Consequently, the amount of glutamate and glutamine, within the 
muscle may be decreased, limiting the amount released. In a 
separate experiment the effect of 3“mercaPtopic'olinate on the 
tissue content of alanine, glutamine and glutamate was measured 
using hemir-diaphragms from 48 h-starved rats. Incubation of 
hemi-diaphragms in 3 mM-valine significantly increased (p <  0.05, 
paired t-test) the tissue content of alanine and glutamate but 
not of glutamine (Table 4.8). However, the presence of 1 mM- 
3-mercapt opicolinate in the incubation media produced no change 
in the tissue levels of alanine and glutamate and the decrease 
in tissue content of glutamine observed in the presence of 3" 
mercaptopicolinate did not reach statistical significance.
The decreased alanine release into the incubation medium 
observed in the presence of 1 mM-3-mercaptopicolinate in the 
previous experiment (Tables 4.6 & 4.7) was not therefore merely
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due to 3-mercaptopicolinate inhibiting transport of alanine from 
the hemi-diaphragm but was in fact an inhibition of alanine 
formation in the muscle.
3-mercaptopicolinate was also found to inhibit PEPCK 
of EDL muscle (Table 4.9) and-to substantially decrease the rate 
of valine ^stimulated alanine production by that muscle (Table 
4.10). No compensatory build-up of alanine in the muscle was 
observed, again indicating that 3“me^catopicolinate inibits 
alanine formation in muscle and not merely alanine release from 
muscle.
Other workers have exploited the inhibition of PEPCK 
activity in muscle by 3~mez,eaptopicolinate. Connett (1979) 
proposed a pathway for glyconeogenesis from lactate in frog 
striated muscle involving PEPCK based on experiments showing a 
decreased incorporation of lactate into glycogen in the presence 
of approximately 0.3 mM-mercaptopicolinate. A previous report 
from this laboratory (Snell & Duff, 1977b) and later work by Odedra 
& Palmer (1981) have indicated that 1 mM-mercaptopicolinate 
reduced alanine release from rat hemi-diaphragms incubated with 
glutamate, suggesting that the pathway involving PEPCK described 
in the present study was involved in withdrawing carbon derived 
from glutamate from the tricarboxylic acid cycle for alanine 
formation.
Lee & Davis (1979) however have proposed that malic 
enzyme is the -more likely route for carbon withdrawal for alanine 
formation in skeletal muscle following their observation that
0.1 mM-3-mercaptopicolinate failed to affect alanine release in
TABLE 4.9 Effect of 3-M ercapt opi colinat e on Muscle
Phosphoenolpyruvate Carboxykinase (PEPCK) Activity
Values shown are means ± S.E.M. for measurements on crude 
muscle extracts from 4 fed rats. PEPCK activity was determined 
in each extract in the absence and presence of 1 mM-3-mercapto- 
picolinate (3MP) by method A as described in Chapter 2
i.e. QPEP] = 3 mM. Statistical differences (by paired t-test) 
between enzyme activity determinations in the presence and 
absence of 1 mM-3MP are denoted byt *** p <  0.001.
Muscle PEPCK Activity (nmol/min/g of muscle)
-3MP + 1 mM-3MP
Diaphragm 17.8 ± 2.8 4.6 ± 1.4 ***
Extensor 17*5 — 2.4 1.2 ± 0.5 ***
digitorum longus
TABLE 4.10 Effect of 1 mM-3-Mercaptopicolinate (3MP) on
Valine-Stimulated Alanine Production by Extensor 
Digitorum Longus Muscle (EDL)
Values shown are means ± S.E.M. with the number of observations 
shown in parentheses. One of each pair of EDL muscle preparations 
from 48 h-starved rats was incubated in the absence and one in 
the presence of 3 mM-valine. Statistical differences (by paired 
t-test) between alanine determinations in the presence or 
absence of 3 mM-valine are denoted by: ** p < 0.01.
Addition 
To Medium
None
3 mM-valine 
Mean difference
Alanine Released Alanine Tissue Content
(jkmol/2 h/g of muscle) ( jmol/g of muscle)
0.67 ± 0.09 (6) 0.69 ± 0.26 (3)
1.18 ± 0.11 (6)** 0.87 ± 0.22 (3)
+0.51 +0.18
1 mM-3MP
3 mM-valine + 
1 mM-3MP
O.73 ± 0.06 (6) 
1.00 ± 0.18 (6)
0.56 ± 0.18 (3) 
0.64 ±0.15 (3)
Mean difference +0.27 +0.08
hindlimb perfusions in the presence of 2 mM-propionate. The 
concentration of mercaptopicolinate used by these workers was 
relatively low in comparison with the present study. Furthermore 
it has been suggested that 3“mercaptopicolinate rapidly becomes 
inactivated in solutions not containing reducing agents and 
readily forms a disulphide with itself or other molecules 
(MacDonald & Grewe, 198l). It is possible that the high oxygen 
tension of the perfusion system of Lee & Davis (1979) which 
involved a fluorocarbon emulsion-based medium, could have 
oxidatively inactivated some of the 3“mercaptopicolinate. The 
further lowering of active mercaptopicolinate concentration could 
therefore have rendered it insufficient to cause appreciable 
inhibition of muscle PEPCK.
The results of the present experiments using 3“mercapto­
picolinate and hydroxymalonate provide strong evidence that PEPCK 
and not malic enzyme is principally involved in the withdrawal 
of carbon from the tricarboxylic acid cycle for alanine synthesis 
de novo. •
It is interesting that the inhibition of PEPCK by 3~mercapto- 
picolinate caused a significant decrease in alanine release 
from hemi-diaphragms incubated with 3 mM-leucine. Similar results 
have previously been reported from this laboratory (Snell & Duff, 
1977b). In that study alanine release from hemi-diaphragms from 
rats starved for 2 days was 1.48 ±0.02 and 2.07 ± 0.12^\mol/2 h/ 
g tissue when incubated with no addition to the medium and in the . 
presence of 3 mM-leucine respectively, a mean increase of 0.59 
umol/2 h/g tissue in the presence of 3 mM-leucine. Alanine
release was 0.99 — 0.14 and 1.55 — 0.06 ^ mol/2 h/g tissue when 
incubated in the presence of 1 mM-3-mercaptopicolinate and 1 mM- 
mercaptopicolinate + 3 mM-leucine respectively, a mean increase 
of 0.56 juunol/2 h/g tissue in the presence of 3 mM-leucine. From 
those results it was concluded that 3*-mercaptopieolinate had no ‘ 
effect on 3 mM-leucine-stimulated alanine release, although it 
was found to inhibit 3 mM-valine-stimulated alanine release by 
over 60 % and 3 mM-glutamate-stimulated alanine release by over 
50 %• However, comparing the values for alanine release when 
leucine was present in the incubation medium, 2.07 ± 0.12 and 
1.55 ± 0.06 ^ xmol/2 h/g tissue in the absence and presence-of 
3-mercaptopicolinate respectively, it can be seen that they 
are similar to those of the present study (Table 4.6), the 
presence of 3-mercaptopicolinate producing a lower rate of 
alanine release. When the figures of the Snell & Duff (1977b) 
report are examined it can be seen that the presence of 3“mercapto- 
picolinate decreased alanine release even when no other additions 
were present in the incubation medium (1.48 ± 0.02.and 0.99 ±
0.14 jamol/2 h/g tissue in the absence and presence of 1 mM- 
3-mercaptopicolinate respectively for the unsupplemented incubations 
paired to those where 3 mM-leucine was present). Taken together 
with the results for alanine release from muscle incubated 
in 3 mM-leucine and 3 mM-leucine + 1 mM-3-mercaptopicolinate, 
these results suggest that the PEPCK inhibitor is blocking alanine 
formation from endogenous sources and not inhibiting alanine 
formation from the added leucine. However, this conclusion may 
not be valid in view of the observed effects of 3*’mercaPtopicolinate
and the reported effects of leucine (or one of its metabolites) 
on muscle protein breakdown (Goldberg & Tischler, 1981). It 
is possible that the inhibitory effect of leucine on net protein 
breakdown is affected by the presence of 3“mercaP'topicolinate.
The alanine release when leucine + 3-mercaptopicolinate are 
present may then be partially the result of decreased inhibition 
of proteolysis by leucine. Hence the increase in alanine release 
observed in the presence of leucine and 3-mercaptopicolinate may 
include a contribution from proteolysis which the increase in 
alanine release observed in the presence of leucine alone may 
not. Therefore before it can be definitely stated that 3-mexca.j)to- 
picolinate does not affect leucine-stimulated- alanine production 
some knowledge of the net protein breakdown in those different 
situations is required. If 3-mercaPtopicolinate does affect 
leucine-stimulated alanine production it is possible that leucine 
may exert its effect of increasing muscle alanine release by 
stimulating the withdrawal of tricarboxylic acid cycle inter­
mediates for pyruvate and hence alanine formation. The inter­
mediates in question could not be supplied by the carbon skeleton 
of leucine itself, as leucine is considered to' be-a purely 
ketogenic amino acid (Meister, 1965)• Perhaps leucine (or one 
of its metabolites) can channel the carbon of other amino acids, 
derived from muscle protein degradation, from the tricarboxylic 
acid cycle to provide the carbon skeleton of alanine.
Regardless of the mechanisms involved for leucine 
stimulation of muscle alanine release, 3-mercapt opi colinate was 
found to decrease alanine release from muscle without affecting
muscle alanine tissue content. As alanine release derived 
from proteolysis increased in the presence of 3-mercaptopicolinate 
this suggests that de novo alanine formation in muscle is 
decreased in the presence of the inhibitor and that alanine 
formation in muscle involves PEPCK.
Alternatively, 3-mercapt opicolinate may have additional 
effects to the inhibition of PEPCK which might interfere with 
a step common to both valine and leucine-stimulated alanine 
release, for example, inhibition of BCAA or alanine transamination 
or of alanine transport. However, the latter possibility seems 
unlikely in view of the observation that intracellular muscle 
alanine content was not increased in the presence of 3-mercapto­
picolinate (Tables 4.8 & 4.10) and experiments described in 
Chapter 7 (Tables 7«1 & 7*4) have shown that 3-mercaptopicolinate 
does not inhibit BCAA transamination.
4.2.4 Proposed Pathway for Alanine Formation from Valine
in Muscle
The proposed pathway for alanine formation from valine 
in muscle involves the coupling of branched-chain aminotransferase 
and alanine aminotransferase to bring about the transfer of 
nitrogen from the BCAAs to pyruvate. Reports of the sub-cellular 
locations of the enzymes involved, however, are conflicting 
(ichihara et al., 1975? Odessey & Goldberg, 1979)* Over 90 % 
of muscle alanine aminotransferase activity has been reported 
to be in the cytosolic fraction (De Rosa & Swick, 1975)*
However, most of the branched-chain aminotransferase activity
(over 70 %) of muscle has been reported to be located in the 
particulate fraction (ichihara et_al., 1975; but c.f. Odessey 
& Goldberg, 1979)* In addition, oxidation of branched-chain
2-oxo acids is known to occur in the mitochondria (Dancis & 
Levitz, 1972; Van Hinsbergh et al., 1978; Odessey & Goldberg, 
1979)• These observations suggest that there must be a transfer 
of BGAA derived nitrogen from the mitochondria to the cytosol 
where it can be used for alanine formation by alanine amino­
transferase. A possible carrier for this transfer is aspartate. 
Safer & Williamson (1973) have shown that in the perfused rat 
heart aspartate efflux from the mitochondria is associated with 
increased formation of alanine. Aspartate entering the cytosol 
from the mitochondria would serve as a carrier of BGAA nitrogen 
and of oxaloacetate, the carbon of which may be derived from 
the metabolism of the carbon skeleton of valine.
Transamination of aspartate in the cytosol by the enzyme 
aspartate aminotransferase would donate amino nitrogen for 
glutamate formation and hence, by further transamination, alanine 
formation.'. Cytosol aspartate transamination would also 
generate oxaloacetate. The oxaloacetate can then be converted 
to pyruvate for alanine formation via the enzymes PEPCK and 
pyruvate kinase. The presence of aspartate aminotransferase 
in both the cytosolic and the mitochondrial compartments is 
required for this scheme (Fig. 4.8a) which serves to channel 
both the nitrogen and carbon of valine into alanine. Evidence 
that aspartate transamination is involved in the formation of 
alanine was obtained from experiments using 2-amino-4-methoxy-
FIG* 4*8 Intracellular Gompartmentalisation of the Proposed
Pathway of Alanine Formation from Valine in Muscle of 
Starved Bats, Assuming a) Branched-Chain Aminotransferase 
is Located in Mitochondria, and b) Branched-Ghain 
Aminotransferase is Located In the Cytosol
Phosphoenolpyruvate *■
GlutamatePyruvate Oxaloacetate
Cytosol
Alanine 2-Oxoglutarate Aspartate
Mitochondria
Valine 2-0xoglutarate Aspartate
3-Methyl-^
2-oxobutyrate
Glutamate Oxaloacetate
Succinyl-CoA
Valine Alanine
3-Methyl- <*r 
2-oxobutyrate
Glutamate Pyruvate*— Phosphoenol
Pyruvate
GlutamateOxaloacetate
Cytosol.
Aspartate
Mitochondria
Aspartate 2-0xo-
glutarate
3-Methyl-2- — ► -► Succinyl CoA-►Oxaloacetate
oxobutyrate
Glutamate 4r
trans-but-3-enoic acid (AMB) which is a relatively specific 
inhibitor of aspartate aminotransferase (Rando et al., 1976;
Smith et al., 1977; Snell, 1978). Table 4.11 shows that AMB 
decreased the valine-stimulated release of alanine try diaphragm 
muscle. This effect was particularly marked with muscle from 
48 h-starved rats (Fig. 4.9)* These results show that aspartate 
aminotransferase is involved in alanine formation and are 
consistent with the proposal that alanine can be derived from 
the carbon skeleton of valine, particularly in the fasted state. 
Alanine -production by muscle from fed animals was'.not so affected 
by inhibition of aspartate transamination. The carbon for alanine 
formation in the fed state is therefore probably not supplied 
by valine to such an extent as during starvation. This is in 
agreement with the results of experiments involving sodium 
malonate inhibition of alanine formation. In the fed state a. 
large proportion of the pyruvate required for alanine formation 
is most probably derived from glycogenolysis.
The increased lactate/pyruvate ratios obtained in the 
presence of 1 mM-AMB (Table 4.12) indicate its effectiveness 
as an inhibitor of aspartate aminotransferase. In aerobic muscle 
the mitochondrial electron-transport chain providesftfie obvious 
means of oxidation of glycolytically-derived NADH. A problem 
arises from the impermeability of the mitochondrial membrane 
to NADH. To overcome this problem in muscle, one means of .j 
transporting NADH from .the cytoplasm into mitochondria is the 
malate-oxaloacetate shuttle (Newsholme & Start, 1973)* the 
cytosol oxaloacetate is reduced to malate (and NADH is oxidised
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FIG. 4.9 Effect of 1 mM-AMB on Valine-Stimulated Alanine
Formation by Hemi-Diaphragms Prepared From Fed and 
•^8 h-Starved Rats
H  No AMB 2 + 1  mM-AMB
200 r-
150
100
Starved Fed
Valine concentration was 3 mM.
Controls were incubated in the absence of 3 mM-valine.
TABLE 4.12 Effect of 1 mM-2-Amino-4-inethoxy-trans-but-3-enoate
(AMB) on the Ratio of Lactate to Pyruvate Released 
by Hemi-Diaphragms From a) Fed and, b) 48 h-Starved 
Rats
Values are ratios of the mean values of lactate release to the 
mean values of pyruvate release shown in Table 4.10.
a) Fed
Ratio of. Lactate to -Pyfuvate .Release
Additions to Control + 1 mM-AMB
Incubation Medium
None 7*5 34*9
3 mM-valine 7-7 19.8
3 mM-leucine 19*6 35*9
b) 48 h-Starved
Ratio of Lactate to Pyruvate Release
Additions to Control + 1 mM-AMB
Incubation Medium
None 3.6 45.4
3 mM-valine 3*9 79*0
3 uiM-leucine ~~12.8 53*5.
3 mM-glutamate 9*2 120
to NAD) by malate dehydrogenase. The malate crosses the mito­
chondrial membrane and is then oxidised to oxaloacetate by 
mitochondrial malate dehydrogenase, hence transferring, 
reducing equivalents from the cytosol into mitochondria. 
Oxaloacetate, however, does not cross the mitochondrial membrane 
very readily and so leaves as aspartate which requires trans­
amination reactions in both the cytosolic and mitochondrial 
compartments. Thus aspartate aminotransferase is involved in 
the malate-oxaloacetate shuttle in muscle. Inhibition of 
aspartate aminotransferase by AMB would therefore prevent the 
transfer of NADH from the cytosol by the shuttle, thereby making 
the cytosol more reduced and so increasing the ratio of lactate/ 
pyruvate release.
As noted above, in contrast to Ichihara et al. (l975)» 
Odessey & Goldberg (1979) have reported that branched-chain 
aminotransferease activity is largely (^70 %) cytosolic in 
muscle. If branched-chain aminotransferase activity is indeed 
located in the cytosol a different scheme for the reactions 
involved in alanine formation from valine is required (Fig. 4.8t). 
In this scheme, aspartate aminotransferase is still required to 
provide cytosolic oxaloacetate in order to produce pyruvate for 
alanine formation by the pathway involving PEPCK. However, in 
this scheme no net transfer of amino nitrogen occurs from the 
mitochondria to the cytosol; the amino groups of aspartate entering 
the cytoplasm return to the mitochondria as glutamate.
The experiments reported in this chapter indicate that 
muscle has the metabolic capacity to utilise the carbon and
nitrogen of valine (and possibly other amino acids whose 
catabolism results in a net formation of tricarboxylic acid 
cycle intermediates) for the formation of alanine. The metabolic 
route involves the enzymes PEPGK and aspartate aminotransferase 
and it is more active during starvation. The extent to which 
this metabolic route operates during starvation in vivo is 
unknown but it does provide an explanation for .the net conversion 
of amino acids arising from proteolysis into alanine which, 
following its release from muscle, can be used by the liver as 
a gluconeogenic precursor.
4.2.5 Appendix! Apparent Stimulation of PEPGK Activity by
3-Aminopicolinate
The effect of an inhibitor of muscle PEPCK, 3“mercaPto-
1
picolinate, on valine-stimulated alanine release provided evidence 
for the proposed pathway for alanine formation from valine 
carbon detailed above. Experiments were also carried out, 
however, on the effect7 of 3-aJiiinopicolinate» (3“AP), (an activator 
of PEPGK activity, MacDonald & Lardy, 1978b). on valine-stimulated 
alanine release. 3“AP increased the valine-stimulated release 
of alanine by EDL muscle preparations without increasing net 
protein degradation (as measured by tyrosine release) (Table 4.13). 
However, 3~AP did not increase valine-stimulated alanine release 
from soleus muscle (Table 4.13). A compound which stimulates 
muscle PEPGK activity would be expected, from the evidence of 
preceding experiments, to increase valine-stimulated alanine 
release. The lack of increase in alanine release could not be
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accounted for by decreased protein breakdown in the presence of- 
3-AP because tyrosine release was similar in the presence or 
absence of 3“AP» It was observed however, that 3~AP increased 
the valine-stimulated release of glutamine from both soleus 
and ELL muscles. This is a further demonstration that the 
BCAA-stimulated release of alanine and glutamine by muscle do 
not necessarily respond in the same manner to certain circum­
stances.
The effects of 3”AP on alanine release were puzzling.
In order to clarify the situation, experiments were carried 
out to measure ,the effect of 3-aminopicolinate on muscle and 
liver enzyme activities. Liver was used as previous work which 
had demonstrated J-XP to be an activator of PEPCK activity 
employed liver PEPGK (MacDonald & Lardy, 1978b). PEPGK activity 
was assayed by method A as described in Chapter 2. No activation 
of liver cytosol PEPGK activity, or the PEPGK activities in 
crude extracts of soleus and EDL muscles were observed (results 
not shown). The effect of J-kV on the activity of PEPGK was 
also determined by assaying in the direction of PEP formation 
(i.e. by method D, Chapter 2). As is mentioned in the following 
chapter (Chapter 5)# no muscle PEPGK activity was measurable at 
the limits of detection of this assay and so no effect of 3~AP 
could be observed. However, liver PEPGK activity was slightly 
inhibited by 1 mM-3-aminopicolinate (by 15 %)•
It has previously been reported that when liver PEPGK,
2^ . 2*1"
3-AP, dithiothreitol and a divalent metal ion (Fe or Mn ) are 
pre-incubated before assay, 3”AP can activate the enzyme (MacDonald
2+
& Lardy, 1978b). In the present study pre-incubation with Fe
and dithiothreitol was found to slightly increase muscle and
liver PEPGK activities ( ^ 10 %) but the presence of 1 mM-3-
aminopicolinate in the pre-incubation caused no further stimulation
of PEPGK activities. Reynolds (1980b) has also failed to observe
activation of rat liver PEPGK activity by 3”aminopicolinate in
2+
the presence of Fe and dithiothreitol. The same author has
also reported that the PEPGK ferroaetivator protein of rat liver
acts by protecting PEPCK from inactivation when the enzyme is
in the presence of Fe (Reynolds, 1980c). He suggests that
PEPGK may be in dynamic equilibrium between inactivation by
ferrous ions and reactivation by thiol compounds and that 3“AP
may act in the same manner as the ferroaetivator protein by
chelating the potentially inhibitory metal ions (Reynolds,
1980b). * However, it is not known whether muscle PEPCK activity
2+can be regulated in this manner by Fe . No PEPGK ferroaetivator 
was detected in rat skeletal muscle (MacDonald et al., 1978)• 
Nevertheless, incubations with 1 mM-3-aminopicolinate stimulated: 
alanine (and glutamine) release from EDL muscle. Investigations 
on the effect of 3“AP on muscle pyruvate kinase activity were 
also carried out (Fig. ^.10). 3“AP acted as an inhibitor of„ 
muscle pyruvate kinase activity in a non-competitive manner with 
respect to phosphoenolpyruvate concentration. In addition 
experiments on LDH activity were conducted with crude extracts 
of muscle and liver cytosol pre-incubated in the presence of 
0.1 mM-FeClg and 0.8 mM-dithiothreitol, with and without 3“AP.
Pre-incubating either liver or muscle samples in the presence of
FIG. 4.10 Effect of 1 mM-3-Aminopicoiinate on Muscle Pyruvate
Kinase Activity
• - 3-aminopicolinate 
O + 3“ai&inopic'olinate
200
( jxmol/jnln/g tissue)
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3-AP greatly inhibited LDH activity (Table 4. lA). The inhibition
apparently depended more on the presence of thiols in the pre-
2+ 2+ incubation mixture than Fe , although substituting Mn for
2+Fe in the pre-incubation mixture relieved 3~AP inhibition of 
LDH activity.
The assay for pyruvate kinase makes use of LDH as a 
coupling enzyme. It is therefore possible that the observed 
inhibitory effects of 3”AP on pyruvate kinase were in fact 
secondary to the inhibition of the added LDH. The inhibition of 
LDH by 3-AP may also have been responsible for the slight 
inhibition found in liver PEPGK activity when assayed in the 
direction of phosphoenolpyruvate synthesis. The PEPGK assay 
method in this direction involves measuring phosphoenolpyruvate 
produced in a given time, by making use of a coupled enzyme 
system involving commercial preparations of pyruvate kinase and 
LDH.
With regard to the effect of 3~AP' on alanine release 
observed in the present study, a possible explanation may be 
that 3-AP inhibited LDH to such an extent that more pyruvate 
was available for alanine formation. White muscle (EBL) has a 
higher rate of glycolysis than red muscle (soleus). If this 
explanation is correct then more pyruvate would be expected to 
build up in white muscle in the presence of 3~AP and this could 
account for the increase in alanine release found with EDL in the 
presence of 3"AP but not with soleus muscle. The increase in 
glutamine release observed in the presence of 3“AP may be a 
result of the increased amount of pyruvate permitting more acetyl'
TABLE 4-. 14 Effect of 1 mM-3-Aminopicolinate on Liver and Muscle
(EDL) Lactate Dehydrogenase Activity
Tissue samples were pre-incubated for 10 min at 0°C prior to 
assay in the presence of 1 mM-FeCl^, 0.8 mM-dithiothreitol (DTT) 
and with or without 2.5 mM-3AP. The amount of pre-incubation 
mixture taken for assaying for lactate dehydrogenase activity 
was such that X3AP] in the assay mixture = 1 iriM.
Tissue Pre-incubation Conditions Lactate Dehydrogenase
Activity (jxmol/min/g tissue)
Muscle -3AP + __ 2+ Fe * DTT 230
Muscle +3AP + TP 2+Fe + DTT >7.3
Liver -3AP + TP 2+Fe + DTT 425
Liver +3AP + tp 2+Fe + DTT 22.4
Liver +3AP - TP 2+ Fe + DTT 15.2
Liver +3AP + TP 2+Fe - DTT 52.1
Liver -3AP - TP 2+ Fe + 1 mM-Mn2* + DTT 402
Liver +3AP - TP 2+ Fe + 1 mM-Mn2+ + DTT 322
GoA to he formed via pyruvate dehydrogenase. This could stimulate 
citrate formation and hence increase levels of 2-oxoglutarate 
which could he removed from the tricarboxylic acid cycle to 
form glutamine. It should he noted that in the present study, 
experiments were not conducted on purified enzyme preparations.
3-AP may well activate purified PEPGK from muscle (and liver, 
as shown hy MacDonald & Lardy, 19?8h) hut the inhibitory 
effect on LDH activity may confound this observation in tissue 
incubation studies or with crude tissue extracts.
In view of the doubt as to the action of 3-aminopicolinate 
on muscle enzyme activities, the results obtained from these 
experiments did not provide any useful information for the 
elucidation of the proposed pathway from valine to alanine.
3-mercaptopicolinate was found to have no effect on 
muscle LDH and pyruvate kinase when assayed with or without 
the pre-incubation procedure detailed above.
C H A P T E R  F I V E
STUDIES ON MUSCLE ENZYMES IMPLICATED IN THE REMOVAL OF CARBON 
FROM THE TRICARBOXYLIC ACID CYCLE TO FORM PYRUVATE
STUDIES ON MUSCLE ENZYMES IMPLICATED IN THE REMOVAL OF CARBON
FROM THE TRICARBOXYLIC ACID CYCLE TO FORM PYRUVATE
5.1 INTRODUCTION
As discussed previously, leucine is regarded as a solely 
ketogenic amino acid (Meister, 19&5) 'that the accepted route 
of catabolism of leucine results in the formation of acetyl-CoA 
and acetoacetate. Leucine would only be able to contribute 
carbon for pyruvate formation if another, as yet unknown, path­
way for leucine catabolism existed in muscle.
The accepted route of catabolism of valine, on the other 
hand, involves the formation of propionyl-CoA which can feed 
into the tricarboxylic acid cycle. Hence carbon derived from 
valine metabolism can contribute to the carbon skeleton of 
alanine if a metabolic route exists in muscle for the removal 
of carbon from the cycle to yield pyruvate.
The existence of muscle enzymes which are capable of 
removing carbon from the cycle for the formation of pyruvate 
has been reported. Substantial amounts of NADP-dependent 
(Nolte et al., 1972) and NAD-dependent (Lee & Davis, 1979) malic 
enzymes have been reported in rat skeletal muscles, and Opie 
& Newsholme (19&7) ha-va reported the existence of PEPGK activity 
in muscle.
The main aim of the work described in this chapter' was 
to further investigate the enzymes.implicated in carbon with­
drawal from the tricarboxylic acid cycle, with a view to discovering 
by which of the possible alternative routes (see Chapter 1,
Fig. 1.3) valine-derived carbon may provide 3”carbon units for 
de novo alanine synthesis by muscle.
5.2 RESULTS AND DISCUSSION
Alternative Routes for Alanine Synthesis from Valine in Muscle
5*2.1 Muscle Oxaloacetate Decarboxylase Activity
A' similar situation to the present one involving muscle 
was encountered try Watford et al. >, (1979) “who were studying 
the route of alanine formation from the carbon of glutamine by 
enterocytes. The possible enzymes involved were as indicated 
above. Of. the three enzymes, malic enzyme, oxaloacetate 
decarboxylase and PEPGK, oxaloacetate decarboxylase had the 
. highest activity in enterocytes and could have been responsible 
for the formation of pyruvate. For this reason the oxaloacetate 
- decarboxylase activity of muscle was measured.
Oxaloacetate decarboxylase activity can theoretically 
be measured by following oxaloacetate consumption and/or pyruvate 
production. Oxaloacetate is a rather unstable compound and 
undergoes spontaneous decarboxylation to pyruvate. Therefore 
in order to study the enzymatic decarboxylation both the assay 
methods used (Dean & Bartley, 1973» Wojtczak & Walajtys, 1974) 
employ conditions which are optimal for the enzymatic process 
and which decrease the non-enzymatic reaction. Unfortunately 
the decrease in oxaloacetate observed during the reactions 
proved to be highly variable and so oxaloacetate decarboxylase
activity was measured only by the increase in pyruvate production.
The production of pyruvate by crude extracts (600 g 
supernatants) of soleus muscle are shown in Fig. 5*1. An increase 
in pyruvate production was found. However, the rate of pyruvate 
production by soleus extracts was no greater than the rate when 
boiled soleus muscle extract replaced the test extract in the 
assay mixture. This finding was not restricted to red muscles 
as is shown in Fig. 5*2. Fresh extracts of the white muscle,
EDL, formed pyruvate at no greater rate than heat-inactivated 
extracts.
In order to show that the enzyme assay itself was not 
defective, the activity of oxaloacetate decarboxylase in 
100,000 g supernatant of rat liver homogenate was followed.
Fig* 5*3 shows that liver has in fact substantial enzymatic 
activity (l.30 ± 0.28 (4) ^ mol/min/g) being the difference 
between the total pyruvate production rate observed with test 
tissue extract and the pyruvate production rate observed with 
1 boiled liver supernatant". This suggests that'the enzyme assay 
itself is not defective and that muscle contains no appreciable 
oxaloacetate decarboxylase activity. Similarly, Wojtczak & 
Walajtys (1974) detected no skeletal muscle mitochondrial oxalo­
acetate decarboxylase activity.
5*2.2 Muscle "Malic Enzyme" Activity
There is little doubt as to the existence of NADP-malic 
enzyme activity in skeletal muscle (Nolte et al., 1972;Newsholme 
& Williams, 1978; Zahlten & Nejtek, 1979; Nagel et al., 1980;
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Swierczynski et al., 1980; Swierczynski, 1980; Swierczynski &
Davis, 1981). Two types of malic enzyme have been reported to 
be pre sent in several mammalian tissues (Sauer , 1973a; 1973b;
Lin & Davis, 1974; Nagel et al., 1980): one of the enzyme 
forms uses only NADP+ as coenzyme: the other'reduces either 
NAD+ or NADP+, with NAD being the preferred substrate (Swierczynski 
& Davis, 198l). Lee & Davis, (1979) recently stated that rat 
skeletal muscle contained NAD -dependent malic enzyme activity.
The activities of NADP-malic enzyme, and NAD(p)-malic 
enzyme (using NAD and NADP as cofactors) were measured in the 
present study. The activity of NADP-malic enzyme was measured 
on crude extracts of diaphragm muscles from fed rats a,nd found
tp be 1.90 i 0.15 (3) ^ mol/min/g tissue at 30°C by the method
of Swierczynski et al. (1980) and I.96 ± 0.18 (3) ^mol/min/ g 
of tissue by the method of Nagel et al. (1980).
The activity of the NAD(p)-malic enzyme from various 
tissues has been reported to be increased when assayed in the 
presence of fumarate and inhibited by ATP (Sauer, 1973b»
Mandella & Sauer, 1975» Sauer & Dauchy, 1978; Sauer et al., 1979)* 
For this reason 5 mM-sodium fumarate was included in the mixture , 
used for the assay of NAD(p) activity as described* by Nagel et al. 
(1980). With NADP+ as cofactor an activity of 1.10 ± 0.21 (3)
I*mol/min/g tissue was obtained whereas no activity was detectable 
using NAD as the cofactor. These findings are in agreement with
those of Nagel et al., (1980) who were also unable to confirm
the findings of Lee & Davis (1979)•
A recent paper (Swierczynski & Davis, 1981), however,
has again reported a cytoplasmic malic enzyme from rat skeletal
4*
muscle which can use NAD as a cofactor. The enzyme converts 
malate to pyruvate with either co-enzyme present at approximately
the same maximal rates but the Km’s for malate and nucleotide
4  4*
are many-fold higher with NAD as coenzyme than with NADP .
Regardless of which enzyme form is predominant in 
skeletal muscle it was observed that malic enzyme (with NADP 
as cofactor) is present in sufficient activities to convert 
valine-derived carbon to pyruvate for alanine formation.
5.2.3 Muscle Phosphoenolpyruvate Carboxykinase and Pyruvate
Kinase Activity
This route for the provision of pyruvate from tri­
carboxylic acid cycle carbon differs from those above in that 
two enzymatic steps are involved: a decarboxylation’of oxalo­
acetate to phosphoenolpyruvate by PEPGK, followed by conversion 
to pyruvate by pyruvate kinase.
PEPCK activity was measured in crude extracts of rat 
diaphragm using PEPGK assay method A (Chapter 2). The mean value 
(0.0246 yumol/min/g tissue) was low in comparison with muscle 
malic enzyme activity but was more than sufficient to account 
for the valine-stimulated increase in alanine formation 
observed in diaphragm incubations in vitro being 2.95/a.mol/2 h/ g 
tissue compared with the mean valine-stimulated increase in 
alanine production of 0.99 yw.mol/2 h/g tissue from diaphragm 
preparations from fed rats and 0.8? ^mol/2 h/g tissue from 
diaphragm preparations from 48 h-starved rats (Table 3*l)•
Two methods for assaying PEPGK activity in crude
extracts of muscle have been employed by various workers, both
of which supposedly follow the formation fo oxaloacetate from
phosphoenolpyruvate and are coupled to malate formation from
oxaloacetate by added malate dehydrogenase. One method is
a continuous spectrophotometric assay based on the decrease in
absorbance at 3^0 nm -due to the oxidation of NADH by the
conversion of oxaloacetate,formed in the assay, to malate by
malate dehydrogenase (Opie & Newsholme, 1967; Crabtree et al.,
1972). The other method (method A, Chapter 2) measures 
14incorporation of CO^ into oxaloacetate which is trapped for 
radioactive counting as acid-stable malate (Nolte et al., 1972) 
and is based on the assay developed for liver PEPCK (Chang & •
Lane, 1966; Ballard.& Hanson, 1967)*
Although the reaction mixtures for the two methods are 
very similar, two important differences have been observed 
between PEPCK activities in crude extracts of muscle determined 
by the two techniques (Table 5* l) • The PEPCK values obtained 
using assay method A showed that, although in agreement with 
values reported by Nolte et al., (1972), the ^CO^-incorporation 
assay method gave muscle PEPCK activities approximately one 
order of magnitude lower than the spectrophotometric assay (Opie 
& Newsholme, 19&7; Crabtree et al., 1972; Newsholme & Williams, 
1978; Newsholme et al., 1979; McLane & Holloszy, 1979; Odedra 
& Palmer, 198l). In addition, the radioactive assay method 
indicated that red muscle had PEPCK activity similar to or slightly 
higher than white muscle (Nolte et al., 1972), whereas the spectro-
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photometric assay showed substantially higher activity in 
white muscle than in red muscle (McLane & Holloszy, 1979)* In 
this study the basis for the differences between the two assay 
methods was investigated.
Table 5 • 1 shows the PEPCK activity of crude extracts 
of diaphragm, soleus and EEL muscles determined by the four 
PEPCK assay methods described in Chapter 2. The continuous 
spectrophotometrie assays (methods B and C) gave apparent PEPCK 
activities which were in agreement with other workers (Opie & 
Newsholme, 1967; Crabtree et al., 1972; Newsholme & Williams, 
1978; McLane & Holloszy, 1979; Odedra & Palmer, 1981) but which 
were at least ten times greater than the activities obtained 
using the ^CO^-ineorporation method (method A). Assay of muscle 
PEPCK in the direction of phosphoenolpyruvate formation (method 
D) showed negligible activity for all three muscle studies. 
However, it should be noted that the PEPCK activity reported 
using the ^CO^-incorporation assay (method A) would be below 
the level of detection of activity using the phosphoenolpyruvate 
formation method(D).
' . 14 ' ■The specificity of the CO^-incorporation assay for
PEPCK activity was tested using 3 mM-Na pyruvate in place of
14Na phosphoenolpyruvate. Less than 5 % of the CO^ incorporated
with phosphoenolpyruvate as substrate was found with pyruvate
under method A assay conditions.
Spectrophotometrie PEPCK assays by methods B and C were 
14
performed using NaH CO^ in place of 11 cold" NaHCO^ and the
14
incorporation of CO^ into acid-stable products under these
assay conditions compared with the formation of malate as judged 
by NADH oxidation (Table 5*2). Product formation measured by 
radioactivity incorporated .did not correspond with that 
measured by the decrease in [[NADH] during the . assay.
The two continuous spectrophotometrie assays 
for PEPCK activity (methods B and C) were compared. Method B 
(where NaHCO^ was omitted from controls), showed that the presence of 
NaHCO^ increased NADH oxidation. The higher [NaHCO^] in method 
C (50 mM) produced a greater rate of NADH oxidation than method 
B in which [[NaHCO^ ] was 17 mM (Table 5«l)« NADH oxidation in 
the absence of phosphoenolpyruvate (i.e. control of method C) 
was negligible (0.1 fxmol/min/g of muscle), whereas in the 
presence of phosphoenolpyruvate but in the absence of NaHCO^
(i.e. control in method B), NADH oxidation was appreciable 
(0.51 ± 0.08 (4) yumol/NADH;:oxidised/min/g of muscle (mean ±
S.E.M.) for EDL extracts). Substantial NADH oxidation was also 
found when NaHCO^ was. omitted (but phosphoenolpyruvate was 
present) in method G (0.76 ± 0.09 ( 4 ) mol NADH oxidised/min/ 
g of muscle for EDL extracts). As method G included antimycin A, 
an inhibitor of NADH oxidase (Wainio, 1970), some factor other 
than mitochondrial NADH oxidation was responsible for the phospho­
enolpyruvate-dependent NADH' oxidation which was stimulated 
by NaHCO^. Both assay methods B and G had control and test 
assay mixtures where the measured pH was equal (pH 7*5 for 
method B, and pH 7»1 for method C). Varying [^ NaHCO^ D in assay 
B would have altered the pH of the test assay mixture compared 
with controls and so confused any effect of altering nNaHCO^D 
per se. However, using method G, where NADH oxidation
TABLE: 5.2 Muscle PEPCK Activities Determined by NADH Oxidation 
and C 0 ^ -I ncorporation in Individual Assays
- PEPOK was assayed "by methods B and G as described
1/j,
in Chapter 2, except that NaHCO^ was replaced with NaH CO^ .
PEPCK activity is expressed for each assay as yumol NADH oxidised/
min per g of muscle and as pxmole ^CO^ incorporated/min per g of
muscle (both at 30°C). Spectrophotometrie assays were followed
for 15 min after addition of muscle extract and terminated by
1
mixing with 1 ml of 2M-HC1. CO^ not incorporated into acid- 
stable products was removed by bubbling with carbon dioxide for 
10 min. 0.5 ml of sample was removed for counting as described 
. in’Chapter 2..
Assay Muscle type
Method
B Soleus 0.18 0.0188
Extensor 
digitorurn 
longus
C Soleus
Extensor 3*3^ 0.0046
digitorum
longus
0.52
0.62
0.0216
0.0109
PEPCK activity
 \
14yAmol NADH oxidised yAmol CO^-incorporated 
/min per g of muscle /min per g of muscle
was measured with phosphoenolpyruvate omitted from controls, 
the test and control samples had a similar pH at each [[NaHCO^ ] 
in assays of PEPCK activity in crude extracts of soleus and 
EDL muscles. Increasing [jTaHCO^ ] stimulated NADH oxidation 
(Fig. 5«*0 "but this did not account for the phosphoenolpyruvate- 
dependent NADH oxidation observed in the absence of NaHGO^.
NaCl was substituted for NaHCO^, in this case using assay method 
B as the pH would not be so greatly affected by this substitution 
as would assay C. The results with extracts of EDL muscle are 
shown in Fig. 5*5* Assaying soleus muscle extracts in the 
presence of 17 mM-NaHCO^ or 17 mM-NaCl gave NADH oxidation rates 
of 0.37 ± 0.09 (3) &nd 0.4l ± O.O9 (3) /*itiol/min/g of muscle 
respectively (having subtracted the NADH-oxidation attributable 
to the controls to which neither NaHCO^ nor NaCl was added).
Together these findings indicated that ^Na*] and not [HCO~ ] ' 
was responsible for the stimulation of NADH oxidation found with 
increasing [jNaHCO^ D. This would account for the NADH oxidation 
found in controls where NaHCO^ was omitted. Sodium salts of 
phosphoenolpyruvate, IDP and NADH were used in method B, the 
sodium concentration in the assay mixture in the absence of NaHCO^ 
being b,5 mM. Similarly, method C used sodium salts of phospho­
enolpyruvate, IDP and NADH but also included a contribution from 
the Hepes-NaOH buffer employed. Approximately 18 mM-NaOH was 
required to adjust stock 250 mM-Hepes to pH 6,5* The resulting 
sodium ion concentration in the assay due to the buffer was 
therefore 3*6 mM. Thus method C contains a sodium ion concentration 
of approximately 8.1 mM before the addition of NaHCO^.
FIG. 5*4 Effect of Varying fNaHGOo] on NADH Oxidation in
Assays for Apparent PEPCK Activity in Crude Extracts
of Soleus and Extensor Digitorum Longus Muscles
NADH-oxidation attributable to apparent PEPCK activity was 
measured by method C, as described in Chapter 2.
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FIG. 5*5 Effect of Substituting NaCl for NaHCO^ on NADH-Oxidation 
in Assays for Apparent PEPCK Activity in Crude Extracts 
of EDL Muscle
NADH oxidation was measured by PEPCK assay method B, as described 
in Chapter 2.
▲ NaCl O NaHCO,
1.8,-
1.4
1.0
0.6L
60400 10 20
NaHCO^ or NaCl concn. (mM)
The question arose as to what in the crude muscle extracts 
+
was causing the Na -stimulated NADH oxidation, which was not
dependent on HCO^ . Examination of the components of the assay
mixtures of methods B and C suggested that lactate formation
from phosphoenolpyruvate, by the joint action of pyruvate kinase
and lactate dehydrogenase could be responsible . Lactate and
malate produced during assays of apparent PEPCK activity by
methods B and C were measured. Negligible malate was produced
whereas the lactate formed is shown in Table 5 *3* It was found
that lactate production could indeed account for the oxidation
of NADH which had previously been attributed to malate formation
by apparent PEPCK activity. As for apparent PEPCK activity,
+
lactate production was dependent on Na and was greater in EDL 
muscle extracts than in soleus muscle extracts (Fig. 5*6).
Assays for apparent PEPCK activity were performed by method 
C substituting commercial purified preparations.of pyruvate kinase 
and lactate dehydrogenase (both from rabbit muscle) for crude 
muscle extracts. The approximate activities of the two enzymes 
found in diaphragm extracts (see Table 5»l)» equivalent to 1 mg 
of tissue, were added (i.e. at 30°C pyruvate kinase 0.15 jwiol/ 
minj lactate dehydrogenase 0.25 mol/min). The NADH oxidation 
observed was found to be dependent on the amount of pyruvate 
kinase added to the assay mixture (Table 5*4).
Pyruvate kinase activities in crude extracts of muscle 
were measured under various conditions by omitting and/or 
substituting various components of the assay system of Zammit 
et al.. (1978), in order to obtain an indication of the pyruvate
TABLE 5»3 Lactate Production Luring Continuous Spectrophotometrie
PEPCK Assays with Crude Extracts of Muscle
Lactate production under the conditions of PEPCK assay 
was measured as described in the Materials and Methods chapter. 
Apparent PEPCK activity as measured by NADH oxidation is compared 
with lactate production in each assay.
Muscle type Assay method
PEPCK activity Lactate production 
(^mol/min per g (jimol/min perQg of 
of muscle at muscle at 30 C)
30°C)
Diaphragm
Soleus
Soleus
Extensor 
digitorum longus
Extensor 
digitorum longus
Soleus
Extensor 
digitorum longus
Soleus control 
(-NaHCO^)
Extensor 
digitorum longus 
control (-NaHCO^)
B
B
B
B
0.92
0.66
0.6l
3.38
3.20
0.15
0.47
0.81
0.66
0.87
3-54
3.40
0.08
0.57
0.12
0.44
FIG. 5*6 Lactate Production During the Continuous Spectro-
photometric PEPCK Assay a) Time Course of Lactate 
Production by Crude Extracts of Soleus and ELL; 
b) "Effect of Na on Lactate Production by Extract of 
EDL Muscle
Lactate production, in assays of PEPCK activity by method C, 
was measured as described in Chapter 2.
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TABLE 5*^ NADH Oxidation Observed Substituting Commercial
Preparations of Muscle Pyruvate Kinase and Muscle Lactate 
Dehydrogenase for Crude Extracts of Muscle in the Continuous 
Spectrophotometrie Assay of Apparent PEPCK Activity
NADH oxidation, previously attributable to PEPCK activity, 
"was determined by PEPCK assay method C as described in the 
Materials and Methods chapter. 0.15 ^ mol/min at 30°C and 0.25 
jmol/mln at J0°C are approximate, .maximal activities of pyruvate 
kinase and lactate dehydrogenase respectively, determined in crude 
extracts of diaphragm, equivalent to 1 mg of muscle (see Table 5»l) 
Results are expressed as a percentage of the highest rate of 
NADH oxidation observed. Phosphoenolpyruvate was omitted from 
controls. .
Commercial enzyme activity added 
( ^ Ainol/min at J0°G)
Pyruvate kinase Lactate dehydrogenase
% of maximum 
NADH oxidation
0.15 0.25 30
0.15 0.75 35
0.^ 5
0.^5 0.75
0.25
100
88
Control 0.15 0.25 0
Control 0.^ 5 0.75 0
kinase activity of crude muscle extracts under the conditions
used in the assays of apparent PEPCK activity hy methods B and
C (Table 5*5) • K , Mg and NH^ are all known to stimulate
muscle pyruvate kinase (Bucher & Pfleiderer, 1955; Zammit et al.,
1978), but none of these ions was present in the spectrophotometrie
assays for PEPCK by methods B and C. NH^+ is present in the
commercial lactate dehydrogenase preparation normally used
in the pyruvate kinase assay. An aliquot of the commercial
preparation was therefore extensively dialysed against distilled
water to remove NH^ • Cofactor and metal ion conditions
similar to those used in the assay of PEPCK by methods B and
C gave low pyruvate kinase activity in crude muscle extracts
compared to the maximum value obtained. Although Na was slightly
+
inhibitory to pyruvate kinase activity when K was present, in
4* 24" 4* /
the absence of K , Mg and NH^ (as in the assay of PEPCK by
methods B and C) Na stimulated muscle pyruvate kinase activity 
(Table 5.5).
To summarise these studies, it can. be stated that the 
.continuous spectrophotometrie assay methods for PEPCK activity 
in crude extracts of muscle principally measure NADH oxidation 
due to lactate formation, and not malate formation. The crude 
extracts of muscle include the enzymes pyruvate kinase and 
lactate dehydrogenase. Under the conditions of PEPCK assay 
by methods B and C, NADH-oxidation, previously attributed to 
PEPCK activity is due to lactate production by lactate dehydrog­
enase from pyruvate formed from phosphoenolpyruvate by a low 
activity of pyruvate kinase. Compared with the activity of
TABLE 5.5 Pyruvate Kinase Activities of Crude Extracts of
(a) Extensor Digitorum Longus and (b) Soleus Muscles Assayed 
Under Various Conditions
"Normal" activity denotes that the assay mixture 
contained metal ion, cofactor and substrate concentrations as 
described by Zammit et al., (1978): l60 mM-triethanolamine/HCl 
buffer, 10 mM-MgCl^, 80 mM-KCl, 0.17 niM-NADH (sodium salt),
5 mM-ADP (sodium salt), 2 mM-phosphoenolpyruvate (sodium salt) 
and 2 5 of lactate dehydrogenase (5 yul containing 16 ^ mol of 
(NH^)2S0^). "Dialysed LDH" indicates that lactate dehydrogenase, 
which had been extensively dialysed against distilled water to 
remove NH^+, replaced the normal commercial preparation of 
lactate dehydrogenase in (NH^J^SO^ in the assay mixture. "PEPCK 
conditions" indicates that l.j& mM-IDP replaced 5 mM-ADP,
1 mM-phosphoenolpyruvate replaced 2 mM-phosphoenolpyruvate and 
dialysed lactate dehydrogenase replaced lactate dehydrogenase in 
(NH^)2S0^ solution in the assay mixture, and that 1 mM-MnCl^ 
was added but that MgClg and KC1 were omitted. "PEPCK conditions- 
LDH" indicates that the assay conditions were as described for 
"PEPCK conditions" except that lactate dehydrogenase in (NH^J^SO^ 
solution replaced the dialysed lactate dehydrogenase preparation.
(TABLE 5.5 continued)
Assay Conditions and 
Additions Enzyme Activity
QuLmol/min per g of {% of "Normal” 
muscle at 30 C) activity)-'’...
(a) Extensor digitorum longus 
Normal
+ 17 mM-NaHCO^
PEPCK conditions-LDH 
Dialysed LDH 
PEPCK conditions 
PEPCK conditions + 17 mM NaCl
PEPCK conditions + 50 mM NaCl
PEPCK .conditions + 100 mM NaCl 
PEPCK conditions + 150 mM NaCl 
PEPCK conditions + 100 mM NaHCO,
(b) Soleus 
Normal
Dialysed LDH 
PEPCK conditions 
PEPCK conditions + 17 mM NaCl
PEPCK conditions + 50 mM NaCl
PEPCK conditions + 100 mM NaCl 
PEPCK conditions + 150 mM NaCl 
PEPCK' conditions + 100 mM NaHCO,
209.6
199.2
17.9
342.0
0.31
0.78
1.35
1.90
2.37
2.08
56.3
63.8
0.05
0.22
0.35
0.59
0.48
0.51
100
95.0
8.5
I63
0.15
0.37
0.64
0.90
1.13
0.99
100
113.^
0.09
0.40
0.62
1.06
0.86
0.91
muscle pyruvate kinase assayed under optimal conditions, Na -
+ 2+stimulated pyruvate kinase activity in the absence'of K , Mg 
and NH^+ ions reached a maximum value of 1.2 % of optimal.
This is in close agreement with the findings of Kachmar & Boyer 
(1953)t who found that although Na+ inhibited rabbit muscle 
pyruvate kinase in the presence of K , Na stimulated pyruvate
j f .
kinase activity in the absence of K although never to greater 
than 1.5 % of the maximum activity obtained.
Although the Na stimulation of pyruvate kinase activity 
is relatively small, it is nevertheless, sufficient to account 
for the NADH oxidation previously attributed to PEPCK activity 
determined by methods B and C. Table 5*1 shows that in crude 
extracts of diaphragm, soleus and EDL muscles, apparent PEPCK 
activity as determined by method B was substantially less than 
1 % of the corresponding pyruvate kinase maximum activity.
•(p
Na -stimulation of muscle pyruvate kinase also probably 
accounts for the previous findings that crude extracts of red 
muscle have lower apparent PEPCK activity than extracts of white 
muscle (Opie & Newsholme, 1967; McLane & Holloszy, 1979)1 
because red muscle contains less pyruvate kinase activity than 
white muscle. Table 5*1 confirms that extracts of muscle display 
spectrophotometrically-determined apparent PEPCK activity and 
pyruvate kinase activity in the order: soleus < diaphragm <  EDL.
The continuous spectrophotometrie method for measuring 
PEPCK activity in crude extracts of muscle has been widely used 
(Opie & Newsholme, 1967; Crabtree et al., 1972; Zammit & Newsholme, 
1976; 1978; Newsholme & Williams, 1978; Newsholme etal., 1979;
McLane & Holloszy, 1979; Odedra & Palmer, 1981). However, the 
present study indicates that the assay conditions employed 
largely measure Na+-stimulated pyruvate kinase activity and 
demonstrates that this method is unsuitable for PEPCK activity 
determination in muscle preparations which have not been 
extensively purified to remove pyruvate kinase and lactate 
dehydrogenase activities, although it may still prove suitable 
for extracts of muscles which lack lactate dehydrogenase (Zammit 
& Newsholme, 19?6)•
An alternative continuous spectrophotometrie PEPCK 
assay method has recently been described (Petrescu et al., 1979) 
in which pyruvate kinase activity is limited by employing 
deoxyguanosine 5*-diphosphate (dGDP) in place of IDP. This 
method was used to measure PEPCK activity spectrophotometrically 
in guinea pig liver preparations (where pyruvate kinase activity 
exceeds that of PEPCK by 5 to 15 fold) (Petrescu et al., 1979)*
Rat muscle preparations however contain much lower maximal PEPCK 
activities than liver and have maximal pyruvate kinase activities 
which exceed those of PEPCK (measured by method A) by approximately 
2,500 to 10,000-fold. As dGDP still permits slight activity 
of rabbit muscle pyruvate kinase (Petrescu et al., 1979) a 
large error in muscle PEPCK activity estimation could still 
result using this modified spectrophotometrie method.
Experiments were run to test this possibility. Pyruvate 
kinase activity was measured in crude extracts of diaphragm 
muscle. Activity measured as described by Zammit et al., (1978) 
was taken as 100 %, Replacing 5 mM-ADP from the assay mixture
with 5 mM-IDP decreased pyruvate kinase activity to 70 %
whereas replacing with dGDP decreased activity to 8 % of
maximal. Thus the use of dGDP still permits an appreciable
activity of muscle pyruvate kinase. Table 5,6 shows the effect
of using dGDP in place of IDP when measuring apparent PEPCK
activity in crude extracts of muscle by assay method C (Chapter
2). Although ±he use of dGDP substantially lowers the
apparent PEPCK activity measured by the spectrophotometrie assay
the activities obtained were still much higher than those
ik
obtained using the COg-incorporation assay of PEPCK activity.
The use of dGDP brought about the same percentage decrease in 
apparent PEPCK activity in all three muscles studied. The/ 
white muscle (EDL) still had substantially higher activity than 
the red muscle (soleus) suggesting that what was being measured 
in the crude extracts of muscle, under the conditions of PEPCK 
assay method C, with dGDP in place of IDP, was still pyruvate 
kinase activity.
From the above studies it was decided that 
PEPCK activity in crude extracts of muscle is best determined
A h ,
by the CO^-incorporation method. As has already been mentioned, 
despite the relatively low activity of PEPCK in muscle, the PEPCK 
activity observed in rat diaphragm is more than sufficient to . 
account for the valine stimulated increase in alanine formation 
observed in diaphragm incubations in vitro (Chapter 3). The 
proposed pathway of pyruvate formation for muscle alanine 
synthesis involving PEPCK also requires the participation of 
pyruvate kinase. Table 5»1 shows that this is present greatly 
in excess of the requirements for alanine synthesis.
TABLE 5*6 Effect of Substituting Deoxyguanosine 5*-diphosphate 
(dGDP) for Inosine 5'-diphosphate (IDP) in the Continuous 
Spectrophotometrie Assay of Apparent PEPGK Activity of Crude 
Extracts of Muscle
Apparent PEPGK activity m s  measured by assay method C, as 
described in Chapter 2.
Muscle
Apparent PEPGK Activity 
(^mol/min/g of tissue) 
+IDP +dGDP
Activity in presence 
of dGDP expressed as 
a percentage of 
+IDP activity
(%)
Diaphragm 0.66
Soleus 0.60
EDL 1.57
0.13
0.11
0.31
20
18
19
5«2.4 Effect of Conditions Which Cause Increased Muscle Alanine
Release On the Activities of Muscle PEPCK and Malic Enzyme 
It is possible that valine-derived carbon may leave the 
tricarboxylic acid cycle to form pyruvate for alanine synthesis 
either via malic enzyme or via PEPCK and pyruvate kinase. In 
situations where muscle alanine release and/or BCAA metabolism 
are increased the activity of the enzymes involved in such a 
pathway may undergo adaptive changes.
5.2.4.1 Effect of Starvation on the Activities of Muscle PEPCK 
and Malic Enzyme
During starvation muscle valine metabolism, and the 
requirement for the carbon of alanine synthesis de novo to be 
derived from valine, increase. Branched-chain aminotransferase 
(BCAT) activity was determined in homogenates of skeletal muscle 
-from fed and 48 h-starved rats using both valine and leucine as 
substrates (Table 5»7)» Starvation caused an increase in valine 
aminotransferase activity in both soleus (p <  0.05) and EDL 
(p < 0.0l) homogenates whereas leucine aminotransferase activity 
was not so greatly affected. Karl et al., (1976) have also 
reported increased BCAT activity in preparations of muscle from 
48 h-starved rats compared with muscle from fed rats. These 
workers, however, found that the increases in BCAT activity were 
similar with either leucine or valine as substrate.
The results of the present study are in close agreement 
with the response to starvation of transamination values 
obtained in a different manner with incubated hemi-diaphragm
TABLE 5»7 Effect of 48 h-Starvation on Branched-Chain
Aminotransferase Activity in Rat Skeletal Muscles
Branched-chain aminotransferase activity m s  measured 
on crude extracts of skeletal muscle as described in Chapter 2 
with leucine or valine as substrate.
Results shown are means ± S.E.M. of activity 
measured in muscle homogenates from 3 fed- and 3 48 h-starved rats 
on 3 separate days.
Statistical differences between activities in 
extracts of muscles prepared from fed and 48 h-starved rats were 
calculated by Student’s t-test using paired analysis for assays 
performed on the same day. Differences are shown by * p < 0.05,
** p < 0.01.
Muscle
Soleus
Soleus
Soleus
Soleus
EDL
EDL
EDL
EDL
Substrate
Valine
Valine
Leucine
Leucine
Valine
Valine
Leucine
Leucine
Nutritional
State
Fed 
48 h-starved 
Fed 
48 h-starved 
Fed 
48 h-starved 
Fed 
48 h-starved
Branche d-chain 
Aminotransferase activity
( ^ umol/min/g tissue)
O.63 ± 0.06 
0.88 ± 0.12 *
0.61 ± 0.09 
0.76 + 0.11 
O.53 ± 0.07 
0.78 ± 0.10 **
0.56 ± 0.06 
0.61 ± 0.06
preparations (Figs. 3*2 and 3*6). Valine transamination by- 
tissue from 48 h-starved rats was higher than that from fed 
rats, whereas leucine transamination was the same or slightly 
lower in "48 h-starved" hemi-diaphragms than "fed" tissue. It 
has already been shown that as starvation proceeds a greater 
amount of valine carbon escapes losses either through complete 
oxidation or through release as the branched-chain 2-oxo acid 
(Table 3*6). . Also the potential for valine-stimulated alanine 
release is higher in muscle from starved rats than from fed rats 
(Fig. 3.1). Therefore as the withdrawal of valine carbon from' 
the tricarboxylic acid cycle was expected to increase as starvation 
proceeded, the activities of malic enzyme and PEPCK were studied 
to see whether changes occurred during starvation (Fig. 5*7)• 
Starvation caused an increase in the activity of PEPCK whereas 
malic enzyme activity Vas decreased (diaphragm homogenates)' or 
unchanged-(EDL homogenates) by starvation.
In agreement with these findings, Karl et al., (1976) 
reported no difference between the malic enzyme activities of 
epitrochlaris muscle from fed and 48 h-starved rats, and Nolte 
et al.1 (1972) found decreases in the malic enzyme activities 
of rat reptus femoris and soleus muscles after 3 <la,ys of 
starvation in comparison with the activities found in muscles 
from fed controls. Newsholme & Williams (1978) also reported 
that rat muscle malic enzyme activity was not altered by 48 h 
starvation and in addition stated that muscle PEPCK activity 
increased substantially. However, these workers measured 
PEPCK activity in crude extracts of muscle by the spectrophotometrie
FIG. 5*7 Effect of Starvation on Muscle Enzyme Activities
Crude extracts of the muscles were prepared, and enzyme activities 
measured, as described in Chapter 2. PEPCK activity was 
determined by method A.
Each point represents the mean of measurements from 
k different rats. Vertical bars' indicate 'S.E.M.
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method discussed previously (5*2.3) and so their PEPCK activity 
measurements are open to criticism.
5*2,k,2 Effect of Dietary Supplementation With Valine on Muscle
PEPCK and Malic Enzyme Activities
Rats were fed for days on powdered diet, (.Spratts 
Laboratory Diet 2), supplemented with an extra 5 % by weight of , 
L-valine. Feeding rats a diet, rich in BCAAs has previously 
been reported to increase muscle BCAA metabolism as measured 
by branched-chain 2-oxo acid dehydrogenase activity (Shinnick 
& Harper, 1977)* The valine-supplemented group showed increased 
alanine release by hemi-diaphragms incubated with 3 mM-valine 
(Fig. 5*8) when compared.with those fed a normal unsupplemented 
diet (p <  0.01, Student's t-test). It was found in this 
situation of increased muscle BCAA metabolism and resulting 
increased alanine release, that as is the case during starvation, 
the activity of muscle PEPCK was increased (p <  0.05, Student's 
t-test), whereas that of malic enzyme remained the same or 
decreased.
Some rats were fed for 1^ days on powdered-diet 
supplemented with an extra 5 %'\>y weight of L-leucine. Hemi- 
diaphragms of the leucine-supplemented rats did not show increased 
alanine release when incubated with 3 mM-leucine when compared 
with those from rats fed an unsupplemented diet (2.87 ± O.3O (k) 
and 3*02 ± 0.19 00 jxmole/min/g tissue respectively). However.', 
hemi-diaphragms of the leucine-supplemented rats had significantly 
higher PEPCK activities (p <.0,00l) 28.2 ± 0.6 (4) vs 19*7 i 1*5 00
FIG. 5*8 Effect of Dietary Valine Supplementation on
Diaphragm Metabolism
Rats were fed for days on a normal diet supplemented with
an extra 5 % "by weight of L-valine. NADP-dependent malic enzyme
and PEPGK activities were assayed in diaphragm muscle at the
end of the period, and alanine release by hemi-diaphragms incubated
in a glucose-free .bicarbonate medium containing 3 mM-valine
was measured. Open columns are normally fed controls and
hatched columns are valine-supplemented animals.
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nmol/min/g tissue; and lower malic enzyme activities (p< 0.05): 
0.84 ± 0.04 (4) vs O.98 ± 0.03 (4) yumol/min/g tissue; than those 
fed a normal unsupplemented diet.
5.2.4.3 Effect of L-Triiodothyronine (L~T^) Treatment on Muscle
PEPGK and Malic Enzyme Activities
Garter et al., (l98l) observed that isolated epitrochlaris 
muscle preparations from rats which had received daily injections 
of triiodothyronine (L-T^) for 6 days released more alanine 
in vitro than tissue from rats injected only with vehicle.
Rats were therefore treated with L-T^ and the activities of muscle 
malic enzyme and PEPCK measured. Rats injected with L-T^ showed 
an approximately JO % lower weight gain over the 6 day treatment 
period than vehicle only-injected rats (33*2 ± 1.5 g vs 45.0 ± 3*3 S» 
n=6 in each group). No differences were observed in malic; 
enzyme and PEPGK activities between the groups (Table 5*8) 
although Garter et al., (l98l) had found that the muscles of 
the thyroid hormone-treated group released alanine to a greater 
extent than the other. Nolte et al.. (1972) also reported that 
triiodothyronine treatment was without effect on muscle malic 
enzyme activity but stated that the response of muscle PEPCK 
activity to triiodothyronine was varied, being slightly increased 
in red muscle but decreased in white muscle.
An explanation for the increased alanine release from 
muscle of treated rats may be provided by the later findings
of Garter et al., (1982) that L-T^ increases the rate of skeletal 
muscle protein breakdown. Hence the increase in alanine release
TABLE 5*8 Effect of L-Triiodothyronine (L-T0) Treatment---- _  ----- - - - -------------- -------- --  y ----- - ----
on Muscle PEPGK and Malic Enzyme Activities
Rats were injected i.p. with 250 yug L-T^/kg body weight 
dissolved in 0.9 % NaCl-5 mM-NaOH, daily for 6 days. Control 
animals were injected over the same time period with equivalent 
volumes of vehicle. Results given are means ± S.E.M., number 
of observations in parentheses.
Muscle Malic Enzyme Activity (units/g tissue)
Control L-T^ Treated
0.97 ± 0.12 (4) 1.13 ± 0.13 (4)
0.50 ± 0.04 (4) 0.60 ± 0.04 (4)
0.6l ± 0.06 (4) 0.79 ± 0.09 (4)
PEPGK Activity (munits/g tissue)
Control L-T^ Treated
Diaphragm
Soleus
EDL
Diaphragm 19*3 ± ^ .0 (3) 23.6 ± 3.2 (3)
Soleus 22.1 ± 4.8 (3) 19.O ± 4.3 (3)
EDL 18.2 ± 0.6 (3) 15.4 ± 3.9 (3)
was not due to an increase in alanine formation de novo and 
an adaptive change in PEPCK (or malic enzyme) activity might 
not he expected.
Karl et al., (1976) have previously found that thyroxine 
(T^) pretreatment substantially stimulated alanine release by : 
rat epitroehlaris muscle without greatly affecting glutamine 
release. If the effect of the thyroid-hormone was only to 
increase proteolysis it would have been expected that both 
alanine and glutamine release would have been increased to the 
same extent. Taken together with the finding of Karl et al.,
(1976) of no change in malic enzyme activity in treated rat 
muscle, these results suggested that PEPCK might have been 
involved in the formation of the increased.-amount of alanine 
released by treated muscle. However, as no change was 
observed in PEPCK activity in the present study a more likely 
explanation for the alanine release could be as follows. The 
increased alanine release without concomitant increased glutamine 
release was observed from epitroehlaris muscle preparations 
incubated in medium containing 5 inM-glucose and insulin (100 munits 
/ml). Such conditions would ensure a plentiful supply of pyruvate 
within the muscle preparations. The increased proteolysis 
induced by thyroid-hormone treatment would make available 
a substantial amount of amino acids stimulating transamination 
reactions and thus increasing the formation of alanine. Thus 
the substantial amounts of alanine released from the muscles of 
pretreated rats would be derived not only from proteolysis 
but also from transamination of pyruvate with amino groups
derived from other amino acids made available by proteolysis.
5.2.5 Conclusion ,
The results reported in this chapter show that the 
activities of either PEPCK + pyruvate kinase or NADP-malic 
enzyme measured under optimal conditions in muscle homogenates 
are sufficient to account for the observed rates of valine- 
stimulated de__novo synthesis of alanine in vitro. It is 
recognised that the assay of PEPCK activity was in the opposite 
direction to that proposed in its role for removing oxaloacetate 
from the tricarboxylic acid cycle (measurements in that direction 
were below the sensitivity of the assay method). Nevertheless, 
the work of Pogson & Smith, (1975) on the liver and kidney PEPCK
activities suggests that the values in either direction, i.e.
1^measurements of phosphoenolpyruvate formation or C-incorporation 
into oxaloacetate, are not greatly dissimilar.
Although the activity of NADP-malic enzyme is much 
greater (100-fold) than that of. PEPCK, the latter enzyme showed 
adaptive changes that were more appropriate to a physiological 
role in diverting valine-derived tricarboxylic acid cycle carbon 
into pyruvate and alanine formation. Thus, both starvation and 
dietary valine supplementation, which increase BCAA metabolism 
and alanine formation, evoked adaptive increases in PEPCK activity 
but not malic enzyme activity. This circumstantial evidence 
favours the route of alanine formation from valine proceeding 
via PEPCK and pyruvate kinase rather than that via malic enzyme 
(Fig. 1.3) in agreement with the conclusions reached from
experiments using inhibitors of those routes described in the 
previous chapter (Chapter .
Y
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SUBCELLULAR DISTRIBUTION OF ENZYMES INVOLVED IN BRANCHED-CHAIN
AMINO ACID METABOLISM AND ALANINE FORMATION IN MUSCLE
6.1 INTRODUCTION
As stated in the discussion of Chapter k, in order 
to further elucidate the suggested pathway of alanine formation 
from BCAAs by rat muscle preparations, some information was 
required concerning the subcellular distribution of the enzymes 
proposed to be involved in the pathway. The enzymes studied 
included branched-chain aminotransferase, alanine aminotransferase, 
aspartate aminotransferase and PEPCK. It was of particular 
importance to establish the location of branched-chain amino­
transferase within the muscle cell as published reports on 
its subcellular location provide conflicting conclusions.
Odessey & Goldberg (1979) reported the enzyme to be mainly 
cytosolic (approximately 70 %), Knox's group (Cappuccino et al, 
1978? Kadowaki & Knox, 1982), found it was ^ 5 % cytosolic,
Whereas Ichihara et al (1975) stated that only 29 % of muscle 
branched-chain aminotransferase activity was located in the 
cytosol.
6.2 RESULTS AND DISCUSSION
Several methods were employed for the subcellular 
fractionation of muscle tissue from fed rats, as described in 
Chapter 2. Initially, method 1 was used and the distribution 
of the activities of branched-chain aminotransferase and 
succinate dehydrogenase in fractions obtained from a mixture
of soleus and EDL muscles is shown in Fig. 6.1. Succinate 
dehydrogenase was employed as a mitochondrial "marker" enzyme 
as its location within the cell is assumed to he solely within 
the mitochondrion (Greville, 19&9)• Fig. 6.1 shows that the 
majority (63 %) of the branched-chain aminotransferase activity 
(determined with leucine as substrate) was located in the 
soluble (cytosol) fraction and that the activity of the 
mitochondrial marker, succinate dehydrogenase, was negligible 
in this fraction. A certain amount of leucine aminotransferase 
activity (28 %) was detected in fractions with substantial 
succinate dehydrogenase activity. From the distributions of 
the two enzyme activities among the particulate fractions it. 
was assumed that the non-cytosolic leucine aminotransferase 
activity was mitochondrial. In case the apparent dual location 
of branched-chain aminotransferase was due to different intra­
cellular locations of the enzyme in the two different muscle 
"types, the subcellular distribution of branched-chain amino­
transferase was determined separately, in soleus alone and EDL 
alone (Fig. 6.2). Differences were detected between the 
muscles in that whole homogenates of soleus muscle exhibited 
higher aminotransferase activity than EDL homogenates with 
both valine and leucine as substrates. However, the subcellular 
distributions of the enzyme activities were found to be very 
similar in both muscles and agree with the results of Odessey 
& Goldberg (l979)> who found that 70 “ 80 % of the branched- 
chain aminotransferase activity of'rat hindlimb muscles was 
recovered in the cytosol fraction of the cell, and the remaining
FIG. 6.1 Subcellular Distribution of Leucine Aminotransferase
in Soleus and EDL Muscles
Subcellular fractionation was carried out by method 1 as 
described in Chapter 2. Values shown are representative of 
3 fractionations.. _
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amount in the mitochondrial fraction.
Using the same fractionation method as that used to 
determine the location of branched-chain aminotransferase 
activity within the muscle cell (method l), the subcellular 
distributions of muscle PEPCK and "malic enzyme" (NADP- 
dependent malate dehydrogenase) were measured in rat diaphragm 
muscle and in the previously-used mixture of red and white 
leg muscles. Table 6.1 shows the results obtained. 75 “ 80 % 
of the recovered PEPCK activity was found in the 100,000 g 
cytosol fraction with a small percentage (9 - 12 %) recovered 
in the mitochondrial fraction. A similar distribution was 
seen for malic enzyme activity with, in diaphragm, 86 % being 
found in the cytosolic fraction and 9 /£ recovered in the 
mitochondrial fraction. It had already been reported by Nolte 
et al (1972) that in red muscle about 70 % of the total activity 
of both enzymes was located in the mitochondria, whereas in 
white muscle up to 70 % of the total activity of both enzymes 
was found in the cytosol. It therefore appeared surprising 
that in our muscle preparations, containing both red and white 
muscles, such a large proportion of the total activity was 
located in the cytosolic fraction.
A possible reason for the observed difference between 
the results of this study and those of Nolte et al (1972) 
could be deduced from the use of succinate dehydrogenase as 
the mitochondrial marker enzyme in my study (Table 6.l). . 
Succinate dehydrogenase is located within the inner mitochondrial 
membrane and is found in the membrane fractions obtained on
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further fractionation of disrupted mitochondria (De Haan et al, 
1973)* Damage to the mitochondria during homogenisation or 
centrifugation would therefore still result in succinate 
dehydrogenase activity "being centrifuged down in the 
11 mitochondrial pellet" whereas mitochondrial enzymes which are 
not membrane-bound would be freed'into the soluble fractions. 
To test the possibility of mitochondrial damage during the 
fractionation procedure, a more suitable mitochondrial marker 
enzyme was employed, which is believed to be located solely 
within the mitochondrial matrix, glutamate dehydrogenase 
(Pette, 1966).
Table 6.1 shows the subcellular distribution of 
succinate dehydrogenase and glutamate dehydrogenase activities 
obtained from fractions prepared by method 1. Although the 
membrane-bound mitochondrial enzyme activity (succinate 
dehydrogenase) was principally recovered in the 20,000 g 
pellet (i.e. the designated mitochondrial fraction), the 
majority of the glutamate dehydrogenase activity was found in 
the 100,000 g supernatant. As these results indicated the 
presence of damaged mitochondria, other published schemes for 
the subcellular fractionation of muscle were applied. These 
schemes (methods 1 - 4 )  were described in Chapter 2. Methods 
1 - 4  differed with respect to the centrifugation speeds 
employed and the composition of the homogenising medium. The 
initial low speed centrifugation employed to sediment unbroken 
cells, nuclei and cell debris, differed in all 4 methods 
CCrabtree et al, (1972) 800 g x 10 "min; Odessey & Goldberg,
(1979) 800 g x 5 min; Ernster & Nordenbrand, (19^7) 600 g x 
7 min; Surholt & Newsholme, (l98l) 600 g x 5 min]. The super­
natants resulting from this initial spin were therefore contam­
inated with cell debris and nuclei to varying degrees. In 
addition the amount of mitochondria sedimented in the initial 
pellet varied between methods.
Similarly, differing amounts of mitochondria were 
sedimented by the second stage of centrifugation using the 
four different methods [^ Crabtree et al, (1972) 20,000 g x 10 min; 
Odessey & Goldberg, (1979) 10,000 g x 10 min; Ernster & Nordenbrand, 
(1967) 14,000 g x 10 min; Surholt & Newsholme, (l98l) 5t 0^0 g 
x 20 min].
The composition of the homogenising media differed in
methods 1 - 4  (see Chapter 2). All, however, contained EDTA or
J3GTA. Mitochondria of poor quality (poor phosphorylating
efficiency) would otherwise be obtained due to the relatively
2+
high content of Ca in muscle tissue which absorbs to the 
mitochondria during homogenisation (Ernster & Nordenbrand, 1987)*
It has been reported that skeletal muscle mitochondrial 
preparations made in sucrose medium may have very low yields 
of mitochondria (Ernster & Nordenbrand, 1987). The problem of 
yield arises from the fact that skeletal muscle, when homogenised 
in a non-electrolyte medium, often assumes a gelatinous consist­
ency which makes it difficult to obtain a sufficient disintegration 
of the myofibrils. Thus the method of Odessey and Goldberg 
(1979) may suffer from this problem. The non-sucrose containing 
medium used in method 3 (Ernster & Nordenbrand, 19&7) was . '
designed by Chappell & Perry (1954) so that the medium 
maintained the myofibrils in such a physical state that homo­
genisation and subsequent differential centrifugation could 
easily be performed with the resulting mitochondrial preparation 
theoretically being satisfactory both quantitatively and 
qualitatively.
The homogenising medium used in method 4 (Surholt & 
Newsholme, 1981) differed from that employed in the other 
methods as it included 0.1 % (w/v) bovine serum albumin (BSA) 
in an attempt to produce mitochondria of good quality. BSA is 
an inert protein which acts to stabilise the mitochondria 
(Davis, 1967) possibly by binding "toxic" substances released 
when the cell is disrupted ("toxic" to oxidative phosphorylation), 
such as long-ehain fatty acids, which are potent uncoupling 
agents (Pressman & Lardy, 1956).
Application of fractionation method 2, as described by 
Odessey & Goldberg (l979)» revealed only a small amount of 
glutamate dehydrogenase activity associated with the "mitochondrial 
pellet" with by far the majority of the activity being obtained 
in the cytosolic fraction (Table 6.2).
Odessey & Goldberg (1979) used succinate dehydrogenase 
as their only mitochondrial marker enzyme. In view of the 
present findings of damaged mitochondria, and subsequent leakage 
of mitochondrial enzyme-activities into the soluble fraction 
obtained using their muscle fractionation scheme, some doubt 
must be placed on their interpretation of the subcellular 
distribution of branched-chain aminotransferase.
TABLE 6.2 Subcellular Distribution of Glutamate Dehydrogenase
Activity in Diaphragm Muscle
Subcellular fractions prepared according to fractionation 
method 2 (Odessey & Goldberg, 1979)*
Values are the mean of 2 determinations.
Fraction
Glutamate Dehydrogenase
Activity % of Whole
(^mol/min/g tissue) homogenate activity
Whole homogenate 3*18
800 g pellet 0.90
(nuclear)
10.000 g pellet 0.^0 
(mito chondrial)
100.000 g pellet 0.27 
(microsomal)
100.000 g supernatant 2.36 
(cytosol)
28
13
8
7b
Method 3, as described by Ernster & Nordenbrand (19^7)
was followed. Table 6.3 shows that the activity of muscle
glutamate dehydrogenase was recovered mainly in the "cytosolic” 
fraction, again indicating damage to the mitochondria to such 
an extent as to make estimates of the subcellular distribution 
of enzyme activities practically impossible by this method.
Method b, as described by Surholt & Newsholme (1981),
was also applied. Although the damage to the mitochondria was 
not as great using this method for subcellular fractionation 
(Table 6,b) as in the previous methods, substantial glutamate 
dehydrogenase activity was still recovered in the ”cytosolic” 
fraction. A similar pattern was obtained for citrate synthase, 
which is also located in the mitochondrial matrix (Pette, 1966).
The main cause of the damage to mitochondria seemed to 
occur on homogenising muscle. Being a tough tissue, large shear 
forces were required to produce "good” muscle homogenates but 
this also caused damage to the mitochondria. In view of the 
amount of damage caused to muscle mitochondria when following 
the various subcellular fractionation methods, it became 
apparent that trying to identify the subcellular location of 
enzyme activities by using these methods which depended on 
homogenisation followed by differential centrifugation, was 
impractical. Consequently another approach was made to the 
problem and an attempt at locating enzyme activities within 
the muscle cell was made using the fractional extraction ■ 
procedure described for "difficult" tissues by Taylor et al,
(1978)» and pioneered by Pette, (1966). The principle of this
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procedure consists of submitting a tissue sample to repeated 
extractions with buffer solutions which, by means of increasing 
osmotic and mechanical aggressiveness, disclose successively 
different cellular compartments (Pette, 1966). The modification 
of this method used here primarily achieves the separation of 
extra- and intra-mitochondrial enzymes.
Pyruvate kinase and LDH activities were assayed as 
cytosolic markers, whereas glutamate dehydrogenase and citrate 
synthase activities were measured as mitochondrial enzyme markers. 
The percentage of total activity of citrate synthase and 
glutamate dehydrogenase found after the first extraction, was 
a measure of the degree of damage to mitochondria during the 
relatively mild homogenisation and first extraction. As this 
percentage varied from experiment to experiment no attempt was 
made to pool results from individual experiments for statistical 
analysis. Instead, the results of individual experiments using 
the fractional extraction technique are shown in Fig. 6.3» and 
the total tissue activities of the various enzymes studied 
(assayed on homogenates prepared by ground-glass homogenisation 
of tissue in deoxycholate-containing buffer) are shown in Table 
6.5. Enzyme activities shown in the fractional extraction , ■ 
profiles were expressed as the percentage of the sum of the 
enzyme activities found in the five fractions i.e. three 
extractions in KG1-based medium, one extraction in phosphate 
buffer and the homogenate of the sediment from the phosphate 
extraction. Recoveries of enzyme activities in the five 
fractions obtained by this technique were always 80 - 110 %
FIG. 6.3 Fractional Extraction of Extra- and Intra-Mitochondrial 
Enzyme Activities in Rat Diaphragm Muscle. The 
Percentage of the Total Cellular Activity Extracted 
at Different Steps is Plotted Against the Time 
Course of the Extraction
Enzyme activities shown in the fractional extraction profiles 
are expressed as percentages of the sum of the enzyme activities 
found in the five fractions i.e. three extraction in KCl-based 
medium, one extraction in phosphate buffer and the homogenate of 
the sediment from the phosphate extraction.
The results of 3 extractions are shown overleaf..
AlaAT = Alanine aminotransferase
AspAT = Aspartate aminotransferase
BCAT = Branched-chain aminotransferase
CS = Citrate synthase
GDH = Glutamate dehydrogenase
LDH = Lactate dehydrogenase
PEPCK = Phosphoenolpyruvate carboxykinase
PK = Pyruvate kinase
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TABLE 6.5 Whole Tissue Activities of Enzymes Studied. During
Fractional Extraction of Diaphragm Muscle
Whole tissue activities were assayed on homogenates 
of diaphragm prepared by ground-glass homogenisation of tissue 
in deoxychblate-containing buffer. Values represent the.means 
of measurements from different rats and are given ± S.E.M. with 
the number of observations in parentheses.
Enzyme Activity _
( yumol/min/g tissue)
Lactate dehydrogenase 319 ± 29 (3)
Pyruvate Kinase 21? ± 2 (3)
Citrate Synthase 36*3 ± 2.2 (3)
Glutamate Dehydrogenase 3 *5^ - ±- 0.^1 (3} -.
Alanine Aminotransferase 5*86 ± 0.4l (3)
Aspartate Aminotransferase 178 ± 10 (3)
Branched-chain Aminotransferase 1.15 ± 0*12' '(3)
Phosphoenolpyruvate Garboxykinase O.O33 ± 0.005 (3)
of the enzyme activities of the minced tissue homogenised in 
deoxycholate-containing "buffer.
From the fractional profiles obtained (Fig. 6.3)» 
branched-chain aminotransferase was found to be extracted with 
the mitochondrial matrix markers, citrate synthase and glutamate 
dehydrogenase. This suggested a mitochondrial location for the 
bulk of the branchedrchain aminotransferase activity in 
contrast to what had been inferred from the differential 
centrifugation studies (Table 6.l) and by Odessey and Goldberg,
(1979).
On this basis, PEPCK, aspartate aminotransferase and 
alanine aminotransferase activities were all located in both 
the cytosol and mitochondrial fractions. However, some idea of 
the relative distribution of these activities between the two 
compartments can be obtained, In extracts of diaphragm, higher 
percentages of aspartate aminotransferase and PEPCK activities 
were located in the mitochondrial fraction than alanine amino­
transferase, and aspartate aminotransferase and PEPCK activities 
were slightly more mitochondrial than cytosolic. Alanine 
aminotransferase activity on the other hand, was located to a 
greater extent in the cytosol fraction of the muscle cell than 
in the mitochondrial fraction.
Unfortunately, malic enzyme activity could not be 
assayed in the fractions obtained by this technique. It appeared 
that a component of the fractionation medium interfered with 
the malic enzyme assay and so no information concerning the 
subcellular location of malic enzyme could be obtained. However,
studies by other workers have shown that NADP-specific malic 
enzyme is located in both the mitochondrial (Swierczynski, 1980) 
and cytosolic (Swierczynski et al, 1980) compartments.
The finding that branched-chain aminotransferase activity 
is predominantly located in the mitochondrial fraction is in 
contrast to most other reports of its intracellular location.
These reports can be critisised, as subcellular fractionation 
methods have been employed which, in my experience, cause 
varying amounts of damage to mitochondria, allowing enzyme 
activities to leak into the soluble fractions. Odessey &
Goldberg (l979)» who reported a predominantly cytosolic location 
for branched-chain aminotransferase, used the membrane- - 
bound succinate dehydrogenase as their mitochondrial marker, 
and so would not have detected the damage caused to mitochondria 
by their fractionation procedure. Kadowaki & Knox (1982), 
although finding a partial mitochondrial location, prepared 
skeletal muscle mitochondria by the method of Ernster & 
Nordenbrand (198?) which in the present study was found to 
result in mitochondrial damage. No mention was made in that 
study of marker enzymes for subcellular fractions of skeletal 
muscle.
Cappuccino et al (1978), who reported a similar partially 
mitochondrial location, obtained their values for soluble and 
particulate activities by measuring activity in whole homogenates, 
centrifuging the homogenate at 30,000 g for 30 min, assaying 
the supernatant for enzyme activity and denoting this the 
cytosolic activity. The particulate activity was obtained
from the difference between the cytosolic and whole homogenate 
activities and therefore assumed a total of 100 % recoverey 
of branched-chain aminotransferase activity between the 
particulate and cytosol fractions. It was also assumed that 
no damage to the subcellular particles occurred during the 
fractionation-procedure although no mitochondrial marker 
enzymes were employed to establish this.
The findings of Ichihara et al (1975) that muscle 
branched-chain aminotransferase activity was 70 % mitochondrial 
come closest to the findings of the present study. The present 
finding of a predominantly mitochondrial location for branched- 
chain aminotransferase would suggest that the pathway of 
alanine formation from valine in skeletal muscle was as proposed 
in a previous chapter (Fig. ^.8a ).
Using the present fractional extraction of muscle 
experiments, alanine aminotransferase was shown to be mainly 
cytosolic, in agreement with the previous findings of De Rosa 
& Swick, (1975)• This finding and the observation that aspartate 
aminotransferase activity was associated with both the cytosolic 
and the mitochondrial fractions provide further support for the 
proposed pathway (Fig. ^.8 a).
However, the intracellular location of PEPCK activity 
observed did not fit so neatly into the scheme as suggested.
PEPCK activity was found associated with:the cytosol and the 
mitochondria. The scheme of alanine formation from valine 
assumed a solely cytosolic location for PEPCK, thus enabling 
valine-derived oxaloacetate, exported from mitochondria in the
form of aspartate, to "be converted to PEP and from there to 
pyruvate and then alanine. The present finding of substantial 
mitochondrial PEPCK activity in skeletal muscle was however, not 
altogether unexpected. As mentioned earlier, Nolte et al (1972) 
have previously reported that PEPCK activity of red muscle 
was approximately 70 % mitochondrial. Although PEPCK activity 
was found to be associated with both the cytosolic and the 
mitochondrial fractions, this does not necessarily mean that 
the pathway for conversion of valine carbon to alanine cannot 
proceed as previously proposed. It is difficult to propose 
a pathway for the formation of alanine from valine which involves 
mitochondrial PEPCK and adheres to the properties already 
discovered for the pathway. For example, it was found u)sing 
the aspartate aminotransferase inhibitor, AMB, that in muscle 
from ^ 8 h-fasted rat, blocking aspartate aminotransferase 
activity inhibited the formation of alanine (Chapter ^ ). A 
pathway involving mitochondrial PEPCK would require the export 
of PEP from the mitochondria following oxaloacetate decarboxylation 
and would not therefore require aspartate aminotransferase. 
Therefore it is probable that a substantial proportion of the 
decarboxylation of valine-derived oxaloacetate occurs in the 
cytosol. The function of mitochondrial PEPCK activity with 
regard to valine metabolism could possibly be explained by the 
following suggestion which concerns the cofactor requirement of 
the PEPCK reaction. When oxaloacetate is decarboxylated to PEP 
by PEPCK, GTP is converted to GDP. The enzyme succinate 
thiokinase,. which converts succinyl-CoA to succinate and is
the point of entry of valine carbon into the tricarboxylic 
acid cycle, also uses those factors, converting GDP to GTP 
with succinate formation. As high GTP/GDP ratios would inhibit 
the thiokinase reaction, the conversion of oxaloacetate to PEP, 
and hence GTP to GDP by mitochondrial PEPCK, would lower the 
GTP/GDP ratio and potentially increase the rate of entry of 
valine-derived carbon into the tricarboxylic acid cycle inter­
mediates pool.
There are, however, other ways in which mitochondrial 
PEPCK activity may be involved with muscle alanine production 
and these will be discussed in Chapter 8.
C H A P T E R  S E V E N
INCORPORATION OF ^C-LABEL FROM [U-^C] BRANCHED-CHAIN AMINO
ACIDS INTO OTHER AMINO ACIDS IN MUSCLE TISSUE IN VITRO
INCORPORATION OF -LABEL FROM Qj-^Cl BRANCHED-CHAIN AMINO
ACIDS INTO OTHER AMINO ACIDS IN MUSCLE TISSUE IN VITRO
7.1 INTRODUCTION
Branched-chain amino acids have been observed to stimulate 
the de novo synthesis of alanine by muscle tissue preparations. 
Evidence has been presented that supports a pathway for branched- 
chain amino acid-stimulated alanine formation that involves the 
withdrawal of carbon from the tricarboxylic acid cycle and 
decarboxylation via the enzyme PEPCK to yield 3“cart>on precursors 
(Chapters k & 5)• Such a pathway is consistent with the proposal 
that valine itself is a source of the carbon skeleton of the 
alanine synthesised de novo. The experiments described in 
this chapter were performed to test the'above proposal by
jk r -i
measuring the incorporation of C from the \JJ- CJ BCAAs into' 
the carbon skeletons of amino acids which were subsequently 
released by muscle tissue.
Hemi-diaphragm preparations were incubated in the 
presence of 3 mM-L-£u-^\f]“valine or L-£u-^\f]“leucine. The 
tissues were incubated for 2 h after which time the amino acids 
present in the incubation medium were isolated by ion-exchange 
chromatography and separated and identified by thin-layer 
electrophoresis (iLE) and thin layer chromatography (TLC). 
Radioactivity that was found to be associated with particular 
amino acids was measured. Of particular interest was the extent 
to which G from UJ- Cj-valine was incorporated into alanine 
which was released by the hemi-diaphragm preparations.
The following experiments were conducted to investigate
the route of valine-stimulated alanine formation. Using paired
*14 r i4
tissue incubations, the ratio of GO^ produced from [_U- GJ-
Ak, r 14 *vlabelled amino acids to GO^ produced from Li- Cj-labelled 
amino acids (when both Qj-^cQ and Cl-^c] are initially present 
at the same specific radioactivity) yields information -onjfche 
extent to which the amino acid skeleton is oxidised (see Chapter
3). If the metabolism of valine were consistent with it being 
a precursor for the carbon skeleton of alanine, valine would 
be oxidised, according to the proposed pathway, via PEPCK. In 
this case, the addition of the PEPCK inhibitor, 3-mercapto-
picolinate (3M?) to incubations containing either Ll- C] or
r l4-i 14LU- CJ-valine would be expected to lower the ratio of
produced from Qj-^cf]-valine relative to £ 1 - -valine. The
14
PEPCK-catalysed decarboxylation and hence some of the ^ 2
produced from Lu-^cj-valine would be inhibited.
Experiments were carried out with paired hemi-diaphragm
preparations from 48 h-starved rats in which valine-stimulated
de novo alanine synthesis has been shown to involve PEPCK
(Chapter 4). The ratios of ^GO^ produced from Qj-^C]-valine
r 14 1to that produced from Ll“ GJ-valine in paired incubations were 
compared with ratios obtained in similar incubations containing 
1 11M-3MP. Similar experiments were also carried out using the 
malic enzyme inhibitor, hydroxymalonate, with the intention of 
comparing these with the 3®* experiments to evaluate further 
the proposal that valine metabolism, and conversion to alanine, 
does not occur via-malic enzyme, but proceeds via PEPCK.
7.2 RESULTS AND DISCUSSION
7.2.1 Effect of Metabolic Inhibitors on Valine Metabolism
In Vitro
A h
The effect of 1 mM-3MP on the ratio of GO^ released 
from L-[U-lZ,C]-valine to L-£i-^cQ-valine is shown in Table 7*1.
A h
No decrease in the ratio of CO^ released from incubations in
_  Ah -j
the presence of pJ- Cj-valine to those incubated with Ll- Cj- 
valine was'found when tissue preparations were incubated in the 
presence of the PEPCK inhibitor. This result suggests that 
PEPCK is not involved in the metabolism and oxidation of valine 
by muscle. In addition, no-change, in the Lu-^C]-valine-derived
_ 14 -1 14to Ll- GJ-valine-derived GO^ production ratio was observed
when hemi-diaphragms were incubated in the presence of the malic 
enzyme inhibitor, hydroxymalonate. Thus neither PEPCK nor malic 
enzyme appears to be involved, to any great extent, in the further 
metabolism of the carbon skeleton derived from valine. However, 
it is possible that, when the oxidative pathway via PEPCK is 
inhibited, the valine-derived carbon is removed from the 
tricarboxylic acid cycle via malic enzyme. Similarly, when 
malic enzyme is inhibited, metabolism might proceed via PEPCK. 
Assuming that valine is catabolised as is conventially accepted,
(Meister, 19^ 5? Rodwell, 1969)> the predicted lowering of the
14 r 14 r 14 -1COg release ratio from LU- CJ to Li- Cj-valine can not have
been countered by any other diversion e.g. of the "blocked'1
carbon into the tricarboxylic acid cycle with subsequent loss of 
14GO^ . The "blocked” carbon skeleton could not be oxidised
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"directly by the cycle. As the cycle oxidises only the carbon 
(Skeleton of acetyl-GoA, the "blocked” carbon would first require 
to be converted into pyruvate and then into acetyl-GoA (Goldstein 
& Newsholme, 1976). Thus it might appear that, when PEPCK is 
inhibited, pyruvate is produced from the carbon skeleton via 
malic enzyme and so no change in the ^  production ratio 
could be observed. This explanation for the lack of change in
jk
the COg production ratio is considered unlikely as it has 
previously been; shown that the net valine-stimulated alanine 
production is inhibited to a much greater extent by the PEPCK 
inhibitor than by the malic enzyme inhibitor. If the suggested 
routes operated as alternatives for removing carbon from the 
tricarboxylic acid cycle then the presence of either JMP or 
hydroxymalonate would have had no effect on valine-stimulated 
alanine production.
Thus this experiment casts some doubt on the proposed 
pathway of valine carbon metabolism to alanine via PEPCK in 
muscle, .
1^ r -i7.2.2 Incorporation of' C-Label from LU- C.l-Branched-Chain 
Amino Acids Into Other Amino Acids Released by Muscle 
In Vitro
It has previously been shown that the carbon skeletons 
of branched-chain amino acids are only partially oxidised by 
skeletal muscle (Chapter 3) and thus make available to the 
muscle carbon which can possibly be utilised for the formation 
de novo of compounds, such as alanine, which are subsequently
released by muscle. In this set of experiments the incorporation
<• ilj> -| p* iii> —j
of C-label from LU- GJ-valine and Qjr Gj-leucine into other
amino acids released "by hemi-diaphragm muscle in vitro was
studied. Muscle may he able to form alanine from valine carbon
by a pathway involving PEPCK and so one of each pair of hemi-
diaphragms was incubated in the presence of 1 mM-3MP (an inhibitor
of PEPCK) to determine whether this would decrease the incorporation
of G into alanine. Hemi-diaphragm preparations were incubated
in the presence of valine or leucine at an initial specific
—1radioactivity of 167 mCi. mole . As each incubation was
performed with an initial QbCAAJ of 3 in a 2 ml volume, each
hemi-diaphragm was therefore incubated in the presence of 6yjunol
BGAA and thus the radioactivity in each flask was 1 ^ Ci. (2.2 x 
610 d.p.m.) at the start of incubation. The relatively high
specific activity of BGAA employed was required because it was 
calculated, assuming a 100 % recovery of radioactivity at each 
stage involved in the processing of incubation medium for amino 
acid separation i.e. after acidification, neutralisation, ion- 
exchange chromatography, freeze-drying and taking the residue up 
in solution again, that only about l/l5 of the original 
amount of radioactivity could be applied to the thin-layer 
plates for TLE and TLC. The main reason for this was that 
although the minimum volume of H^O which could be used to 
reproducibly take up the residue obtained after freeze-drying 
was 200yul, no more than 20yul of sample could be applied to 
the TLC plate for separation of the amino acids.
The actual recoveries of radioactivity at different
stages of sample preparation were calculated. For example, 
recovery up to the point of applying sample onto the TLC plate 
was found to he approximately 68 % for valine (48 h-starved rat 
hemi-diaphragm). This, of course, was partly because some 
radioactivity associated with compounds other than amino acids 
would he removed by the ion-exchange chromatography. Qj-^cQ- 
3-methyl-2-oxobutyrate, for example, was removed from the 
sample at this stage. The subsequent recovery of radioactivity 
from the plates in the form of the amino acids being investigated 
was between 73 and 82 % (3 observations) of that applied.
Thus, a figure of only about l/30 of the original amount
of radioactivity was expected to be recovered from the plate
i.e. approximately 75»000 d.p.m., and from this the incorporation 
14of G-label into other amino acids was calculated. No more 
sample could be applied to the plate because problems in separation 
arose when the plate was loaded with sample volumes > ZOjxX. As 
it was not practical to measure the actual amounts of each amino 
acid present in the incubation medium at the end of the incubation 
period (as explained above, the medium was required to ensure 
that radioactivity applied to the plate was as high as possible), 
actual measurements of radiolabelling of amino acids could not 
be expressed on a d.p.m./yumol basis. Therefore the amounts of 
radioactivity associated with individual amino acids were 
expressed as percentages of the sum of the radioactivities 
associated with the amino acids studied.
The rates of oxidation of 3 mM-[[u-^G]-leucine and 3 mM- 
Qj-^cf]-valine observed in these experiments were similar to
.those described previously (Chapter 3)• For example, 3 mM- 
ftj- C]-leucine was oxidised at a rate of 2.40 ±0.03 (3) and.
2.55 i 0.15 (3)ywmol/2 h/g tissue, in the absence and presence 
of 1 11M-3MP respectively, by hemi-diaphragms from 48 h-starved 
rats. 3 mM-Qj- c]-valine was oxidised at a rate of 1.68 ± 0.13 
(3) and 1.70 ± 0Tl2 (3) ^ imol/2 h/g tissue in the absence and 
presence of 1 mM-3MP respectively, by hemi-diaphragms from 48 h- 
starved rats.
14 r 14 -iThe incorporation of C-label from £U- CJ-leucine into
other amino acids which were released by hemi-diaphragm *
preparations is shown in Table 7*2. . Incorporation was mainly
into glutamine and glutamate in both the fed and 48 h-starved
states. This is in agreement with the findings of Hutson &
*1 2l
Zapalowski (l98l) who studied the incorporation of C-label
from -leucine into the perfused hindquarter free dispensable
amino acid pool of fed and 3 -day starved rats. Similarly Spy devoid
(1976) found substantially more ^C-label from Q j - l e u c i n e
was incorporated into glutamate than into alanine and aspartate
released by perfused hind-limbs of fasted rats. In the present
study, much more label appeared in glutamine than in glutamate
in the fasted state, whereas in the fed state more label was
found in glutamate than glutamine. The presence of 1 mM-3MP
14
appeared to cause an increase in the percentage of C appearing
in glutamine, glutamate and alanine but decreased the amount of 
14C appearing in aspartate. However, these differences were 
not statistically significant (p > 0.05, Student's t-test).
As leucine is reported to be a purely ketogenic amino
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acid, its catabolism leading to acetyl-GoA and acetoacetate
production, (Rodwell, 1969), a problem arose as to how ^G
from £u-^cQ-leucine could have appeared in alanine and
aspartate released by the muscle.
14-The G-labelling of glutamate and glutamine can be
simply explained by the formation of citrate from endogenous 
Ah
oxaloacetate and C-labelled acetyl-CoA derived from the
metabolism of [U-^\f]-leucine. On the formation of 2-oxoglutarate
14 1Zj,
from iso citrate derived from this G-citrate, GO^ would be
evolved. However, this would still leave one of the carbon
atoms of 2-oxoglutarate radiolabelled. Glutamate and glutamine
i4
formed from such 2-oxoglutarate would • therefore contain G on
one carbon atom/molecule.
The -labelling of aspartate observed with Qj-^C]-’
14-leucine as the sole source of G was very much less than that-
found of , glutamate and glutamine. An explanation for the'
14-finding of C-aspartate could be as follows; A net increase in 
the level of tricarboxylic acid cycle intermediates in skeletal 
musde has been reported under conditions when the acetyl-CoA 
concentration is elevated (Lee & Davis, 1979) and the mechanism 
responsible for this net increase is thought to be the fixation 
of carbon dioxide via earboxylation of pyruvate or phosphoenol- 
pyruvate (Lee & Davis, 1979)* If the carbon dioxide fixed was
Ah. _ Alj,
COg derived from LU- Cj-leucine oxidation, then the oxaloacetate
formed would be radiolabelled. Transamination of this oxalo-
14-acetate would therefore, yield G-containing aspartate.
14GO^ fixation via earboxylation of pyruvate or phospho-
iZj,
enolpyruvate could also account for the finding of C-labelled
alanine albeit in very small amounts in the present study in
r 14 -i 14which LU- CJ-leucine was the sole source of C.
14It is possible that the C-oxaloacetate formed by
the fixation can undergo rapid equilibration with malate, fumarate
and succinate. Radioactivity in citrate subsequently formed,
would then be distributed evenly between the 1- and 3~carboxyl-
ik
G-positions. . Some G-labell-ing of pyruvate could then occur
via decarboxylation of a four carbon unit derived from the
labelled citrate mixture and would depend on randomisation of
label between the two carboxyl groups via the symmetrical 4-
14
carbon carboxylic acids. Transamination of the G-pyruvate so
14formed would thus yield the G-alanine observed. A similar
explanation has been reported by Lee & Davis (1979).for finding
14 14G-lactate when C-labelled bicarbonate was added to perfusions
of rat hindqiiarter.
lij, _ 14 -i
The incorporation of C-label from 3 mM-LU- GJ-valine
into other amino acids released by rat hemi-diaphragm preparations
is shown in Table 7»3» Very little incorporation of C into
other amino acids took place, (again in agreement with Hutson
& Zapolowski, 198l), although more label was found associated
with glutamate, glutamine and particularly alanine in the fed
state. In the experiments using hemi-diaphragms from 48 h-starved
rats only a very small amount of label was found in the alanine
released into the medium, the majority being found in glutamine
and glutamate. These findings are similar to those reported
by Chang & Goldberg (1978a) using incubated quarter-diaphragms.
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In the experiments reported here, amino acid spots 
were visualised prior to radioactivity counting by spraying 
the thin-layer chromatography plates with ninhydrin reagent 
which would have caused decarboxylation of the amino acids.
Thus assuming a uniform distribution of label in amino acids
rr A h  *
derived from |JJ- GJ-valine, the ensuing percentage loss of 
label by a three carbon amino acid, such as alanine, is
proportionately greater than by a larger amino acid, such as
glutamate. Ho we very even allowing for alanine decarboxylation 
by the ninhydrin reaction, the amount of G-label recovered 
in alanine seemed very small. The increase in alanine release 
by hemi-diaphragms from ^ 8 h-starved rats, brought about by . 
incubating in the presence of 3 mM-valine, has previously been 
shown to have a mean value of 0.87 jmmol/2 h/g tissue (Table 3«l)• 
If this alanine was formed de novo in muscle from the carbon 
of valine by the pathway proposed (Fig. .8 a), the radioactivity 
expected to be associated with alanine in the present experiment 
could be calculated.
Assuming a hemi-diaphragm weight of about 60 mg, approx­
imately 50 nmol of alanine would be formed de novo from valine 
carbon in 2 h. If carbon from valine was not utilised for any 
purpose other than the formation of alanine the ratio of alanine/ 
valine in the incubation medium would be 50/5950* This figure 
is an under-estimate as no account is taken for the amount of 
valine oxidised, released as 3“^ e'thyl-2-oxobutyrate or metabolised 
to other products. As alanine contains 3 carbon atoms and valine 
contains 5 carbon atoms, the radioactivity expected to be
associated with alanine would he 3/5 x 50/5950 of that associated 
with valine. However, as the detection method employed in 
these experiments caused decarboxylation of the amino acids, a 
minimum of 2/k x 50/5950 of the recovered radioactivity 
associated with valine would be expected to be recovered with 
alanine. Thus 0.^2 % of the radioactivity associated with valine 
would be expected with alanine and as stated previously, this 
is an under-estimate. The observed values of 99*8 % of the 
total radioactivity associated with valine, alanine, glutamine, 
glutamate and aspartate being found associated with valine and 
only 0.02 % associated with alanine suggest that the quantitative 
contribution of valine carbon to de novo alanine synthesis by 
muscle is not very great. Taken together with the previous 
finding that valine oxidation was not affected by inhibiting 
PEPCK or malic enzyme, these results may implicate an alternative 
route of valine metabolism in muscle which would not include 
the formation of a four-carbon compound and subsequent de­
carboxylation to yield a three-carbon precursor for alanine 
formation.
It has been proposed that leucine can be formed from 
valine via 3-leueine (Poston, 1980a), although the physiological 
role of such a pathway is not clear.
The proposed steps involved ares transamination and 
decarboxylation to yield isobutyryl-CoA; incorporation of acetate 
to give ^-methyl-3-oxopentanoate (3-oxoisocaproate); transamination 
to 3-leucine; conversion of 3-leucine to leucine catalysed by 
the enzyme leucine 2,3-aminomutase (Poston, 1980b).
m
Valine ^  3“ine'thyl-2-oxobutanoate ^1sobutyryl-GoA
Leucine ■methyl-3-oxopentanoate
Valine_-carbon, after the formation of leucine by this
pathway, could then be oxidised as for leucine i.e. catabolism 
to acetyl-GoA and subsequent oxidation in the tricarboxylic acid 
cycle. The reaction sequence involved in forming leucine from 
valine carbon involves two irreversible steps. Thus this 
proposed pathway can bring about the formation of leucine from 
valine, but not the reverse transformation.
of an alternative route of valine oxidation in skeletal muscle.
In support of this suggestion is the report that although leucine 
2,3-aminomutase is widely distributed in rat tissues the 
activity of the enzyme is highest in skeletal muscle (Poston, 
1980b). If valine was indeed metabolised via leucine by muscle 
it would explain why inhibition of PEPCK and malic enzyme had 
no significant effect on the oxidation of valine by muscle from 
48 h-fasted rats.
route of valine oxidation is merely a consequence of the relatively 
high valine concentration used in the tissue incubations of this 
study. If valine metabolism were limited via the 1 conventional" 
route e.g. at the stage of isobutyryl-GoA, then the build up of 
isobutyryl-GoA could conceivably drive metabolism towards the
It is possible that the above pathway could form part
The question arises as to whether the "alternative"
putative alternative oxidative pathway via leucine.
To examine this point the effect of the PEPCK inhibitor,
3-MP, on valine oxidation was studied using a more physiological
concentration of valine, 0.2 mM (Table 7*^)« Again it was 
1L
shown that the CO^ ratio was not affected by the presence of 
the inhibitor (c.f. Table 7«l)« In comparison with the 
experiment using 3 mM-valine, it was observed with 0.2 mM-valine 
that a much higher proportion of the 3“methyl-2-oxobutyrate 
formed was released and hence that a lower proportion was 
oxidised. The transamination rate observed with 0.2 mM-valine 
was only about 10 % of that found with 3 mM-valine. Similar 
results"have been reported by Spydevold (1979) who showed that 
the oxidation rate of valine by perfused rat hindquarters 
increased approximately JO times when the concentration of 
valine was increased from 0,1 mM to 5 mM. No difference in the 
^U-^C]-valine / Cl-^C]-valine ratio was observed in the 
presence or absence of 1 mM-3MP, suggesting that even at 
physiological concentrations of valine, muscle preparations 
oxidise'-valine carbon by a route which does not involve PEPCK.
7.3 CONCLUSION /
Although valine stimulates de nfrvo alanine synthesis by 
muscle from fasted rats and although valine-stimulated de novo 
alanine synthesis proceeds via PEPCK, exogenous valine is not 
appreciably metabolised via PEPCK and is.not itself a major' 
source of carbbn for the formation of alanine by muscle. The 
source of carbon for the PEPCK-dependent formation of alanine 
remains obscure.
TABLE 7 »4 Effect of 1 mM-3-Mercaptopicolinate on the Metabolism
of 0.2 mM-L-[~U-^  Gl-Valine and 0.2 mM-L-ri-^C!~l-Valine by Hemi- 
Diaphragm Preparations Prepared from 48 h-Starved Rats
Oxidation of 
£l-^cQ-valine 
( yumol/2 h/g tissue)
Oxidation of 
[~U~^cQ -valine 
( jxmol/Z h/g tissue)
3-methyl-2-oxobutyrate 
released ( yuunol/2 h/g tissue)
Transamination of 
£l-^C] -valine 
( ^ umol/2 h/g tissue)
1 h
Oxidation ratio Qj- C]-valine 
Cl-^Gj-valine
Additions to Incubation Medium
None 1 mM-3-mercapto-
picolinate
0.40 ± 0.04 0.55 ± 0.11
(3) (3)
0.27 ± o.eft 0.36 + 0.13
(3) (3)
0.15 ± 0.02 0.10 + O.Cft-
(3) (3)
0.55 ± 0.03 0.65 + 0.06
(3) (3)
0.69 + 0.10 0.64- + 0.12
(3) (3)
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In the present study a possible relationship between 
BCAA catabolism and alanine synthesis by muscle has been 
investigated.
Alanine released by muscle is a very important precursor 
for hepatic gluconeogenesis during starvation (see Introduction).
It has been proposed that alanine is formed by the transamination 
of glycolytically-derived pyruvate i.e. glucose enters the 
muscle and is metabolised to pyruvate and converted to alanine 
by transamination. The alanine then is released from muscle 
into the bloodstream where it is taken up by the liver and converted 
back to glucose. This concept, the glucose-alanine cycle,
(Mallette et al., 1969a; Felig et al., 1970) thus makes available 
the 2-oxo acid which is obtained from amino acid transamination 
for oxidation in the muscle. However, on a whole body basis, 
this cycle does not account for any net synthesis of glucose 
during starvation. The present study was therefore in part 
concerned with determining whether muscle was capable of releasing 
alanine which had been formed de novo in muscle via transamination 
with non-glycolytically derived pyruvate, as such a situation 
would enable a net contribution to the whole body glucose pool 
to be made as would be required during starvation.
The alanine released by muscle preparations incubated 
in unsupplemented medium is comprised in part of alanine derived 
from net protein degradation and from de novo synthesis. When
muscle is incubated in the presence of BCAAs, alanine release 
is stimulated. As the presence of BCAAs does not lower the 
intracellular content of alanine and does not increase net 
protein breakdown (as measured by tyrosine release) (see Chapter
4) it can be concluded that BCAA-stimulated alanine release is 
the result of de novo alanine formation. Experiments -using 
inhibitors of transamination reactions (cycloserine, amino- 
oxyacetate) verified that the increased alanine release observed 
when muscle preparations are incubated in the presence of BCAAs 
is largely due to increased de novo alanine formation via 
transamination of pyruvate.
The source of the pyruvate was then investigated. Muscle 
preparations from fed animals mobilised substantial amounts of 
glycogen during incubations carried out in the absence of glucose 
whereas, under similar conditions, very little net glycogenolysis 
was observed in muscle from 48 h-starved rats. Thus although 
muscle glycogen was a possible source of the pyruvate required 
for de novo alanine synthesis by muscle from fed animals, the 
rate of net glycogen breakdown by muscle preparations from 
48 h-starved rats was insufficient to provide the pyruvate for 
de novo alanine synthesis. Similar results have been reported 
by Goldstein & Newsholme (1976). ' A lack of relationship between 
the rate of muscle alanine release and glycolysis has been 
demonstrated using metabolic inhibitors of glycolysis (Goldstein 
& Newsholme, 1976; Garber et al., 1976a; but c.f. Chang & Goldberg, 
1978b) and using insulin which in the present study was observed 
to increase the rate of glycolysis in muscle without producing
a corresponding increase in alanine release. These findings 
could appear to contradict the glucose-alanine cycle as proposed 
(Mallette et al.t 1969a; Felig et al., 1970)•
Incubated muscle tissue from 48 h-starved rats was 
observed to release appreciable amounts of lactate, pyruvate and 
alanine even when no substrate was added to the incubation 
medium which suggested that pyruvate (and hence lactate and alanine) 
can be formed from endogenous precursors present in muscle. As 
mentioned above, when valine was added to muscle incubations 
alanine release from muscle from 48 h-starved rats increased and 
occurred without lowering the tissue content of alanine,implying 
that the increased release-of alanine was not a result of 
increased alanine loss from an intracellular pool. Goldstein 
& Newsholme (1976) have obtained similar results, observing that 
when alanine release from rat hemi-diaphragm preparations is 
stimulated by 3 mM-isoleucine or 3 mM-glutamate, the tissue content 
of pyruvate is increased.
Studies on the transamination and decarboxylation of 
valine and to what extent the carbon skeleton of valine was 
metabolised in the incubations of the present study showed that, 
as starvation proceeded, increased amounts of valine were 
transaminated and more valine-derived carbon appeared to be made 
available to the muscle. Together with the observations from 
experiments using clofibric acid and hypoglycin, which showed 
that when BGAA metabolism beyond transamination was inhibited 
by these agents muscle alanine release decreased, these results 
suggested that the carbon skeleton of valine can provide the carbon
for pyruvate formation and hence for alanine:synthesis in muscle.
14It should he noted however that only CO^ and BGOA 
release from muscle were measured. It is possible that further 
metabolites of the BGAA beyond the BGOA stage were released from 
the muscle. If this did in fact occur the calculated BGAA-derived 
carbon made available to the muscle would be an overestimate.
Valine metabolism is reported to proceed via propionyl- 
GoA and,,after earboxylation, to form an intermediate of the 
tricarboxylic acid cycle, succinyl-CoA. For pyruvate to be 
formed from valine-derived carbon would therefore require a step 
whereby carbon could be withdrawn from the cycle to yield a 3" 
carbon compound. Enzymes which might be involved in this step 
are oxaloacetate decarboxylase, NAD/NADP-dependent.malic enzyme(s) 
and PEPCK. No oxaloacetate decarboxylase activity was detected 
in skeletal muscle. Although both malic enzyme and PEPCK 
activities were found present in muscle; only PEPCK activity 
exhibited metabolic adaptations in situations of increased BGAA 
catabolism and increased muscle alanine release which were 
consistent with it being involved in the proposed pathways 
during starvation and on feeding rats dietary supplements of 
BGAA, the PEPCK activity of muscle increased while malic enzyme 
activity did not. Further support for the proposal that, in 
muscle from 48 h-starved rats, valine contributed carbon for 
de novo pyruvate formation came from experiments using the 
specific PEPCK inhibitor, 3“mercaPtopicolinate. Blocking PEPCK 
activity with this agent caused a substantial inhibition of valine- 
stimulated alanine release from muscle. However, against all
expectations, experiments using Qj-^cQ-valine failed to 
verify that the alanine carhon was to any great extent derived 
from the carbon of the added valine.
Leucine was also found to stimulate alanine release from 
muscle. Again the enzyme PEPCK was implicated in the formation 
of alanine i inhibition of the enzyme with 3”me^captopicolinate 
caused a decrease in leucine-stimulated alanine release and 
supplemental feeding with leucine stimulated muscle PEPGK activity. 
However, leucine is a ketogenic amino acid which is oxidised to 
acetoacetate and acetyl-GoA and so cannot itself be a precursor 
for de novo pyruvate and hence alanine synthesis. This was
r jZj, _ jlj. .
verified in experiments using [JJ- CJ-leucine. Very little C 
was found incorporated into the alanine released from the muscle 
preparations. Therefore, although BGAAs stimulated muscle alanine 
release and a close relationship between BGAA catabolism and 
muscle alanine release has been observed, the BGAAs themselves 
did: not appear to serve as the source of carbon for alanine 
synthesis to any great extent.
BGAA stimulation of alanine release has been observed 
with muscle preparations from 48 h-starved rats where negligible 
glycogenolysis occurred and the BGAAs were the only substrates 
added to the incubation medium. As the BGAAs were not the 
principal precursors for pyruvate formation, it would appear 
that other amino acids derived from muscle protein breakdown 
played an important role in this respect. This source of the 
alanine released from muscle would be consistent with the 
suggestion that during fasting there is net conversion of amino
acids to glucose (Cahill et al., 1966) and that muscle, being 
a major store for protein, is capable of being an important 
metabolic regulatory organ helping to maintain acceptable levels 
of glucose in the circulation (Daniel et al., 1977)»
The pool of tricarboxylic acid cycle intermediates in 
muscle is increased in fasting, in diabetes (Davis et al., 1980) 
and by fatty acids and ketone bodies (Lee & Davis, 1979)* Thus 
the concentration of cycle intermediates is increased when muscle 
is metabolising a non-carbohydrate fuel which results in the 
formation of acetyl-GoA. The metabolism of glucose is suppressed 
under these conditions (Williamson & Krebs, 1961; Shipp et al., 
1961; Newsholme et al., 1962), the inhibition being most marked 
at the level of pyruvate dehydrogenase which is inactivated at 
high acetyl-GoA/GoA ratios (Davis & Quastel, 1964; Randle et al., 
1970). The addition of exogenous leucine to starved muscle 
preparations (leucine is metabolised to acetyl-GoA) may therefore 
cause an increase in the levels of tricarboxylic acid cycle 
intermediates present in muscle mitochondria. Leucine has also 
been reported to inhibit glucose and particularly pyruvate 
oxidation by muscle from fasted animals (Chang & Goldberg, 1978c).
Differential compartmentation of leucine for oxidation 
and for protein synthesis has recently been reported in cultured 
skeletal muscle (Schneible et al., 1981). In cells cultured in 
buffered saline with 0.05 mM-leucine, 70 % of the oxidised leucine 
briginated extracellularly while 60 % of the leucine for protein 
synthesis was derived from degraded protein, In fact these 
workers found that the preferential use of extracellular leucine
for oxidation was greatly enhanced at higher external leucine 
concentrations, the relative contribution of extracellular leucine 
to oxidation was 99 % at 5 mM-leucine and the proportion coming 
from protein degradation was greatly decreased.
Comparing that situation with the present study it can 
be concluded that exogenous leucine (or exogenous valine via 
its possible transformation to leucine; Poston, 1980a, b) would 
be an important source of acetyl-CoA which could subsequently 
be oxidised in the tricarboxylic acid cycle.
It is possible that some of the added valine carbon is 
catabolised to form metabolites capable of feeding in to the
1^
tricarboxylic acid cycle. However the negligible amount of C-
labelling of alanine found when ftj- C]-valine was added to the
incubation medium shows that the amount of alanine which is
derived from metabolites of valine which are withdrawn from the
tricarboxylic acid cycle is very small. A possibility for negligible
r 1C-alanine formation from {JJ- Cj-valine is that the rate at 
which carbon derived from endogenous amino acids feeds into the 
tricarboxylic acid cycle intermediates pool is very much greater 
than the rate at which exogenous valine-derived carbon can enter.
A further possibility is that at the relatively high 
valine concentration employed in these incubations, (3 mM), 
valine in excess of the amount that can be metabolised via succinyl- 
GoA may be metabolised via the "leucine formation" route described 
by Poston, 1980a, b).
It has been suggested that an increase in the levels of 
intermediates of the tricarboxylic acid cycle allows for a more
sensitive control of metabolic processes and that there is a 
continuous flux of intermediates in and out of the cycle pool 
(Lee & Davis, 1979)* It has been reported by Swierczynski (l980) 
that the extramitochondrial malic enzyme of skeletal muscle is 
readily reversible whereas the mitochondrial malic enzyme 
preferentally catalyses the decarboxylation reaction. Therefore 
in some situations malic enzyme may carboxylate pyruvate extra- 
mitochodrially to malate which is transferred into the mitochondria 
as a tricarboxylic acid cycle intermediate which could help 
fulfil the requirement for increased pool levels in certain 
situations e.g. when mucle is metabolising fatty acids or ketone 
bodies. In other circumstances malic enzyme may catalyse the 
formation of pyruvate from malate should the need arise.
It has been shown. (Chapters 4 & 5) that PEPCK activity 
is apparently linked with muscle alanine formation de novo and 
release, particularly during starvation. Proposals of hew this 
enzyme could be involved were put forward in Chapters 4 & 6. It 
is possible that the PEPCK catalysed reaction proceeds towards 
oxaloacetate formation. However in the situation where amino 
acids are being used as oxidative fuels by muscle in times of 
carbohydrate sparing, it is doubtful whether phosphoenolpyruvate 
would be generated in sufficient amounts to permit this to any 
great extent. Possibly PEPCK functions as an overflow system 
whereby, when the level of tricarboxylic acid cycle intermediates 
becomes elevated the excess can be removed. Phosphoenolpyruvate 
so formed would then cross the mitochondrial membrane to the 
cytosol. This may occur via the tricarboxylate carrier in exchange
for malate as reported to occur in kidney (Bryla & Dzik, 1981) 
and liver (Robinson, 1971 )• Once in the cytosol phosphoenolpyruvate 
may be converted to pyruvate via pyruvate kinase and subsequently 
via transamination to alanine.
Thus in fasting it is proposed that muscle has the 
capability to metabolise - amino acids as a source of fuel for the 
muscle itself, spare carbohydrate and, when the muscle has adequate 
energy provision, to mobilise more amino acids than are required 
to merely fuel the muscle to provide alanine as a precursor for 
hepatic gluconeogenesis which will subsequently increase the total 
body glucose pool.
The involvement of aspartate aminotransferase in the 
pathway for muscle alanine formation was suggested by the experiments 
in which 1 mM-AMB greatly inhibited alanine formation by hemi- 
diaphragms from fasted rats (Chapter 4, Fig. 4.8a )# However 
such an involvement depended on a cytosolic location for PEPCK 
whereas the majority of muscle PEPCK activity was subsequently 
shown to be mitochondrial (Chapter 6).
It is possible, though, that aspartate aminotransferase 
is not principally concerned with the transfer of carbon into the 
cytosolic compartment but of nitrogen. The nitrogen of BCAAs is 
made available in the mitochondria and as alanine aminotransferase 
is mainly cytosolic, aspartate efflux from mitochondria would 
serve to transport the nitrogen (Fig. 8.l)0
These studies have provided an insight into the properties 
and capabilities of muscle with regard to supplying a major 
precursor for hepatic gluconeogenesis,. alanine, and how BCAA.
FIG. 8.1 Proposed Pathway of Alanine Formation in Muscle
from Starved Rats
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metabolism is involved in this process.
It should be borne in mind that the findings of this
study show the metabolic capabilities of rat muscle but are not
necessarily indicative of muscle metabolism in vivo.
Further work is required to assess the possible pathway
for valine catabolism via leucine in muscle (Poston, 1980a, b),
in view of the results shown in Chapter 7» and to determine its
role in physiological circumstances. Such a pathway would
obviously preclude the contribution of valine to the net formation
of tricarboxylic acid cycle intermediates and would require a
re-evaluation of some of the concepts put forward in this thesis.
Experiments similar to those of the present study in
which muscle preparations were incubated with -valine or
r  -i[_U— GJ-leucine should be repeated and by measuring the specific
radioactivities of intracellular metabolites and intermediates on
1 Zj,
the pathways of amino acid metabolism the fate of the C should 
be traced. It would be of interest to investigate the fate of 
C when muscle from starved rat is incubated in the presence of 
physiological concentrations of [U- C]-BCAAs and other oxidisable 
substrates such as fatty acids and ketone bodies. Future work 
could also include in vivo investigations of BCAA turnover and 
its role in alanine formation in various dietary states.
The observations of the present study have been made on 
the basis of exogenously provided amino acids and require extension 
to explore their validity to amino acids generated endogenously 
in order to investigate whether the carbon of the alanine released 
by muscle can be derived from amino acids made available by
protein degradation. Further understanding of the mobilisation 
of muscle amino acids and its control by the BCAAs could prove 
useful in developing treatments for a variety of muscle wasting 
conditions, including diabetes, muscular dystrophy and tumour- 
induced cachexia.
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